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1 Introduction
An influenza epidemic was first described in 1173, although there are reports of 
influenza as early as 412 BC [1]. Recurrent epidemics and incidental pandemics 
caused by influenza virus are documented since the last 400 years [1, 2]. These were 
based upon clinical observation and epidemiology. Although a virus was suspected 
to be the cause of influenza infections, it was not until 1933 that influenza viruses 
were first isolated during an influenza epidemic in London [3]. Only recently the 
virus causing the 1914-1918 pandemic (“Spanish flu”) was isolated from conserved 
lung tissue of an American soldier [4]. The first influenza vaccine was licensed in 
1945 [1].
2 The influenza virus 
The influenza virus belongs to a family of viruses called Orthomyxoviridae. Three 
genotypes of influenza virus exist, namely influenza A, influenza B, and influenza 
C. Type A is commonly associated with epidemics and has many mammalian hosts. 
Type B infects only humans and causes disease, however, less severe than type A. 
Type C only infects humans but is thought to be harmless. This strain is genetically 
and morphologically distinct from the A and B genotypes. Influenza virus particles 
are pleiomorph, mostly ovoid or spherical, with a diameter of 80-120nm. The capsid 
of the virus is surrounded by a lipid envelope, attached to which are two types of 
glycoprotein spikes (haemagglutinin and neuraminidase) and one type of ion chan-
nel.
figuur 1. influenza virus
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3 Influenza epidemiology
Today, epidemics are generally caused by influenza A (H3N2 or H1N1) or B viruses. 
Influenza A/H2N2 subtypes have not been isolated since 1967. Influenza C virus is 
often isolated during epidemics with either influenza A or B viruses.
Annual influenza epidemics are associated with substantial morbidity and morta-
lity, especially in elderly and in those with underlying diseases [5-8]. During winter 
periods, up to 30% of elderly may experience acute respiratory infections of which 
up to 20% are attributed to influenza virus [9-12]. Although viral pneumonia accounts 
for a higher mortality rate than bacterial pneumonia [2], in elderly mostly secondary 
bacterial pneumonia associated with influenza (P&I) contributes substantially to ex-
cess mortality [5]. In the US, the combined cause of death category ranks pneumonia 
and influenza as the sixth leading cause, mostly in elderly patients. In 1992, persons 
aged ≥65 years accounted for 89% of all pneumonia associated with influenza deaths 
[13]. Based on data from Statistics Netherlands (CBS) it was estimated that during a 
22.5 year period more than 2000 people died from influenza each year [8]. Incidence 
of influenza related mortality increases substantially with increasing age, from 82 
per 100,000 in persons aged 60-69 to 280 per 100,000 in persons older than 80 years 
[8] In the US, similar death rates are reported [13]. For the 2004-2005 season, the 
CBS calculated an excess of 800 deaths in the Netherlands, despite the relatively 
mild epidemic activity [14]. Although in healthy adults clinical influenza infections 
generally have an uncomplicated course, it may have a substantial economic impact, 
e.g. due to days lost from work [15].
In the Netherlands an epidemic is declared when at least 15 per 10,000 inhabitants 
report symptoms of influenza like illness (ILI) (i.e., the epidemic threshold) [16]. 
During the last 10 years, epidemics in the Netherlands were generally of mild to 
moderate severity. The highest incidence was reached in the 1994-1995 season with 
43 reported cases of ILI per 10,000 inhabitants [17]. During the 2000-2001, 2001-2002 
and 2002-2003 seasons the epidemic threshold was not reached. In the 1994-1995, 
1995-1996 and 2004-2005 seasons there was a moderate match between circulating 
strains and virus strains [14, 17, 18]. In the 1997-1998 season there was a mismatch 
for A/H3N2 [19] and in 2003-2004 there was a mismatch for the B strain, but a good 
match for A/H3N2 [20]. The other seasons were characterised by a good match 
between circulating strains and vaccine strains [21]. 
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4 Clinical symptoms and complications following influenza infections
Clinical manifestations of influenza infection include abrupt onset of fever, myalgia, 
sore throat, non-productive cough, headache and malaise. In most cases an influenza 
infection is presented as influenza like illness. 
For the purpose of registration of epidemic activity different definitions are used 
to reach uniform recording of influenza like infection cases. In the Netherlands, the 
definition of the sentinel station is used [16]. Fulfilment of this definition requires 
an acute onset of clinical disease, with a maximum duration of the prodromal stage 
of 3-4 days (including pre-existing respiratory infection at a non-sickening level). 
Furthermore, the infection should be accompanied by an increase in rectal tem-
perature to at least 38oC and at least one of the following symptoms: cough, coryza, 
sore throat, frontal headache, retrosternal pain, myalgia. The internationally used 
ICHPPC-2 definition [22] is somewhat different. This definition also assumes a sud-
den onset with cough, shivering, fever, malaise, headache, myalgia, sore throat or 
rhinitis, but also contact with influenza. Diagnosis should furthermore fulfil at least 
one of the following 3 criteria: a proven infection by virus culture or serology, or a 
declared influenza epidemic plus at least 4 of the above mentioned symptoms or no 
declared epidemic with at least 6 of the above mentioned symptoms.
Most frequently reported complications associated with influenza are primary 
influenza viral pneumonia and secondary bacterial pneumonia. Influenza viral pneu-
monia occurs predominantly among persons with cardiovascular disease (especially 
rheumatic disease with mitral stenosis). Secondary bacterial pneumonia occurs most 
often in elderly who have chronic pulmonary, cardiac and metabolic or other disease 
[2, 23]. Other pulmonary complications of influenza are croup and exacerbations of 
chronic obstructive pulmonary disease, both mainly afflicting high risk children and 
adults [2, 23]. 
The non-pulmonary complications include myositis (mostly children), cardiac com-
plications (myocarditis and pericarditis), toxic shock syndrome (healthy children and 
adults) central nervous system complications (Guillain-Barré syndrome, transverse 
myelitis, encephalitis) and Reye syndrome (almost exclusively in children between 
2-16 years with a mortality rate of 10-40%) [2, 23].
5 Influenza vaccination 
The main objective of influenza vaccination in elderly is reducing the number of 
deaths caused by influenza infections. Prevention against influenza is possible 
through active immunisation with influenza vaccine. The composition of this vaccine 
14
Ch
ap
te
r 1
is determined yearly at a WHO consensus meeting, and is based upon the expected 
circulating strains.
Each vaccine used in annual influenza vaccination programs combines the anti-
genic components of 2 influenza A strains (H3N2 en H1N1) and 1 influenza B-strain, 
the so-called trivalent influenza vaccines. In adults and elderly, vaccination against 
influenza is recommended as a single injection containing of each of the three com-
ponents of the trivalent vaccine (i.e., the A/H3N2, A/H1N1 and B strain). Antibody 
development may start as early as one week following vaccination [24], but peak 
antibody responses are observed after approximately 4 weeks [25] and these may last 
for at least 24 weeks in healthy elderly [26].
A main limitation for the possible effectiveness of influenza vaccination programs 
is that the composition is determined by the circulating strain(s) of the previous 
year. 
6 Influenza vaccination program in the Netherlands
Since 1997 the Dutch government recommends influenza vaccination of all elderly 
over 65 years of age. This is a centralised program executed by General Practitioners 
(GPs). The GPs invite the patients from their practice fulfilling the predefined inclu-
sion criteria. During national campaigns in October and November, most individuals 
who were invited are vaccinated during mass vaccination days at the GP practice. 
For the vaccinee, the immunisation is free of charge. The GPs are reimbursed by the 
government for each patient vaccinated in the campaign through the General Law 
on Special Medical Expenses (AWBZ). 
7 Influenza vaccines 
Influenza vaccines currently on the market in the EU are prepared as either split 
virus vaccines or subunit vaccines. The split virus vaccine contains inactivated puri-
fied split virion. The subunit vaccine contains purified envelope antigens through 
selective solubilisation of the envelope. Subunit vaccines are suggested to be less 
reactogenic. On the other hand, however, a comparative study between a subunit 
vaccine and split vaccine indicated better immunogenicity of the split vaccine [27].
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7.1 Immune response following influenza vaccination
To prevent influenza infection, adequate quantities of anti-haemagglutinin (HI) an-
tibodies must be present (i.e. the humoral response) in the vaccinated person. An-
tibody to the virion surface neuramidase (anti-NA) and activated cellular immunity 
through cytotoxic T cell activation can aid in reducing the severity and duration of 
infection [28]. 
The humoral immune response against influenza virus infection is predominated 
by immunoglobulin G (IgG) antibodies. Intramuscularly administered inactivated 
influenza vaccines stimulate primarily IgG antibodies and after intramuscular im-
munisation most recipients develop these serum IgG antibodies. However, in the 
upper respiratory tract immunoglobulin A (IgA) produced locally by submucosal 
lymphocytes may predominate [28, 29]. The rate of locally produced IgA antibodies 
in nasal washings is variable (10-30% of young adults, <10% in elderly) and (when 
present) of short duration [30, 31]. 
Contrary to the humoral immunity which is strain-specific, cell-mediated immunity 
following vaccination, conferred by T-helper cell and cytotoxic T lymphocytes, is 
cross-reactive with many other strains of influenza A and B [31]. Thus cell-medi-
ated immunity stimulated by vaccination will, in principle, offer protection against 
many influenza viral strains. Ageing affects B cell function [32] and T cell function 
[33]. Since for the production of antigen specific antibodies, B cells are dependent 
upon T cell helper function, T cell dysfunction in elderly may lead to a reduction 
in humoral responses. This is also occurring in healthy elderly. Improvement of 
the cellular immunity is thus important to improve the humoral immune response 
to vaccination. Different strategies are investigated to achieve this goal. For the 
regular inactivated vaccines these include annual revaccination [34-37], an increase 
in the dose [38-40] or the recommendation of a booster dose [26, 41-44]. Other 
developments include live attenuated virus vaccines [42, 45-47], alternative routes of 
administration [48, 49], and the use of adjuvants or other immunomodulators [50-53]. 
Only annual revaccination is generally recommended. None of the other strategies 
have yet proven to be successful. 
7.2 Immunogenicity and clinical protection following influenza vaccination
In immunogenicity trials seroresponse following vaccination is usually measured 
with the haemagglutination inhibition (HI) assay as proxy for clinical protective 
efficacy. For the HI assay, three parameters are regarded.
1. The proportion of subjects exceeding a post-vaccination titre of 40 (seroprotec-
tion rate).
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2. The mean geometric increase (also called mean fold increase, MFI), i.e. the geo-
metric mean of the quotients of post- and pre-vaccination titres.
3. The combined proportion of previously seronegative subjects (prevaccination HI 
titre<10) exceeding a post-vaccination titre of 40 and that of previously seroposi-
tive subjects (prevaccination titre ≥10) with a ≥4-fold increase in GMT (response 
rate). 
The parameters are described in the CHMP Note for Guidance on harmonisation of 
requirements for influenza vaccines [54].
The primary endpoint in clinical studies depends upon the target population. 
For elderly persons, the primary endpoint is usually hospitalisation for (influenza 
associated) pneumonia or other respiratory diseases and mortality. Clinically defined 
influenza like illness and serologically or virologically confirmed influenza infection 
is a less often used endpoint in elderly, especially in observational studies.
In experimental randomised, controlled trials, the clinical protection achieved in 
the vaccinated group compared to the non-vaccinated group is expressed as vaccine 
efficacy. In observational cohort or case control studies clinical protection achieved 
in the vaccinated population compared to the non-vaccinated population is ex-
pressed as effectiveness of vaccination. 
In a randomised, placebo controlled trial, performed in healthy elderly aged 60 
years and older seroprotection was found in 43-68% of the vaccinated group [55]. 
In the same study population, vaccination also halved the risk of developing se-
rologically defined influenza, i.e., vaccine efficacy was 50% (CI
95%
: 29-67%). The 
corresponding incidences of serologically defined influenza were 9% in the placebo 
group and 4% in the vaccine group [56]. But in the vaccinated group, this incidence 
was only 0.9% in patients with a vaccination history, whereas it was 5.1% in those 
not previously vaccinated.
Effectiveness of vaccination depends upon other population factors and environ-
mental factors in addition to the intrinsic efficacy of the vaccine. The population 
factors include age, health status and living conditions of the vaccinee.
Meta-analyses have reported a benefit of vaccination in a variety of outcomes 
[57-59]. In a meta-analysis from cohort studies in institutionalised elderly, the pooled 
risk reductions were substantial: 56% for respiratory illness, 53% for pneumonia, 
50% for hospitalisation and 68% for mortality [58]. For community dwelling elderly 
the pooled estimates appeared slightly less favourable, with a 35% risk reduction for 
influenza like illness, 47% for hospitalisation for pneumonia and influenza and 50% 
for all cause mortality [57]. In a meta-analysis addressing single vs. multiple vaccina-
tions, the pooled protection rate difference for the outcome confirmed influenza was 
close to 0, indicating no difference between single and multiple vaccination [60]. In 
this meta-analysis only 2 out of the 4 included studies were in elderly. 
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The environmental factors include antigenic match of vaccine strain and circulating 
strain and vaccination coverage. The annual changes in the existing A and B strains 
(i.e. “antigenic drift”), may result in variable effectiveness of vaccination, even when 
adequate serological responses would be achieved. Systematic surveillance during 
the influenza season has confirmed widespread infection among older patients, both 
in the community and in institutions [61]. Increased vaccination coverage might posi-
tively influence vaccine effectiveness through indirect protection (herd-immunity), 
although this may be better achievable for institutionalised persons than for elderly 
living in the community. Herd immunity is associated with a lower dependency on 
the antigenic match between vaccine and virus [62-64]. For example, in a study in a 
nursing home outbreak, overall influenza vaccination failed to protect against mor-
bidity or mortality outcomes, but not in those individuals vaccinated annually during 
the last 5 years [63]. A surveillance in 58 nursing homes during the same year showed 
that outbreak frequencies were inversely related to vaccination coverage and the 
number of beds [64]. To increase or sustain clinical protection, annual revaccination 
and/or achieving a high vaccination coverage might therefor be instrumental. 
8 Licensure of influenza vaccines
Influenza vaccines submitted for first time use within the European Union, are li-
censed following assessment of their quality, efficacy and safety. Because in general, 
influenza vaccine composition changes each year, following recommendations of 
WHO, vaccines need to be relicensed on an annual basis. For annual relicensure 
purposes and in accordance with the European Committee of Human Medicinal 
Products (CHMP) Note for Guidance (CHMP/BWP/214/96) marketing authorization 
holders of influenza vaccines perform small scale immunogenicity trials in a selected 
population of healthy adults (age 18-60 years) and elderly (age >60 years) [54]. 
Such trials are evaluated using predefined criteria described in the Note for Guid-
ance. For adults, postvaccination seroprotection rate should be achieved in at least 
70% and response rate in at least 40%. For elderly the corresponding frequencies 
should exceed 60% and 30% respectively. A current limitation of the guideline is, 
however, that it does not specify criteria for children or indivuals with underlying 
chronic disease for which influenza vaccination is recommended. Therefor, the clini-
cal relevance of these criteria is frequently questioned.
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9 Aim and outline of this thesis
The first aim of this thesis was to get a better insight into the benefit of annual 
influenza vaccination in community dwelling elderly immunised as part of the na-
tional influenza vaccination program. For this purpose 4 epidemiological studies 
were conducted in a population of community dwelling elderly which was selected 
and characterised from the IPCI database. These studies are summarised in chapters 
2-5. In this population the impact of annual vaccination on mortality and lower 
respiratory infections was studied. 
A second aim of this thesis was to study the ability of clinical trials performed 
for annual relicensure of influenza vaccines to detect (differences in) the vaccines’ 
immunogenicity of that particular year (chapter 6).
A final aim was to investigate the impact of vaccination on immunological and 
clinical outcomes. For this purpose we performed a meta-analyses described in a 
review in chapter 7.
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Abstract 
Background
Influenza-related morbidity and mortality have been extensively studied with hospi-
tal and reimbursement data. However, little is known about the effectiveness of the 
annual vaccination programs in generally healthy community-dwelling elderly. The 
objective of our study was to investigate the effectiveness of influenza vaccination in 
community-dwelling elderly during the 1996 to 1997 influenza epidemic. 
Methods 
We performed a population-based cohort study using the computerized Integrated 
Primary Care Information database in the Netherlands. Subjects who were 65 years 
and older in 1996 with a permanent status in a practice in the source population 
were considered eligible for study participation. Two cohorts were defined on the 
basis of vaccination status. We estimated and compared all-cause mortality, pneumo-
nia, and clinical influenza infection rates between the cohorts. 
Results 
Influenza vaccination was associated with a significant reduction of morbidity and 
mortality in vaccinated elderly (relative risk [RR], 0.72; 95% confidence interval 
[CI
95%
]: 0.60-0.87). Influenza infections decreased significantly in the vaccinated 
population (RR, 0.48; CI
95%
: 0.26-0.91). Mortality was reduced significantly in elderly 
with comorbidity (RR, 0.67; CI
95%
: 0.48-0.94). The risk reduction for pneumonia was 
nonsignificant (RR, 0.77; CI
95%
: 0.55-1.07) but was temporally related to the peak 
influenza activity. 
Conclusions  
In this study, influenza vaccination was associated with decreased mortality and 
influenza infections in community-dwelling elderly. Our results indicate that, in a 
season of mild influenza activity and good antigenic match between vaccine strains 
and circulating strains, influenza vaccination reduced mortality in the vaccinated 
population. Our data support an annual vaccination strategy for all community-
dwelling elderly.
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Introduction
Epidemics caused by influenza virus are associated with considerable morbidity and 
mortality, especially in patients with high-risk conditions [1, 2]. It has been estimated 
that persons who are 65 years and older account for more than 80% of all pneumonia- 
and influenza-related deaths [3]. In the Netherlands, the excess mortality caused by 
influenza is estimated at more than 2000 persons per year. Generally, the increased 
incidence in influenza-associated mortality is thought to be age related [2]. 
Although seasonal epidemiologic surveillance of influenza infections is standard 
practice, effectiveness of influenza vaccination programs is not evaluated systemati-
cally. In the published literature, morbidity and mortality data are mostly obtained 
from hospital records or reimbursement data or are studied in institutionalized elderly 
[4]. It is likely that institutionalized elderly are less healthy and have a higher risk of 
mortality and influenza-associated morbidity than community-dwelling elderly. Al-
though in healthy adults influenza vaccination has been shown to be effective, this is 
not unequivocally shown in patients with asthma or chronic obstructive pulmonary 
disease [5-7]. 
In general, little is known about the effectiveness of annual influenza vaccination 
programs in community-dwelling elderly. One study addressed the issue during one 
season in a placebo-controlled trial in one general practice [8] and another recent 
study focused on reduction of mortality of patients admitted to the hospital, but did 
not include outpatient morbidity and mortality [9]. The need for more data has been 
expressed before [10]. 
For regulatory purposes, immunogenicity and safety of the yearly produced inac-
tivated influenza vaccines are studied in small-scale, open, uncontrolled trials [11]. 
These trials cannot be considered representative of vaccine effectiveness assessment 
in that particular season or the target population defined by the influenza vaccination 
programs. For clinical protection in defined target populations, the antigenic match 
between vaccine strain(s) and circulating strain(s), vaccination coverage, annual 
revaccination, demographic characteristics, health status, and possible attack rate of 
the population of interest are at least as important as immune responsiveness. 
The influenza season of 1996 to 1997 was of mild severity, with a good match 
between vaccine strain and the predominant circulating strain (A/H3N2/Nan-
chang/933/95). A peak activity of influenza-like illness of 28.8 per 10,000 persons 
was observed in week 4 of 1997, with a distribution in elderly similar to that of the 
general population [12]. 
The objective of the present study was to investigate the effectiveness of influenza 
vaccination in community-dwelling elderly who were 65 years or older during this 
influenza season. 
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Methods
Setting
Since 1992, the Integrated Primary Care Information (IPCI) Project at the Department 
of Medical Informatics of the Erasmus Medical Centre in Rotterdam, the Netherlands, 
monitors a population of approximately 485,000 patients. The IPCI Project gathers 
all medical data from 125 general practitioner (GP) practices, including demographic 
information, patient complaints and symptoms, diagnoses, results of laboratory tests, 
referral notes from consultants, and hospital admissions. The International Clas-
sification for Primary Care is used as the coding system for symptoms and diagnoses 
[13] but these can also be included as free text. In the database, all prescriptions 
are recorded and include drug name, anatomical therapeutical chemical code, dos-
age form, dose, prescribed quantity, and indication. Repeat prescriptions are also 
recorded. As the system is fully automated, no paper records are held concurrently. 
Patient and practice identifiers are omitted to ensure anonymity. The system com-
plies with European guidelines on the use of data for medical research and has been 
shown to be valid for pharmacoepidemiologic research [14]. 
Design and exposure definition
To assess the effectiveness of influenza vaccination, we conducted a retrospective 
cohort study. Persons who were 65 years or older in 1996 with a permanent status 
in one of the practices in the IPCI source population, and who had visited the GP at 
least once during the study period, were considered eligible for study participation. 
The study period ran from September 1, 1996, until June 1, 1997, including a 3-month 
enrolment period and a fixed period of 6 months of follow-up. For every individual 
who had received an influenza vaccination, 1 age- and sex-matched unvaccinated 
control subject was randomly selected. To facilitate age matching, the complete eli-
gible population was split into 5-year categories (65-69, 70-74, 75-79, 80-84, and >84 
years). The index date was defined as the date of vaccine administration and was 
thus the start of follow-up. Data on influenza vaccination were gathered from the 
prescription file (anatomical therapeutical chemical code J07BB) and from free-text 
notifications in individual patient records. Matched controls had the same index date 
as their vaccinated counterparts. 
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Outcome and co-variate definition
All-cause mortality was defined as the primary outcome. Pneumonia and influenza 
infection without pneumonia were defined as secondary outcomes. In the first analy-
sis, all cohort members were followed up until death or the end of the study period. 
In a second analysis, they were followed up until pneumonia, a notification of 
influenza, death, or end of the study period occurred. Influenza was identified by 
International Classification for Primary Care code R80.0 (“proven infection without 
pneumonia”). Four disease clusters were identified as covariates that might act as 
potential confounders: respiratory tract disease (pulmonary emphysema, chronic ob-
structive pulmonary disease, and asthmatic bronchitis); cardiovascular tract disease 
and related diagnoses (heart failure, angina pectoris, hypertension, and diabetes 
mellitus); renal function impairment; and cancer (lung carcinoma, breast carcinoma, 
prostate carcinoma, colon carcinoma, and other types of malignancy). Their baseline 
prevalences were derived from diagnosis codes and free-text searches of all avail-
able medical history preceding the index date. Confounding by indication for these 
clusters was anticipated because high-risk patients might be more readily vaccinated. 
Furthermore, confounding by vaccination status was anticipated because individuals 
who had received an influenza vaccination in the preceding year might have a dif-
ferent health status and might thus have been more readily vaccinated. 
Analyses
For univariate comparisons between proportions we used χ2-statistics with Yates 
correction. All tests were 2-sided with a rejection of the null hypothesis at P<.05. 
Continuous variables were compared with a t-test or a Mann-Whitney test when non-
normally distributed. The incidence rates of events were calculated by dividing the 
number of each event by its corresponding person-time. Incidence rates were com-
pared between exposed and non-exposed subjects and expressed as incidence rate 
ratios with 95% confidence intervals. Confidence intervals for the crude and adjusted 
incidence rate ratios were calculated with a Cox proportional hazards regression 
model. Adjusted estimates for incidence rate ratios were calculated with inclusion 
of all potential confounders at baseline, which were univariately associated with the 
outcome. Subsequently, the cohort was stratified into persons with risk factors at 
baseline and persons with no risk factor at baseline. In these strata, incidence rate 
ratios and the number needed to treat to prevent 1 fatal outcome were calculated. 
Time-to-event analyses were visualized in life tables. To calculate preventive frac-
tions, we used the following formula:
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(IR
controls
 – IR
vaccine
)/IR
controls
, in which IR is the incidence rate. Numbers needed to treat 
were calculated by the following formula:
1/[(1 – e-IRcontrol x follow-up time) – (1 – e-IRvaccine x follow-up time)]. 
Vaccine efficacy was calculated by (1 – RR) x 100%, where RR indicates relative risk.
Results
The IPCI database contained data on 46,610 persons who were 65 years or older in 
1996, of whom 20,967 were eligible for study entry, which means that they had a 
permanent status in one of the practices and had visited the GP at least once dur-
ing the study period. During the enrollment period, 8911 patients had received an 
influenza vaccination (42.5% of the eligible population). From the remaining 12,056 
non-vaccinated elderly, we selected 8,911 age- and sex-matched controls. 
Baseline characteristics of these patients are given in Table 1. Because of the 
matching procedure, the mean age for the vaccinated (vaccine cohort) and non-
vaccinated (control cohort) groups was almost identical. The vaccine and control 
groups, however, differed significantly in baseline prevalence of underlying diseases. 
Chronic respiratory diseases, including emphysema and chronic obstructive pulmo-
nary disease, were 77% more frequent in the vaccine cohort. Heart failure and angina 
pectoris were, respectively, 49% and 31% more frequently noted. Malignancies were 
24% more prevalent in the vaccine cohort. The prevalences of diabetes mellitus 
and hypertension in the vaccine cohort were, respectively, 51% and 11% higher. A 
greater than 2-fold higher prevalence of renal dysfunction was seen, albeit at a low 
background incidence. Overall, the prevalence of any serious comorbidity was 25% 
higher in the vaccine than in the control cohort. There was no substantial difference 
between the vaccine and control cohorts in duration of the comorbidity. In the vac-
cine cohort, 3 times as many individuals had been vaccinated against influenza in 
the preceding year.
Table 2 gives the relative risks of the outcomes of interest in the index and con-
trol cohorts. In the total population, vaccination was associated with a significantly 
lower incidence of pooled events (death, pneumonia, or influenza), all-cause mortal-
ity, and influenza infections, after adjustment for respiratory tract disease, cardiac 
disease, hypertension, diabetes mellitus, renal dysfunction, cancer, and vaccination 
history. Vaccine efficacy for mortality was 24% (CI
95%:
 3%-40%) in the total population 
and 33% (CI
95%
: 6%-52%) in the subpopulation with comorbidity. This meant that, 
in the total population, 1 death was prevented in approximately every 400 vac-
cinated individuals. In the subpopulation with comorbidity, 1 death was prevented 
in approximately every 170 vaccinated individuals. 
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Table 1. Baseline characteristics of the study population
No. (%)
Variable Vaccine cohort (n=8911) Control cohort (n=8911) RR (± CI95%)
Sex
  Male 3589 (40.3) 3589 (40.3%) Reference
  Female 5322 (59.7) 5322 (59.7) 1.0 (0.94-1.06)
Age,y
  65-69 2428 (27.2) 2428 (27.2)
  70-74 2372 (26.6) 2372 (26.6)
  75-79 1954 (21.9) 1955 (21.9)
  80-84 1227 (13.8) 1226 (13.8)
  85-89  651 (7.3)  651 (7.3)
  ≥ 90  279 (3.1)  279 (3.1)
Vaccination year before#
  No 5851 (65.7) 7538 (84.6) Reference
  Yes 2857 (32.1) 906 (10.2) 3.06 (2.86-3.27)
Respiratory system 784 (8.8) 444 (5.0) 1.77 (1.58-1.98)
  Emphysema/COPD 568 (6.4) 342 (3.8) 1.66 (1.46-1.89)
  Asthmatic bronchitis 211 (2.4) 175 (2.0) 1.21 (0.99-1.47)
Cardiovascular system/DM 1484 (16.7) 1039 (11.7) 1.43 (1.33-1.54)
  Heart failure  471 (5.3) 316 (3.5) 1.49 (1.30-1.71)
  Angina pectoris 309 (3.5) 236 (2.6) 1.31 (1.11-1.55)
Cancer 287 (3.2) 232 (2.6) 1.24 (1.04-1.47)
  Lung carcinoma  41 (0.5) 29 (0.3) 1.41 (0.88-2.27)
  Breast carcinoma 104 (1.2) 102 (1.1) 1.02 (0.78-1.34)
  Prostate carcinoma  75 (0.8) 55 (0.6) 1.36 (0.96-1.93)
  Colon carcinoma  70 (0.8) 50 (0.6) 1.40 (0.98-2.01)
Miscellaneous 
  Diabetes mellitus  866 (9.7) 575 (6.5) 1.51 (1.36-1.67)
  Hypertension 1934 (21.7) 1735 (9.5) 1.11 (1.05-1.18)
  Renal dysfunction  38 (0.4) 18 (0.2) 2.11 (1.21-3.70)
No co-morbidity # 5349 (60.0) 6050 (67.9) Reference
Any co-morbidity # 3562 (40.0) 2861 (32.1) 1.25 (1.20-1.30)
  < 1-y history  904 (10.1) 702 (7.9) Reference
  1- < 2-y history  873 (9.8) 771 (8.7) 0.94 (0.88-1.00)
  2- < 3-y history  591 (6.6) 401 (4.5) 1.09 (0.98-1.20)
  3- < 4-y history  300 (3.4) 229 (2.6) 1.01 (0.87-1.18)
  ≥ 4-y history  894 (10.0) 758 (8.5) 0.96 (0.89-1.02)
(#) Less than 1 year history in 1995: 670 persons (3.8%); Co-morbidity: any of the above mentioned types of respiratory-, cardiovascular-, 
malignant- or miscellaneous diseases; history pertains to the earliest notification of one or more of these diseases in the automated 
patient profile 
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Table 2. Crude and adjusted relative risks of death, pneumonia or influenza after influenza vaccination
Outcome Vaccine cohort Control 
cohort
Preventive
fraction(a)
Crude RR 
(CI95%)
Adjusted RR 
(CI95%)
No. rate* No. rate*
Total population
  Any event# 226 5.3 275 6.5 0.226 0.83 (0.69-0.99) 0.72 (0.60-0.87)
  Death 143 3.3 164 3.8 0.132 0.88 (0.70-1.10) 0.76 (0.60-0.97)
  Pneumonia  72 1.6  83 1.9 0.158 0.87 (0.63-1.19) 0.77 (0.55-1.07)
  Influenza  16 0.4  32 0.7 0.429 0.51 (0.28-0.94) 0.48 (0.26-0.91)
With co-morbidity 
  Any event# 122 7.2 115 8.3 0.133 0.86 (0.66-1.11) 0.73 (0.56-0.96)
  Death  75 4.3  76 5.5 0.214 0.79 (0.57-1.09) 0.67 (0.48-0.94)
  Pneumonia  44 2.5  29 2.1 -0.190 1.22 (0.76-1.94) 1.08 (0.66-1.76)
  Influenza   5 0.3  10 0.7 0.571 0.44 (0.15-1.33) 0.37 (0.12-1.17)
Without co-morbidity (**)
  Any event# 104 4.1 160 5.6 0.268 0.74 (0.58-0.95) 0.71 (0.55-0.92)
  Death  68 2.6  88 3.0 0.133 0.89 (0.65-1.23) 0.87 (0.62-1.20)
  Pneumonia  28 1.1  54 1.8 0.389 0.58 (0.37-0.92) 0.56 (0.35-0.89)
  Influenza   11 0.4  22 0.7 0.429 0.56 (0.27-1.16) 0.55 (0.26-1.17)
(#) Any event was defined as either death or pneumonia or influenza whichever came first
(*) Incidence rate expressed as number of cases per 100 patient-years
(a) Preventive fraction calculated as (IRcontrols – IRindex cases)/IRcontrols
($) In the total population and the subpopulation with co-morbidity: adjusted for respiratory tract disease, cardiac disease, hypertension, 
diabetes mellitus, renal dysfunction and vaccination history
(**) In the population without co-morbidity: only adjusted for vaccination history 
Figure 1. Time to event analysis - Pneumonia
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In the subpopulation with comorbidity, vaccination was associated with a signifi-
cant risk reduction of death but not pneumonia. The reduced risk of influenza infec-
tion in this subpopulation was nonsignificant. In the absence of comorbidity, relative 
risks adjusted for revaccination status showed a risk reduction for the pooled events 
and for pneumonia. For the total population, the risk reduction for pneumonia was 
visualized in a life table as the time to event (Figure 1). Risk reduction became 
prominent approximately 2 months after vaccination (i.e., the first weeks of 1997, 
the time of peak influenza activity). 
Finally, effect modification by age and sex is shown in Table 3. Only in the age 
category 65 to 74 years was vaccination associated with a significant reduction of all 
events, and effectiveness decreased with increasing age; in addition, men seemed to 
benefit more than women from influenza vaccination. 
Comment
In our study, influenza vaccination effectively prevented mortality and morbidity 
in elderly under everyday circumstances in a season with a good match between 
vaccine strain(s) and circulating strain(s). Although in individuals with comorbidity, 
influenza vaccination failed to show a protective effect against pneumonia, mortality 
was significantly reduced. It is known that most of the excess mortality caused by 
Table 3. Adjusted relative risks of death, pneumonia or influenza after influenza vaccination, stratified by age and gender
Outcome Adjusted RR* (+/-CI95%)
Males
  Any event# 0.67 (0.52-0.87)
  Death 0.71 (0.51-0.99)
Females
  Any event# 0.79 (0.60-1.03)
  Death 0.83 (0.59-1.16)
65-74 years of age
  Any event# 0.67 (0.49-0.93)
  Death 0.70 (0.43-1.14)
75-84 years of age
  Any event# 0.78 (0.58-1.04)
  Death 0.78 (0.54-1.11)
≥85 years of age
  Any event# 0.76 (0.52-1.09)
  Death 0.88 (0.58-1.33)
(#) Any event was defined as either death or pneumonia or influenza whichever came first 
(*) Adjusted for respiratory tract disease, cardiac disease, hypertension, diabetes mellitus, renal dysfunction and vaccination history 
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influenza and/or pneumonia is attributed to elderly with high-risk conditions [15]. 
Possibly, elderly with an impaired clinical condition die as a result of influenza 
before developing pneumonia, or pneumonia is not recognized because symptoms 
in the elderly may be less prominent. 
Our data suggest that the effectiveness of influenza vaccination declines with age. 
This has also been shown in a randomized, placebo-controlled trial in healthy elderly 
followed up in one GP practice [8]. As in our study, that trial showed a risk reduction 
of approximately 50% in clinical influenza in healthy elderly. Observational cohort 
studies mostly address influenza-related hospital admissions or focus on elderly in 
institutions or with high-risk conditions [4, 16-18]. In a recent large-scale cohort study 
[9] in community-dwelling elderly, a significant risk reduction of hospital admis-
sion–associated mortality was observed. Limitations of that study, however, were that 
outpatient mortality and morbidity were not included and that potentially confound-
ing cofactors were not adjusted for. 
Annual influenza vaccination has been proposed as a strategy to increase effective-
ness [19-20]. In institutionalized elderly, annual revaccination as well as vaccination 
coverage was shown to be the most consistent contributors to survival [21-22]. This 
is supported by evidence from a meta-analysis [23]; however, the evidence has been 
questioned [24]. Also in our study, preliminary assessment of annual revaccination 
appeared to enhance survival, although numbers were too small in the different 
subpopulations to allow for appropriate conclusions. 
Epidemiologic studies under everyday circumstances may suffer from selection 
bias, information bias, and confounding. As GPs play a central role in the Dutch 
health care system and cover the complete population, selection bias was highly un-
likely. Also, information bias was unlikely, since influenza vaccination was recorded 
by computer, the vaccination is supplied almost exclusively by GPs in the Nether-
lands, and the primary outcome “mortality” is difficult to misclassify. Misclassification 
of pneumonia is probably modest; all cases were confirmed radiologically and/or 
microbiologically. However, it is possible that influenza was underestimated in the 
vaccine cohort because physicians were aware of the vaccination status of their 
patients. A potential problem was confounding by indication. Although the national 
recommendation was to vaccinate those who were 65 years and older, generally 
healthy individuals do not always follow such advice. In our study, confounding by 
indication was likely, since pre-existing respiratory or cardiovascular tract disease 
were independent risk factors for increased mortality, as was a history of influenza 
vaccination. These factors were thus adjusted for. As we may not be aware of all co-
morbidity, residual confounding cannot be excluded. However, this probably means 
that our estimates are conservative and that true protection may be higher. 
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In conclusion, our results indicate that, in a season of mild influenza activity and 
good antigenic match between vaccine strain(s) and circulating strain(s), influenza 
vaccination reduces influenza-related morbidity and all-cause mortality in commu-
nity-dwelling elderly. The decrease in mortality was most prominent in elderly with 
high-risk conditions. Vaccine efficacy, calculated as a risk reduction in mortality of 
33% in this subpopulation, could be translated to approximately 170 vaccinated 
individuals to prevent 1 death. Hence, our data suggest that a national policy to vac-
cinate all those who are 65 years and older against influenza can be successful. We 
argue that the assessment of the benefits of annual influenza vaccination programs 
should focus on survival and primary and secondary influenza-related morbidity in 
community-dwelling elderly. Such data may improve the cost-effectiveness estimates 
of influenza vaccination programs, where health care resource use includes GP visits 
and drug use in addition to hospitalizations [25].
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Abstract 
Context  
Although large-scale observational studies have demonstrated the effectiveness of 
influenza vaccination, no large studies have systematically addressed the clinical 
benefit of annual revaccinations.
Objective 
To investigate the effect of annual influenza revaccination on mortality in commu-
nity-dwelling elderly persons.
Design, Setting, and Participants  
A population-based cohort study using the computerized Integrated Primary Care 
Information (IPCI) database in the Netherlands including community-dwelling indi-
viduals aged 65 years or older from 1996 through 2002. For each year, we computed 
the individual cumulative exposure to influenza vaccination since study start. 
Main Outcome Measure  
Association between the number of consecutive influenza vaccinations and all-cause 
mortality vs. no vaccination after adjusting for age, sex, chronic respiratory and 
cardiovascular disease, hypertension, diabetes mellitus, renal failure, and cancer. 
Results  
The study population included 26,071 individuals, of whom 3,485 died during fol-
low-up. Overall, a first vaccination was associated with a nonsignificant annual 
reduction of mortality risk of 10% (hazard ratio [HR], 0.90; 95% confidence interval 
[CI
95%
], 0.78-1.03) while revaccination was associated with a reduced mortality risk of 
24% (HR, 0.76; CI
95%
: 0.70-0.83). Compared with a first vaccination, revaccination was 
associated with a reduced annual mortality risk of 15% (HR, 0.85; CI
95%
: 0.75-0.96). 
During the epidemic periods this reduction was 28% (HR, 0.72; CI
95%
: 0.53-0.96). 
Similar estimates were obtained for persons with and without chronic comorbid-
ity and those aged 70 years or older at baseline. Overall, influenza vaccination is 
estimated to prevent 1 death for every 302 vaccinees at a vaccination coverage that 
varied between 64% and 74%. 
Conclusion  
Annual influenza vaccination is associated with a reduction in all-cause mortality 
risk in a population of community-dwelling elderly persons, particularly in older 
individuals
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Introduction 
Influenza-associated morbidity and mortality increase with age, especially for in-
dividuals with high-risk conditions [1,2]. The estimated impact of annual influenza 
epidemics on morbidity and mortality on elderly persons and the effectiveness of 
influenza vaccination have been the basis for implementing nationwide influenza 
vaccination programs for elderly individuals [3]. 
The effectiveness of vaccination has been reported to decrease in high-risk persons 
[4-7]. Annual influenza revaccination has been proposed as a strategy to increase 
vaccination effectiveness [8-11]. However, clinical studies have not always shown 
a consistent benefit of annual revaccination. In institutionalized elderly persons, 
annual revaccination resulted in improved survival [12-13], whereas, in a placebo-
controlled trial among 1,838 community-dwelling elderly persons, prior vaccination 
did not further reduce the occurrence of clinical influenza [4]. In a trial of healthy 
adults (aged 30-60 years), annual influenza vaccination had no additional effect on 
the risk of clinically diagnosed influenza like illness, although both first vaccination 
and repeat vaccination showed a greater decrease in virus shedding and better an-
nual protection against influenza virus infection compared with placebo [14-15]. In a 
clinical trial among boarding school students, revaccination did not confer any ben-
efit with respect to serologically or virologically confirmed influenza [16]. A recent 
meta-analysis comparing single and multiple vaccinations showed that although 7 of 
10 field trials supported sustained protection against laboratory-confirmed influenza 
like illness upon revaccination, the pooled rate difference of 1.1% was not significant 
[17]. 
Recommendations regarding annual vaccination are often based on the reported 
influenza-attributed mortality and morbidity and effectiveness of vaccination without 
systematic data on revaccination status [18-21]. So far, studies to establish the ef-
fectiveness of repeated influenza vaccinations within the scope of national programs 
have not been performed in a population-based setting. 
Our objective was to investigate the relationship of influenza revaccination status 
on mortality in community-dwelling persons aged 65 years or older during the epi-
demic influenza seasons covering 1996-2002
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Methods 
Setting 
In the Netherlands, a nationwide influenza vaccination program has been active 
since 1997. In the Dutch health care system, all persons are designated to their 
own general practitioner (GP) who files all relevant medical details on patients 
from primary care visits, hospital admissions, laboratory examinations, and visits to 
outpatient clinics. The vaccination program is executed by GPs during annual mass 
vaccination days in October and November, during which all individuals aged 65 
years and older and adults and children with predefined risk factors are invited to 
participate in the vaccination campaign. General Practitioners register the vaccina-
tion date in the electronic patient record. 
Since 1994, the Integrated Primary Care Information (IPCI) Project at the De-
partment of Medical Informatics of the Erasmus Medical Center in Rotterdam, the 
Netherlands, has assembled electronic patient records on a cumulative population 
of approximately 500,000 patients from approximately 150 GPs. The IPCI database 
is a general practice research database that contains information on all medical 
data, including demographic information, patient complaints and symptoms, di-
agnoses, results of laboratory tests, referral notes from consultants, and hospital 
admissions. 
The International Classification for Primary Care is used as the coding system 
for symptoms and diagnoses [22] but these can also be included as free text. All 
prescriptions are recorded in the database, which includes drug name, Anatomical 
Therapeutical Chemical (ATC) code, dosage form, dose, prescribed quantity, and 
indication. The IPCI database is the sole repository of medical records, and no 
additional paper records of the patients are kept by the GPs. Patients and practice 
identifiers are altered to warrant anonymity. The system complies with European 
Commission guidelines on the use of data for medical research and has shown to 
be valid for pharmacoepidemiologic research [6, 23]. The IPCI internal review board 
approved the project and patient consent was not required.
Study population
In the IPCI database 49,818 individuals were 65 years or older at any time during 
the study period. First, we excluded all practices that did not consistently register 
influenza vaccination over the study years. Non-consistent registration was defined 
as a difference between minimum and maximum annual vaccination coverage of 
at least 50% and / or a minimum vaccination coverage recording of less than 25%. 
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After exclusion, 34,991 persons remained. In this remaining study population, we 
conducted a cohort study during the period between October 1, 1996, and Septem-
ber 30, 2002. 
We included patients who were 65 years or older on January 1 of the year of study 
start, who had a permanent status in 1 of the practices in the IPCI source population, 
and who had at least 1 year of recorded database history prior to study start to deter-
mine heath status and vaccination status. We excluded 8,920 individuals who did not 
have a recorded database history in the GP practice of 1 year or more. The eligible 
population thus included 26,071 persons. Censoring was performed at death, moving 
out of the GP practice, or at the end of the study period, whichever came first. 
Exposure definition 
The cumulative number of influenza vaccinations was determined between October 
1 and December 31 of each calendar and was assigned to each individual on January 
1 of the next year. This date was chosen to compensate for the slight variability in 
vaccination dates, mostly between late October and early December, and the lag 
time before vaccination becomes effective. (An additional analysis using actual date 
of vaccination did not substantively affect the results.) 
Exposure status was categorized into 9 mutually exclusive categories including 
non-exposed, first vaccination, second, third, fourth, fifth, and sixth (or seventh) 
vaccination, vaccination interruption, and restart. A first vaccination status was as-
signed to individuals who received the first vaccination after study entry with no 
recorded influenza vaccination prior to study entry. If persons were vaccinated prior 
to study entry they started with the number of previously recorded vaccinations. 
Upon each additional consecutive vaccination during the study period, the cumula-
tive number of influenza vaccinations increased by one. When a vaccination series 
was interrupted, it was categorized as such. Finally, restart after 1 or more years 
of interruption was also categorized separately. Once in the interruption category, 
individuals remained in it until vaccination restart and vice versa. Consequently, in 
this time-varying approach of exposure analysis, individuals contributed information 
to different exposure categories during follow-up.
Outcome definition 
The primary outcome in this study was all-cause mortality. Death was identified from 
the demographic patient file and validated in the medical chart. Deaths occurring 
during the period January 1 and December 31 were allocated to the vaccination sta-
tus defined in the period between October 1 and December 31 of the preceding year. 
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In an extra analysis, we compared mortality during the epidemic periods (defined as 
the first day of the first week of the recorded epidemic until the last days of the last 
week of the recorded epidemic) with a reference period during the summer months 
(July and August).
Co-variates 
Selection of covariates was based on an earlier study from our group in the same 
database [6]. In addition to age, sex, and epidemic year, we identified 6 disease clus-
ters as potential confounders: chronic respiratory tract disease (chronic obstructive 
pulmonary disease, emphysema, chronic bronchitis, asthma); chronic cardiovascular 
disease (heart failure, angina pectoris, history of myocardial infarction or cerebro-
vascular accident, aortic aneurysm, chronic arterial dysfunction); hypertension; dia-
betes mellitus; chronic renal insufficiency; and malignancies. The presence of these 
conditions at study entry or their development at any time during follow-up was 
retrieved from the medical charts through automatic screening and further manual 
validation. Those who had no comorbidity at baseline and did not develop any 
of the predefined conditions during follow-up were considered as the population 
without comorbidity. 
Information on the size of each influenza epidemic was obtained from Jan C. de 
Jong, PhD, of the National Influenza Center, Erasmus MC Rotterdam (written com-
munication, August 21, 2003, and March 5, 2004) [24]. 
Analyses 
To estimate the univariate association between vaccination, covariates, and death we 
used a Cox proportional hazards model. Multivariate time-varying Cox proportional 
hazard models were developed to estimate the hazard ratios (HRs) for different 
vaccination states while adjusting for all other risk factors [25]. In most analyses the 
non-exposed category was used as reference category. For the estimation of the 
HRs of revaccination vs. first vaccination, the first vaccination was used as reference 
category. To fully adjust for the strong influence of age on death in this analysis, we 
used age in days as time axis. The exposure status of an individual on the date of 
death was compared with all individuals in the cohort on that moment during fol-
low-up on which they had exactly the same age as the individual who died. We also 
adjusted for sex and for time since the beginning of the study to adjust for epidemic 
year. To adjust for comorbidity that occurred during follow-up, time-dependent co-
variates were used for the diseases defined above. 
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The association of vaccine exposure with mortality risk was evaluated in 3 analyses: 
any vaccination vs. no previous vaccination; a first vaccination, revaccination, inter-
ruption, and restart vs. no vaccination; and any revaccination vs. a first vaccination. 
Subsequently, revaccination was further analyzed by second, third, fourth, fifth, and 
sixth or seventh vaccination. 
Stratified analyses were conducted on the presence of comorbidity and age at 
study entry (65-69, 70-79, or >79 years). 
All results were expressed as HRs with 95% confidence intervals (CI
95%
). In the total 
population, numbers needed to vaccinate to save 1 death were calculated as: 
1/[(1–e-IRcontrol x follow-up time]–[1–e-IRindex x follow-up time]), where IR is the incidence rate.
All analyses were performed using SAS software, version 8.2 using the procedure 
Proc Phreg. Statistical significance was set at P<0.05.
Results 
Baseline characteristics of the population and univariate associations of covari-
ates with all-cause mortality are provided in Table 1. Of the 26,071 persons who 
were eligible for study entry, 3,485 died during follow-up. The mean duration 
of participation in the study was 3 years. The mean (SD) age at study entry was 
73.1 (7.4) years and 58% were women. At baseline 53.3% of the population had 
some form of comorbidity, mostly hypertension (24.6%) and chronic cardiovascular 
diseases (23.4%). Mortality was strongly associated with age, sex, and comorbidity. 
The mortality rate was highest for individuals with chronic renal dysfunction or 
malignancies. 
The vaccination coverage and vaccination status for each study year are shown 
in Table 2. During the total study period, the population studied received 62,476 
influenza vaccinations. Ninety-six percent of the vaccinations were given in October 
or November, and 3.6% in December. The annual vaccination coverage ranged from 
64% in 1996 to 74% in 1999. A total of 5,095 eligible individuals (19.5%) never 
received influenza vaccination during follow-up. 
Influenza epidemics during the study period were of mild to moderate sever-
ity (Table 3); the 2000-2001 season showed no clear epidemic activity. Generally, 
vaccine strains and the predominant circulating strain (mainly A/H3N2) were well 
matched except for the 1997-1998 season [24]. The peak activity of influenza like 
illness ranged between 7 cases per 10,000 persons (2000-2001 season) and 32 cases 
per 10,000 persons per week (1999-2000 season) and was observed between weeks 
2 and 13. 
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In the total population, any vaccination was associated with a 22% lower risk of 
all-cause mortality (adjusted HR, 0.78; CI
95%
: 0.72-0.85; Table 4). First vaccination 
was associated with a nonsignificant reduction in mortality risk of 10% in the total 
population (adjusted HR, 0.90; CI
95%
: 0.78-1.03). Any revaccination was associated 
with a risk reduction of approximately 24% (adjusted HR, 0.76; CI
95%
: 0.70-0.83), 
which was strongest during the epidemic period (adjusted HR, 0.72; CI
95%
: 0.59-0.89) 
and was not significant during a reference summer period (July and August; adjusted 
HR, 0.89; CI
95%
:0.70-1.12). 
Table 1: Characteristics of the study population at study entry
No. (%)
Variable
Population 
characteristics
at study entry
Deaths in
Follow-up
Risk of dying during 
follow-up
(n=26071) (n=3485) Univariate HR (CI95%)
Sex
 Female 15131 (58.0) 1818 (12.0) Reference
 Male 10940 (42.0) 1667 (15.2) 1.27 (1.19-1.35)
Age, y
 65-69 10490 (40.2)  537 (5.1) Reference
 70-74  5863 (22.5)  608 (10.7)
 75-79  4669 (17.9)  747 (16.0)
 80-84  2761 (10.6)  686 (24.8) 1.77 (1.73-1.81)
 ≥ 85  2288 (8.8)  907 (39.6)
Year of study entry
 1996 10195 (39.1) 2089 (20.5) Reference
 1997  1325 (5.1)  142 (10.7) 
 1998  4667 (17.9)  493 (10.6) 
 1999  7178 (27.5)  664 (9.3) 0.66 (0.65-0.68)
 2000  1528 (5.9)   70 (4.6) 
 2001  1178 (4.5)   27 (2.3) 
Co-morbidity
None at study entry 12173 (46.7) 1034 (8.5) Reference
Co-morbidity at study entry# 13898 (53.3) 2451 (17.6) 2.15 (2.00-2.31)
 Hypertension  6414 (24.6)  837 (13.0) 0.94 (0.87-1.01)
 Diabetes mellitus  3000 (11.5)  583 (19.4) 1.59 (1.46-1.74)
 Respiratory system  3487 (13.3)  689 (19.8) 1.69 (1.57-1.84)
 Cardiovascular system  6099 (23.4) 1378 (22.6) 2.30 (2.15-2.46)
 Cancer  1034 (4.0)  330 (31.9) 2.81 (2.50-3.15)
 Renal dysfunction   221 (0.8)   87 (39.4) 3.41 (2.75-4.21)
Abbreviations: CI95%: 95% confidence interval; HR: Hazard ratio
(#) During the follow-up period comorbidity developed in another 2903 individuals resulting in a total of 16701 subjects with comorbidity at 
baseline or any time during follow-up. 
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Compared with a first vaccination, revaccination was associated with a significantly 
reduced mortality risk of 15% (adjusted HR, 0.85; CI
95%
: 0.75-0.96). During the epi-
demic period this risk reduction was 28% (HR, 0.72; CI
95%
: 0.53-0.96). 
When each individual vaccination was modelled separately, the mortality risk 
showed a decreasing trend with additional consecutive vaccinations (Figure). Inter-
ruption of the vaccination series was associated with a strong and significant increase 
in mortality risk (adjusted HR, 1.25; CI
95%
: 1.10-1.42). When the vaccination series 
was interrupted for more than 1 year, this risk estimate increased further, although it 
was no longer significant (adjusted HR, 1.83; CI
95%
: 0.94-3.78). Restarting vaccination 
after an interruption resulted in a mortality risk reduction similar to that observed 
following revaccination. 
Table 2: Vaccination coverage and vaccination status per influenza epidemic season 
1996-1997 1997-1998 1998-1999  1999-2000   2000-2001  2001-2002#
Eligible population*
Total      10195     10991     14302      19676      17234      16590
With comorbidity       5445      6382      8532      11721      10571      10426
Total died        487       490       647        821        711        329
Vaccination coverage, No. (%)*/**
Not vaccinated 3655 (35.9) 3676 (33.4) 4608 (32.5)  5130 (26.1)  4567 (26.5)  4831 (29.1)
Vaccinated 6540 (64.1) 7315 (66.6) 9694 (67.5) 14546 (73.9) 12667 (73.5) 11759 (70.9)
With comorbidity 3906 (71.7) 4664 (73.1) 6245 (73.2)  9249 (78.9)  8218 (77.9)  7894 (75.7)
Vaccination status
No vaccination       3655      2707      3130       4020       3114       2955
      1st       3030      1497      1061        849        824        395
     2nd ##       3510      2661      3181       5477       1106        969
     3rd           -      3157      2390       2783       4361        996
     4th           -           -      2832       2175       1667       3937
     5th           -           -           -       2595       1588        930
    6th or 7th           -           -           -            -       2123       3284
   Interrupted           -       969      1523       1110       1453       1876
   Restarted           -           -       185        667        998       1248
Abbreviations: Elllipses indicate no data
(#) Follow up in the 2001-2002 season ended in September. 
(*) With comorbidity at baseline; a proportion of subjects developed comorbidity during follow-up (see table 3)
(**) Percentage in parentheses indicates the proportion of subjects with comorbidity being vaccinated 
(##) May also include multiple vaccinations of subjects who only had 1-year history available before study entry and who were vaccinated in 
that year. For these subjects, it is not known if they had any previous vaccinations. 
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every 195 revaccinations. 
Exclusion of the population with a history of vaccinations prior to study entry did 
not change the effect estimates (data available on request). Stratification for comor-
bidity showed that the largest effects following any vaccination and revaccination 
were observed in the subpopulation without comorbidity (Table 4). Revaccination 
was not associated with a reduction in mortality risk in persons aged 65 through 69 
years at baseline (adjusted HR, 0.98; CI
95%
: 0.78-1.23) but was significantly reduced 
in persons aged 70 through 79 years at baseline (adjusted HR, 0.78; CI
95%
: 0.68-0.91), 
and persons aged 80 years and older at baseline (adjusted HR, 0.69; CI
95%
: 0.61-
0.78). 
This age-related difference following revaccination seemed to reflect age-related 
differences in causes of death. In the highest age groups, relatively more individuals 
died from causes that may be more likely to be influenced by influenza vaccination, 
such as infectious causes (HR following vaccination, 0.58; CI
95%
: 0.43-0.79) or old age 
or “frailty” (HR following vaccination, 0.63; CI
95%
: 0.55-0.73; Table 5). 
We assessed the possibility of confounding by indication, ie. the possibility that 
those who were not vaccinated were sicker than those who were. However, in our 
population, the proportion of the population with comorbid illnesses was 50.9% for 
those with no previous vaccination, 55.8% for those who refused (34% of all those 
who were not vaccinated), 68.9% for those who had an interruption, and 68.5% 
Table 3: Epidemiological characteristics of the influenza epidemic seasons*
Vaccine strains Pre-
dominant 
epidemic 
strain(s)
Anti-
genic 
match#
Epidemic period
(weeks)
A/H3N2 A/H1N1 B
Start Peak End
Peak 
ILI$
1996-1997 Wuhan/353/95 Singapore/6/86 Beying/184/93 A/H3N2 +++  2  4  8 29
1997-1998 Wuhan/353/95 Bayern/7/95 Beying/184/93 A/H3N2     +  8 13 15 18
1998-1999 Sydney/5/97 Beying/262/95 Beying/184/93 A/H3N2 +++  6  8 11 22
1999-2000 Sydney/5/97 Beying/262/95 Beying/184/93 A/H3N2 +++ 51  2  5 32
2000-2001 Moscow/10/99 N.Caladonia/20/99 Beying/184/93 B +++  1  4  8  7
2001-2002 Moscow/10/99 N.Caladonia/20/99 Sichuan/379/99 A/H3N2 +++  2  9 12 13
Information in this Table was provided by Jan D de Jong, PhD. 
N.Caledonia indicates New Caledonia
(#) +: indicates poor match (some cross protection); ++: fair match (moderate cross protection); +++: good match (substantial cross 
protection); ++++: excellent match (identical strains or minimal differences) [21]
($) Influenza like illness (ILI) was defined as prodromal phase with feverishness plus at least one of the following symptoms: cough, coryza, 
soar throat, frontal headache, retrosternal pain, myalgia.
(*) peak ILI denotes the maximum number of cases of ILI per week per 10,000 inhabitants in the Netherlands as reported by the GPs 
participating in the Continuous Morbidity Registration system of NIVEL (Netherlands Institute for Primary Health Care) during the peak of  
the epidemic
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Table 4: Annual adjusted hazard ratios of death, stratified by comorbidity and age
HR (+/-CI95%)
Deaths Crude Adjusted*
No. of cases
Total population
 Any vaccination 2225 0.91 (0.84-0.99) 0.78 (0.72-0.85)
 First vaccination  284 0.97 (0.85-1.12) 0.90 (0.78-1.03)
 Revaccination 1941 0.90 (0.83-0.98) 0.76 (0.70-0.83)
 Vaccination interruption  366 1.43 (1.26-1.62) 1.25 (1.10-1.42)
 Vaccination restart  121 0.91 (0.75-1.11) 0.81 (0.67-0.99)
Population without co-morbidity#
First vaccination   47 0.86 (0.62-1.18) 0.84 (0.60-1.16)
Revaccination  217 0.66 (0.54-0.80) 0.66 (0.54-0.80)
Population with co-morbidity
First vaccination  237 0.91 (0.78-1.06) 0.88 (0.76-1.03)
Revaccination 1724 0.82 (0.75-0.90) 0.75 (0.68-0.83)
Age at baseline
65-69 years
 First vaccination   56 1.20 (0.87-1.66) 1.11 (0.81-1.53)
 Revaccination  300 1.25 (1.00-1.56) 0.98 (0.78-1.23)
70-79 years
 First vaccination  109 1.02 (0.81-1.28) 0.93 (0.75-1.17)
 Revaccination  803 0.95 (0.83-1.10) 0.78 (0.68-0.91)
≥ 80 years
 First vaccination  119 0.87 (0.70-1.07) 0.81 (0.66-1.00)
 Revaccination  838 0.78 (0.69-0.88) 0.69 (0.61-0.78)
(*) Adjusted for comorbidity (respiratory tract disease, cardiac disease, hypertension, diabetes mellitus, renal dysfunction and malignancy) and 
gender. Age adjustment by age in days as time axis.
(#) Population without co-morbidity:  No recorded predefined present at comorbidity at baseline or developing at any time during follow up. 
for those who had any vaccination in series, suggesting that those who were not 
vaccinated were at least as healthy as those who were. Furthermore, compared with 
nonusers who refused vaccination, the adjusted mortality risk following the first 
vaccination was an HR of 1.09 (CI
95%
: 0.93-1.28) and following revaccination, an HR 
of 0.93 (CI
95%
: 0.83-1.04). Compared with those who were not vaccinated and did not 
refuse, the adjusted HR for mortality following the first vaccination was 0.73 (CI
95%
: 
0.63-0.85) and following any revaccination, 0.62 (CI
95%
: 0.56-0.70). 
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Figure. Hazard ratios for mortality by individual vaccination states stratified by population 
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Mortality risk is shown by the number of successive vaccinations, i.e. first, second, third, fourth, fifth, more then 6, interruption of vaccination 
(stop) or restart. The hazard ratio indicates the mortality risk following vaccination versus no previous vaccination.
Table 5: Annual adjusted hazard ratios of cause- specific death
Adjusted Hazard Ratio* ± CI95%
Cause of death
No.
age at death
mean (SD)
Any vaccination First vaccination Revaccination
Overall 3485 81.5 (8.1) 0.78 (0.72-0.85) 0.90 (0.78-1.03) 0.76 (0.70-0.83)
Cardiovascular  726 82.1 (7.9) 0.89 (0.73-1.08) 0.89 (0.65-1.23) 0.89 (0.73-1.08)
Chronic respiratory disease  180 80.1 (7.5) 1.13 (0.71-1.79) 1.30 (0.67-2.51) 1.11 (0.70-1.77)
Malignancies  549 77.8 (7.4) 0.87 (0.71-1.08) 0.96 (0.68-1.33) 0.85 (0.68-1.05)
Infections  249 84.2 (7.5) 0.58 (0.43-0.79) 0.56 (0.31-1.00) 0.58 (0.43-0.79)
Diabetes mellitus   33 82.2 (8.9) 1.98 (0.60-6.58) 1.51 (0.25-9.14) 2.02 (0.60-6.76)
Renal insufficiency   34 80.0 (7.2) 1.23 (0.41-3.68) 2.25 (0.55-9.20) 1.11 (0.36-3.38)
“Natural death” 1087 83.8 (8.2) 0.63 (0.55-0.73) 0.83 (0.65-1.05) 0.61 (0.52-0.70)
Acute death  458 79.2 (7.2) 0.82 (0.65-1.03) 1.05 (0.73-1.50) 0.79 (0.62-1.00)
Unnatural causes  169 79.8 (8.3) 1.11 (0.73-1.67) 1.02 (0.53-1.98) 1.12 (0.73-1.70)
(*) Adjusted for comorbidity (respiratory tract disease, cardiac disease, hypertension, diabetes mellitus, renal dysfunction and malignancy) and gender. 
Age adjustment by age in days as time axis.
Cardiovascular: Cerebro-vascular accident, heart failure, cardiac asthma
Chronic respiratory: empfysema, ARDS, exacerbation COPD, respiratory failure
Infections: pneumonia, sepsis, septic shock, urosepsis
Natural death: Alzheimer, Parkinson’s disease, no specific diagnosis, decubitus, “natural death”, old age with other no obvious reason
Acute death: validated sudden cardiac death retrieved from other study in same patient population, found dead without pre-exiting cause
Unnatural causes: euthanasia, “unnatural death”, accident, post operative death, preoperative death, dehydration, Creutzfeld Jacobs disease, 
 gastro-intestinal bleeding, murder, 
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Comment
In this study, we showed that influenza vaccination is associated with a reduced risk 
of mortality in community dwelling elderly despite several mild epidemic seasons, 
and that revaccination is an effective strategy to further reduce or sustain reduced 
mortality risk in both healthy elderly individuals and in those with underlying chronic 
disease. In our population, annual revaccination was associated with a significant 
mortality reduction among those aged 70 years and older. This result may reflect dif-
ferences in age-related causes of death, which probably were less influenced by vac-
cination in those at a younger age than those in the highest age groups. Additionally, 
the observed lack of effect in the youngest age categories may be a result of a lower 
baseline risk of death. Interruption of yearly influenza vaccination was associated 
with a significantly increased mortality, but after restarting vaccination, mortality 
risk reduced again to a revaccination status level. Absence of protection from the 
vaccination may be an explanation for the observed risk increase, since individuals 
who interrupted vaccination for 2 or more consecutive years had a further increase 
in mortality risk. 
Although a protective association between mortality and revaccination status in el-
derly persons has been suggested previously, only 1 case-control study has examined 
this association. In this study, a previous vaccination significantly increased vaccine 
effectiveness in the next season [9]. However, the study was not population-based; 
approximately half of the individuals were institutionalized. Nichol et al [7, 19] and 
Hak et al [5] studied the effect of influenza vaccination on long-term outcomes 
but did not take revaccination status into account. Gross et al. [20] published a 
meta-analysis on mortality risk in 20 cohort studies. Based on the current study, the 
large variability in effects identified by Gross et al. might be explained by different 
revaccination states, variations in epidemic activity, and population characteristics. 
It has also been proposed that variability of revaccination efficacy might be due to 
antigenic differences among the vaccine and epidemic strains [26]. Our study did not 
find an effect of first vaccination, but past studies and our previous study in the same 
database found a significant protective effect [6]. 
Our study has several strengths. We were able to assess the overall annual and 
epidemic effectiveness of annual influenza vaccinations as well as the effect of in-
dividual revaccinations. The study was population-based and less subject to selec-
tion bias, information bias, and confounding. In the Dutch health care system, all 
individuals are designated their own GP, so selection bias is unlikely. Information 
bias may have occurred if the vaccination was not recorded. However, such misclas-
sification would likely be random because exposure is prospectively recorded before 
death occurred. Such random misclassification would tend to reduce the size of the 
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estimate, suggesting that the real protective effect could be even greater. All-cause 
mortality was chosen as an end point because it is an important outcome, which 
cannot be misclassified. Deaths were unlikely to have been missed since death rates 
in IPCI were similar to national data on mortality. As discussed above, confounding 
by indication is possible but in this study, comorbidity and a higher risk of mortality 
would be an indication for vaccination, reducing the likelihood of confounding 
as an explanation for the observed effect. Moreover, perceived good health has, 
among others, been reported as a reason for non-compliance with the influenza 
vaccination program [27]. Indeed, compared with those refusing vaccination, mor-
tality risk was not reduced following a first or revaccination. However, excluding 
those who refused vaccination from the reference category resulted in a significant 
adjusted risk reduction following a first and revaccination. In addition, we adjusted 
for chronic respiratory tract disease, cardiovascular disease, hypertension, diabetes 
mellitus, malignancies, and chronic renal insufficiency, either pre-existing or having 
developed during follow up, because they were both indications for vaccination and 
independent risk factors for mortality. Even if some residual confounding by indica-
tion cannot be excluded, a poorer prognosis in individuals who were vaccinated 
would mean that our results would tend to underestimate the protective effect of 
annual revaccination [25]. 
In summary, our study shows that annual revaccination against influenza in a 
population of community-dwelling elderly persons is associated with a reduction of 
mortality risk. This study supports the recommendation for yearly influenza vaccina-
tion for elderly individuals, not only for those with comorbid illness but also in those 
without comorbidity and in patients 80 years or older. Because influenza vaccination 
is inexpensive and safe, clinicians should recommend annual influenza revaccination 
for such patients.
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Abstract
Context
Influenza infections are associated with an increased risk of acute cardiac events. An 
effect of influenza vaccination on the risk of sudden cardiac death (SCD) has been 
suggested, but has not been systematically studied. 
Objective 
We investigated the effect of a first influenza vaccination and revaccination on SCD 
in community dwelling elderly. 
Design and setting 
We performed a population-based cohort study using the computerized Integrated 
Primary Care Information (IPCI) database in the Netherlands in subjects aged 65 
years or older during the period 1996 through 2002. For each year, the cumulative 
exposure to influenza vaccination since study entry was computed. 
Population
Community dwelling elderly aged 65 years or older on January 1st of the year of 
study entry. 
Main outcome measure
The risk of SCD after a first vaccination or a revaccination was compared to no vac-
cination using a time-varying multivariate Cox-proportional hazard model, adjusted 
for age, gender, smoking and underlying chronic disease. 
Results 
The study population comprised 23,977 persons in whom we identified 267 cases 
of sudden cardiac death. Overall, any influenza vaccination or revaccination was 
associated with a non-significant risk reduction of SCD. A significant 2-3 times higher 
risk of SCD following a first vaccination was observed, in the subjects without co-
morbidity and those with baseline age<70 years. In comparison to a first vaccination, 
revaccination was associated with a hazard ratio of 0.53 (CI
95%
: 0.36-0.77).
Conclusions 
This study supports a protective benefit of influenza revaccination on the risk of 
sudden cardiac death in a population of community dwelling elderly. The observed 
increased risk following a first vaccination requires further study.
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Introduction
Cardiovascular morbidity and mortality, particularly acute myocardial infarction, 
stroke and sudden cardiac death show seasonal variation, with peak incidences 
during winter months [1-5]. Clinicians have long noticed that approximately 30% 
of myocardial infarctions are preceded by an upper respiratory tract infection and 
influenza activity has been suggested as an explanation for the winter peak of myo-
cardial infarctions [6]. Sudden Cardiac Death (SCD) has been suggested as a pos-
sible complication following influenza virus infection [2]. Influenza virus has been 
isolated from myocardial tissues of individuals who died from SCD and SCD cases 
were found to have a significantly higher proportion of influenza infection than did 
matched controls [7, 8]. 
In line with these observations, a significantly decreased risk of all cause mortal-
ity, death from cardiovascular causes and cardiovascular hospitalisations has been 
reported following influenza vaccination [1, 4, 9-11] . Given the increased risk of SCD 
following an influenza infection, and the decreased mortality following influenza 
vaccination it was hypothesized that influenza vaccination may also protect against 
SCD. 
To investigate the association between influenza vaccination and the risk of sud-
den cardiac death we performed a cohort study in community dwelling elderly aged 
65 years or older during the epidemic influenza seasons covering 1996-2002. 
Methods
Setting
In the Netherlands, a nationwide influenza vaccination program has been active 
since 1997. The vaccination program is executed by GPs during annual mass vac-
cination days in October and November, during which all individuals aged 65 years 
and older and adults and children with predefined high risk factors are invited to 
participate in the vaccination campaign free of charge. General practitioners (GPs) 
register the vaccination in the electronic patient record. 
All data for this study were retrieved from the Integrated Primary Care Information 
(IPCI) project, a longitudinal observational database, containing data from computer-
based medical patient records from a group of 150 GPs in the Netherlands. In the 
Dutch health care system, the GP has a pivotal role by acting as a gatekeeper for 
all medical care. Nearly every citizen is registered with a GP. Details of the database 
have been described elsewhere [12, 13]. Briefly, the database contains the complete 
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medical records on approximately 530,000 citizens. The electronic records contain 
anonymous data on demographics, symptoms (in free text), diagnoses (using the 
International Classification for Primary Care and free text) from GPs and special-
ists, referrals, laboratory findings, hospitalisations, and drug prescriptions, including 
their indications and dosage regimen. To maximise completeness of the data, GPs 
participating in the IPCI project are not allowed to maintain a system of paper-based 
records besides the electronic medical records. The IPCI project complies with Euro-
pean Union guidelines on the use of medical data for medical research and has been 
proven valid for pharmaco-epidemiological research in several validation studies 
that evaluated the quality of the available information [12]. The Scientific and Ethical 
Advisory Board of the IPCI project approved this study.
Source population
The source population comprised all subjects of 65 years and older, who were 
registered with a GP who participated in the IPCI project for at least 1 year and who 
registered vaccinations in the electronic patient record. GPs with inconsistent regis-
tration, defined as a vaccination coverage of <25% or a variation of the coverage rate 
of ≥50% over the years, were excluded. The study period started on October 1, 1996 
and ended on September 30, 2002. All subjects were followed until death, transferral 
out of practice, date of last data draw down or end of the study period, whichever 
came first. Individuals with a history of malignancies were excluded. 
Exposure definition
The exposure of interest was influenza vaccination. The cumulative number of influ-
enza vaccinations was determined between October 1st and December 31st of each 
calendar year. Exposure status was categorized into 3 mutually exclusive categories 
including non-exposed (non-vaccinated or vaccination refusal), 1st vaccination, and 
revaccination (any subsequent vaccination). A first vaccination status was defined 
as a first vaccination after study entry with no recorded influenza vaccination prior 
to study entry. Persons who were vaccinated prior to study entry were classified as 
being revaccinated. When a vaccination series was interrupted, it was categorised 
as such. Finally, restart after one or more years of interruption was also categorised 
separately. Once in the interruption category, subjects stayed in it until vaccination 
restart and vice versa. Consequently, in this time-varying approach of exposure, indi-
viduals contributed information to different exposure categories during follow-up. 
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Case definition
The computerized medical and demographic data were screened for deaths that 
occurred during the study period. The medical records of identified cases of death 
were reviewed manually to assess whether death could be classified as sudden 
cardiac death. Validation was performed independently by two physicians who 
were blinded to exposure (SMJMS, GSB) and in case of discrepancy, a third expert 
(BHChS) arbitrated. Case assessment was based on the most recent definition of 
sudden cardiac death [14, 15]. Cases were classified as (probable) sudden cardiac 
death if the medical record indicated that death occurred within one hour after the 
onset of cardiovascular symptoms and if the following wording was found in the free 
text: “sudden cardiac death”, “acute cardiac death”, “mors subita”, “sudden death”, 
“died suddenly”, “died unexpectedly“, or if this was an unwitnessed, unexpected 
death of someone seen in “good health” or in a stable medical condition less than 
24 hours previously and without evidence of a non-cardiac cause (e.g., pneumonia, 
convulsion, choking or stroke). Suicides were excluded. 
Deaths were allocated to the most recent vaccination status. 
Co-variates and risk factors
Known risk factors for sudden cardiac death and other co-variates were gathered from 
the medical records through computerised searches and manual assessment. The co-
variates that were evaluated included age, gender, smoking, chronic respiratory tract 
disease (chronic obstructive pulmonary disease, emphysema, chronic bronchitis, 
asthma); chronic cardiovascular disease (heart failure, angina pectoris, status after 
myocardial infarction or cerebro-vascular accident, aortic aneurysm, chronic arterial 
dysfunction), hypertension, diabetes mellitus and chronic renal insufficiency.
The presence of these conditions at study entry or their development at any time 
during follow-up was included in the analysis. The population without co-morbidity 
were those who had no co-morbidity at baseline and did not develop any of the 
predefined conditions during follow-up. Information on the size and timing of each 
influenza epidemic was obtained from Dr. JC de Jong of the National Influenza 
Center, Erasmus MC Rotterdam. 
Statistical analysis
The association between influenza vaccination and sudden cardiac death was esti-
mated by using multivariate time varying Cox proportional hazard models. To fully 
adjust for the strong influence of age on death, we used age in days as time axis. The 
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exposure status of a subject on the date of the sudden cardiac death was compared 
to all subjects in the cohort, who at that moment in follow-up had exactly the same 
age as the subject who died. 
Over the complete follow up period, we investigated the effect of vaccine expo-
sure on the risk of sudden cardiac death in 3 analyses: firstly, any vaccination (1st or 
revaccination) versus no vaccination. Secondly the effects of a first vaccination or 
revaccination versus no previous vaccination were assessed and finally any revac-
cination versus a first vaccination. 
Co-variates that were univariately associated with SCD (at a p<0.1 level) were 
included in the models. We investigated potential effect modification of the presence 
of co-morbidity, and age. 
Subsequently, we performed several sub-analyses related to the time and to vaccine 
refusers. First, we compared the risk of sudden cardiac death during the epidemic 
season (defined as the first day of the first week of the recorded epidemic until the 
last days of the last week of the recorded epidemic (details were reported elsewhere) 
[9]. Second, we studied the association between influenza vaccination and sudden 
cardiac death in the period between the individuals’ vaccination date and the start of 
the epidemic (pre-epidemic season). Finally, we investigated the risk of sudden car-
diac death in the remaining period between the last day of the epidemic season until 
the individuals’ vaccination date of the next year (post-epidemic period). We also 
investigated whether the effect of vaccination on the risk of SCD differed between 
vaccine refusers and other non-users. 
All analyses were performed with SAS software, version 8.2 using the procedure 
Proc Phreg. 
Results
In the study population of 23,977 persons, we identified 267 cases of sudden cardiac 
death. The mean age at baseline was 73.0 years and 41% of the population was male. 
Cases of SCD had a mean age at baseline of 75.9 years and approximately 51% was 
male (table 1). Known potential risk factors for SCD, notably chronic cardiovascular 
disease, chronic respiratory disease, hypertension and diabetes mellitus were all 
associated with an increased risk (table 1).
In the overall population, influenza vaccination was associated with a non-signifi-
cant 12% reduction in SCD risk which increased to a non-significant 21% following 
revaccination (table 2). A first vaccination was associated with a non-significant 50% 
increase in SCD risk (HR, 1.50; CI
95%
: 0.98-2.32). Compared to a first vaccination the 
risk of SCD following revaccination was 0.53 (CI
95%
: 0.37-0.77).
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Table 1: Characteristics of the study population 
No. (%)
Variable
Population
characteristics
at study entry
(n=23977)
SCD at
follow up
(n=267)
Risk of SCD
during follow up,
univariate HR (± CI95)
Gender
 Female 14101  (58.8) 131  (49.1) Reference
 Male  9876  (41.2) 136  (50.9) 1.74 (1.39-2.22)
Baseline age, y
 65-69  9764  (40.7)  53  (19.8) Reference
 70-79  9583  (40.0) 131  (49.1) 2.52 (1.83-3.46)
 ≥ 80  4630  (19.3)  83  (31.1) 3.30 (2.34-4.65)
Co-morbidities
 No co-morbidity 11711  (48.8)  52  (19.5) Reference
 Co-morbidity # 12266  (51.2) 215  (80.5) 2.07 (1.53-2.81)
  Cardiovascular disease  5553  (23.2) 161  (60.3) 1.98 (1.54-2.54)
  Hypertension  5860  (24.4)  86  (32.2) 1.09 (0.84-1.43)
  Diabetes mellitus  2729  (11.4)  68  (25.5) 2.15 (1.60-2.87)
  Chronic respiratory disease  3124  (13.0)  56  (21.0) 1.31 (0.94-1.82)
  Renal insufficiencies   193  (0.8)   8  (3.0) 3.11 (1.38-6.98)
Life style
 Smoking  4824  (20.2)  48  (18.0) 1.44 (1.02-2.03)
Abbreviations: CI, confidence interval; HR: hazard ratio
(#)  During follow up another 4341 individuals developed one or more co-morbidities, resulting in a total of 14607 individuals with any form 
of co-morbidity anytime during the study. 
Table 2: Adjusted hazard ratios (*) of sudden cardiac death in the overall population
Reference group: persons not previously vaccinated 
Influenza vaccination cases Crude RR Adjusted HR(±CI95%)
Any vaccination
First vaccination
Revaccination
179
 34
145
1.02
1.59
0.94
0.88 (0.64-1.20)
1.50 (0.98-2.32)
0.79 (0.58-1.10)
Reference group: first vaccination
Revaccination 0.59 0.53 (0.36-0.77)
Abbreviations: CI, confidence interval; HR, hazard ratio.
(*): adjustment for gender, underlying chronic diseases (cardiovascular diseases, respiratory diseases, hypertension, renal insufficiency, 
diabetes mellitus, and smoking 
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In the population with comorbidity, any vaccination as well as any revaccination 
was associated with a non-significantly reduced risk of SCD as compared to non-use. 
In the population without comorbidity, a revaccination resulted in a non-significant 
32% reduction, but a first vaccination was associated with significantly increased risk 
of SCD (HR, 2.49, CI
95%
:1.17-5.29). 
Higher baseline age appeared to be associated with a tendency towards a stronger 
beneficial effect of any influenza vaccination or revaccination but the differences 
with younger age-groups were non-significant. 
The influence of the influenza epidemic on the association between vaccination 
and SCD is summarised in figure 1. Both during the pre-epidemic and the epidemic 
season we observed an increased, though non-significant risk of SCD following a first 
vaccination. Following revaccination the risk was lowest during the epidemic period, 
but none of these outcomes was significant. In the epidemic period, however, the 
risk reduction observed for any revaccination compared to a first vaccination was 
significant. In the post-epidemic time period, all point estimates were below 1 but 
none reached statistical significance. 
Figure. Adjusted hazard ratios (*) for sudden cardiac death by time period, stratified by vaccination
  Abbreviations: CI, confidence interval; HR, hazard ratio.
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Table 3: Adjusted hazard ratios (*) of sudden cardiac death, stratified by comorbidity and age.
Co-morbidity Present Absent
Reference group: no previous vaccination
cases adjusted HR(±CI95%) cases adjusted HR(±CI95%)
Any vaccination 149 0.83 (0.57-1.20) 30 0.94 (0.52-1.72)
First vaccination  24 1.20 (0.71-2.04) 10 2.49 (1.17-5.29)
Revaccination 125 0.78 (0.54-1.14) 20 0.68 (0.35-1.32)
Reference group: first vaccination
Revaccination 0.65 (0.41-1.03) 0.27 (0.13-0.56)
Baseline age <70 years 70-79 years ≥ 80 years
Reference group: no previous vaccination
cases adjusted HR(±CI95%) cases adjusted HR(±CI95%) cases adjusted HR(±CI95%)
Any vaccination 34 1.27 (0.60-2.67) 91 0.83 (0.52-1.30) 54 0.55 (0.29-1.07)
First vaccination  8 2.73 (1.10-6.75) 17 1.31 (0.69-2.50)  9 1.16 (0.52- 2.56)
Revaccination 26 1.02 (0.47-2.20) 74 0.76 (0.48-1.22) 45 0.70 (0.41-1.22)
Reference group: first vaccination
Revaccination 0.37 (0.18-0.80) 0.58 (0.33-1.02) 0.61 (0.30-.1.25)
Abbreviations: CI, confidence interval; HR, hazard ratio.
(*)  adjustment for gender, underlying chronic diseases (cardiovascular diseases, respiratory diseases, hypertension, renal insufficiency, 
diabetes mellitus, and smoking 
Discussion
The results of our study indicate that influenza revaccination, but not a first vac-
cination may be associated with a reduced risk of sudden cardiac death. In subjects 
without comorbidity and those younger than 70 years at baseline, an increased risk 
of SCD was seen after a first vaccination. 
We have no biological explanation for the finding of an increased risk after first 
vaccination, especially as it seemed confined to individuals without co-morbidity 
and those at younger age. The number of cases in this subgroup, however, was small 
and precision was low. A trend towards an increased risk was also observed dur-
ing the pre-epidemic and epidemic period, i.e. the winter period where respiratory 
infections, including influenza infections may contribute to cardiovascular morbidity 
and mortality. Recently it was shown that acute infections are associated with a 
transient increase in the risk of vascular events [16]. However, influenza vaccination 
was associated with a decreased risk during the first 4 weeks postvaccination. It is 
not clear whether in that study these were first or revaccinations [16]. In our study 
6 of the 32 persons who died from SCD in the pre-epidemic period died following 
a first vaccination: one patient after 5 day; the other 5 between 17 and 72 days after 
vaccination.
62
Ch
ap
te
r 4
Following revaccination the observed relative risks all showed a protective effect. 
As these risks were measured against non-vaccinated controls, one must assume that 
the observed effect is a consequence of vaccine effectiveness. Also previous studies 
found a reduced incidence of acute ischemic events and death following influenza 
vaccination [9-11, 17], although vaccination was not associated with a reduced risk of 
recurrent coronary events [18]. In one small case control study influenza vaccination 
was associated with a 49% risk reduction of primary cardiac arrest [19]. In this study, 
however, vaccination exposure was assessed by spouse reports, which may have 
resulted in information bias. The observed lack of statistical significance in our study 
might be a result of insufficient power.
In our population, we were able to take advantage of the fact that in the Dutch 
health care system all medical information (including specialist and hospital care) 
is collected at practices that cover the general population instead of selected socio-
economic groups. As a consequence, there was extensive information available on 
drug use, potential confounders and the circumstances around death. As all medical 
data on all population members is available, selection bias was unlikely. Another 
advantage of our study is that we were able to distinguish between first vaccinations 
and revaccinations. Previous studies addressing morbidity and mortality outcomes 
have given variable results, possibly because of variable vaccination histories of the 
study subjects.
Nevertheless, also our study has potential limitations. Although, we cannot exclude 
that some misclassification of outcome occurred, this is probably minimal since 
general practitioners consistently register deaths. Also the incidence of SCD was 
comparable to that of other sources. Misclassification of influenza vaccination is pos-
sible, but will be low and non-differential, since all data were recorded prospectively 
in the database and vaccination is supplied almost exclusively by the GP [9, 10]. 
Confounding by indication may have occurred and explain why we found an 
increased risk of SCD in the group of relatively young elderly without co-morbidity 
who received a first vaccination. It is possible that in this small group of cases the first 
vaccination occurred because of a recently recognized indication which was not yet 
notified in the GP-records. Even if residual confounding by indication also occurred 
in the other subgroups, we will have underestimated rather than overestimated the 
true effect of influenza vaccination on SCD. Moreover, in a direct comparison of 
revaccination to first vaccination which both have the same indication, revaccination 
was associated with a statistically significant risk reduction of SCD. Other potential 
sources for confounding were unlikely as we adjusted for all known factors to be 
associated with an increased risk of influenza associated morbidity and mortality 
and factors associated with an increased risk of SCD. In a subanalysis, those refusing 
vaccination with baseline age< 70 years were at a significantly lower risk of SCD 
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than the remaining non-vaccinated control group. However, this was not observed 
for subjects without co-morbidity. The belief to be in good health has been reported 
as reason for vaccination refusal [20]. A lower risk for those refusing vaccination was 
also observed in a previous study by our group [9]. 
In conclusion, we found an unexplained risk increase of SCD associated with a 
first influenza vaccination in a small subgroup of patients. In the remainder, revac-
cination was associated with a reduced risk of SCD. The results of this study support 
the benefit of annual influenza vaccination in reducing the risk of sudden cardiac 
death.
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Abstract
Context
Influenza vaccination has been associated with a reduction in hospitalisation for 
respiratory conditions in elderly persons. Little is known, however, about the effect 
of influenza vaccination on the whole severity range of respiratory tract infections. 
Objective 
We investigated the effect of annual influenza vaccination on the occurrence of 
lower respiratory tract infections (LRTI) in community dwelling elderly. 
Design and setting 
We performed a population-based cohort study using the computerized Integrated 
Primary Care Information (IPCI) database in the Netherlands in subjects aged 65 
years or older between 1996 and 2002. For each year, the individual cumulative 
exposure to influenza vaccination since study entry was computed. 
Study population
Community dwelling elderly aged 65 years or older on January 1st of the year of 
study entry. 
Main outcome measure
We compared the risk of LRTI after a first vaccination or revaccination with no vac-
cination using a time-varying multivariate Cox-proportional hazard model, adjusted 
for age, gender, smoking and underlying disease. 
Results
In the study population of 26,071 subjects, 3,412 developed LRTI during follow-up. 
A first vaccination did not reduce LRTI risk. During epidemic periods revaccination 
reduced LRTI risk by 33% (95% CI: 8-52%) in individuals without comorbidity. 
Conclusions 
In this study, annual influenza revaccination was associated with a reduction in LRTI 
in community dwelling elderly.
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Introduction
During winter periods, up to 30% of elderly experience acute respiratory infections 
of which up to 20% is attributed to influenza virus [1- 4]. Respiratory complications 
following infection with influenza virus include acute bronchitis, pneumonia and 
exacerbations of chronic bronchitis or asthma [5]. Accordingly, rates of hospitalisa-
tion for pneumonia and influenza, acute bronchitis and chronic respiratory disease 
are significantly higher during influenza periods [6, 7]. Acute bronchitis is the most 
common complication following influenza infection seen in primary care. The risk 
increases with age and in the presence of underlying conditions [8]. 
In one meta-analysis covering 9 cohort studies (including 6 in nursing homes) 
influenza vaccination reduced the risk of hospitalisation for pneumonia on aver-
age by 53%, but with a considerable range [9-11]. In a more recent meta-analysis 
in community dwelling elderly, the risk reduction of hospitalisation for respiratory 
conditions after influenza vaccination was less than 40% [12]. Other recent cohort 
studies in elderly patients confirm the results from the meta-analyses [13, 14] but 
indicate strong effect modification by risk profile [14-17]. 
So far, studies only addressed LRTI leading to hospital admission, whereas most 
LRTIs are dealt with in primary care. To investigate to what extent annual influenza 
vaccination is associated with the risk to develop hospitalized and non-hospitalized 
LRTI in community dwelling elderly, we conducted a population-based cohort 
study.
Methods 
Setting 
In the Dutch healthcare system, all persons have their own general practitioner (GP) 
who files all relevant medical details on their patients from primary care visits, hospi-
tal admissions and visits to outpatient clinics. Since 1997, GPs execute a nationwide 
influenza vaccination program for which they are reimbursed. During annual mass 
vaccination days in October and November, all individuals with predefined risk 
factors and those aged 65 years or older are invited to participate in the vaccination 
campaign free of charge. GPs register the vaccination in their patient records. 
Data for this study were derived from the Integrated Primary Care Information 
(IPCI) database at the Department of Medical Informatics of the Erasmus Medi-
cal Center in Rotterdam, the Netherlands. The IPCI database is a general practice 
research database that contains electronic patient records on a cumulative popula-
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tion of 530,000 patients from approximately 150 GPs. The information includes all 
medical data including demographic information, patient complaints and symptoms, 
diagnoses, results of laboratory tests, referral notes from consultants, hospital admis-
sions and prescriptions. Prescriptions include drug name, Anatomical Therapeutical 
Chemical code, dosage form, dose, prescribed quantity, and indication. Symptoms 
and diagnoses are recorded using the International Classification for Primary Care as 
the coding system [18] but also as free text. As IPCI is the sole repository of medical 
records, the participating GP’s do not keep additional paper records. To warrant 
anonymity, patient and practice identifiers are altered. The system complies with EU 
guidelines on the use of data for medical research and has shown to be valid for 
pharmacoepidemiologic research [19-21]. The IPCI internal review board approved 
the study. 
Study population
For this study we selected all persons of 65 years or older with a permanent status 
in one of the IPCI GP practices. Eligible persons had at least one year of recorded 
database history which was required to adequately determine prior health status and 
vaccination status. To restrict misclassification of exposure we excluded all practices 
that did not consistently register influenza vaccination over the study years. Incon-
sistent registration included recorded vaccination coverage rates of less than 25% or 
a variation of ≥50% over the years. In the remaining population, we conducted a 
cohort study including the period between October 1, 1996 and September 30, 2002. 
The end of follow-up was defined as the first episode of LRTI, death, moving out of 
the GP practice or end of the study period, whichever came first. 
Exposure definition 
The cumulative number of influenza vaccinations since study entry was determined 
between October 1st and December 31st of each calendar year. Exposure was 
categorized into 9 mutually exclusive categories including non-exposed, 1st, 2nd, 
3rd, 4th, 5th and 6th or 7th vaccination, vaccination interruption, and restart. Subjects 
without a recording of vaccination in their history or during follow up were con-
sidered as non-exposed until their first recorded vaccination. Non-exposed subjects 
could be flagged as vaccine refusers in the GP database. These persons were not 
automatically invited for the annual vaccination, until the moment that the individual 
indicated an annual invitation was appreciated. Persons with a vaccination history 
prior to study entry, started with the number of previously recorded vaccinations. 
Upon each additional consecutive vaccination during the study period, the cumula-
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tive number increased by one. Once in the interruption category subjects stayed in 
it until vaccination restart as described previously [21]. In this time-varying approach 
of exposure analysis, individuals may contribute information to multiple exposure 
categories during follow-up. 
Outcome definition 
The primary outcome in this study was a first episode of LRTI, which was defined 
as pneumonia, acute bronchitis or an exacerbation of chronic bronchitis. LRTI was 
identified from the medical chart of the patient. LRTI were considered only as out-
come if they resulted in antibiotic therapy or were confirmed by radiography and/or 
microbiology. To be able to compare our results to other studies we also assessed 
hospitalizations for pneumonia as secondary outcome. Events were allocated to the 
vaccination status defined in the preceding vaccination period. 
Co-variates 
Age, gender, smoking, antibiotic use and the number of GP visits were consid-
ered as co-variates. Furthermore, we identified seven disease clusters as potential 
confounders: chronic respiratory tract disease (chronic obstructive pulmonary 
disease, emphysema, chronic bronchitis, asthma), chronic cardiovascular disease 
(heart failure, angina pectoris, history of myocardial infarction or stroke, aortic an-
eurysm, chronic arterial dysfunction), diabetes mellitus, hypertension, chronic renal 
insufficiency, malignancies and neurological or psychiatric disorders (parkinsonism, 
dementia, polyneuropathy, multiple sclerosis, epilepsy, alcoholism, depression, 
psychosis, schizophrenia, Ménière’s disease). Presence of these conditions at study 
entry or their development during follow-up was retrieved from the medical charts 
through automatic screening and manual validation. The population without comor-
bidity had no comorbidity at baseline and did not develop any of the predefined 
conditions during follow-up. Information on the characteristics of each influenza 
season was obtained from Dr. JC de Jong of the National Influenza Center, Erasmus 
MC Rotterdam. 
Analyses 
For estimation of the univariate association between vaccination, co-variates and 
the development of LRTI or (hospitalized) pneumonia we used a Cox proportional 
hazards model. Multivariate time varying Cox proportional hazard models were de-
veloped to estimate the hazard ratios for different vaccination states while adjusting 
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for all other risk factors. For all analyses, age expressed in days was taken as the time 
axis to fully adjust for age. 
The effect of vaccine exposure on the risk of the outcome was evaluated for a 
first vaccination or revaccination versus no vaccination. Subsequently, the outcomes 
were stratified for presence of comorbidity and age at study entry (65-69 years, 70-
79 years or >79 years). We first investigated these effects during the full follow-up 
period and subsequently during the epidemic period. The epidemic period started 
on the first day of the first week of the recorded epidemic and ended on the last day 
of the last week of the recorded epidemic. Hence the duration of the period varied 
per year. As a comparison, the association of influenza vaccination and LTRI was 
assessed also in the summer period (June, July and August) during which period 
there is almost no circulation of influenza virus in the Netherlands. In each analysis 
the reference group comprised all non-vaccinated subjects. 
All results were expressed as hazard ratios with 95% confidence intervals (CI
95%
). For 
all analyses SAS software, version 8.2 using the procedure Proc Phreg was used. 
Results
The study population comprised 26,071 elderly, of whom 58% was female (table 1). 
Mean (SD) age at study entry was 73.1 (7.4) years. In this population, 3,412 subjects 
developed a first episode of LRTI. In 1,295 patients this first LRTI episode was clas-
sified as pneumonia, and 455 of these patients were hospitalised with this condition. 
The risk of developing LRTI was higher in males, increased with age, was higher 
in the presence of comorbidity, and in smokers. Especially the presence of chronic 
respiratory diseases at baseline was associated with an increased risk of LRTI. 
Vaccination coverage and epidemic characteristics of this population have been 
published previously [21]. In short, vaccination coverage varied between 64% and 
74% and was slightly higher in the subpopulation with comorbidity (72% to 79%). 
Most vaccinations (96%) were given in October or November, the remainder in De-
cember. During the study, 59,111 influenza vaccinations were administered to 20,976 
persons; 5,095 persons never received any influenza vaccination. All epidemics were 
predominated by A/H3N2 strains which showed a good match between circulating 
and vaccine strain(s) except for the 1997-1998 season (mismatch). Epidemic activity 
was mild to moderate in the 1996-1997 and 1999-2000 seasons, absent in the 2000-
2001 season and mild in the other seasons. The peak activity of influenza-like illness 
ranged between 7 cases per 10,000 persons (2000-2001 season) and 32 cases per 
10,000 persons per week (1999-2000 season) and was observed between weeks 2 
and 13 (Personal communication Dr. JC de Jong). 
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Table 1: Demographic characteristics and univariate hazard ratios for any of the outcomes during follow up.
No. (%)
Variable Population characteristics
at study entry
(n=26,071)
Lower respiratory 
infections
at follow up (n=3,412)
Hazard ratio 
(± CI95%)
Sex
 Female 15131  (58.0) 1796  (52.6) Reference
 Male 10940  (42.0) 1616  (47.4) 1.40 (1.31-1.50)
Age, y (mean ±SD)    73.1 ±7.4  77.0 ± 7.5
 65-69 10490  (40.2)  956  (9.1) Reference
 70-79 10522  (40.4) 1478  (14.6) 1.69 (1.67-1.70)
  ≥ 80  5049  (19.4)  978  (19.4) 2.14 (2.11-2.16)
Smoking
 No 20704  (79.4) 2477  (12.0) Reference
 Yes  5367  (21.6)  935  (17.4) 1.53 (1.40-1.68)
Co-morbidity
 None at study entry 12173  (46.7) 1129  (9.3) Reference
 Comorbidity at study entry# 13898  (53.3) 2283  (16.4) 2.49 (2.25-2.75)
 Diabetes mellitus  3000  (11.5)  418  (13.9) 1.12 (1.01-1.24)
 Hypertension  6414  (24.6)  887  (13.8) 1.04 (0.97-1.13)
 Chronic respiratory disease  3487  (13.3)  977  (28.0) 3.15 (2.93-3.39)
 Cardiovascular disease  6099  (23.4) 1065  (17.5) 1.57 (1.46-1.69)
 Cancer  1034  (4.0)  156  (15.1) 1.40 (1.19-1.64)
 Renal dysfunction   221  (0.8)   35  (15.8) 1.41 (1.01-1.97)
 Neurological disease  3200  (12.3)  471  (14.7) 1.33 (1.24-1.43)
Abbreviations: CI, confidence interval; HR, hazard ratio.
(#) During the follow-up period comorbidity developed in another 2903 individuals resulting in a total of 16701 subjects with comorbidity at 
 baseline or any time during follow-up.
Table 2 summarizes the association between influenza vaccination and LRTI. If we 
considered the full follow-up period a first influenza vaccination or revaccination 
was not associated with a reduction in the risk of LRTI. If we restricted follow-up 
to the epidemic period, the risk of LTRI following any revaccination decreased by 
33% but only in subjects without comorbidity (table 2). Influenza vaccination did 
not protect against LTRI in persons with co-morbidity nor with chronic respiratory 
disease. Stratification by age suggested a tendency towards lower hazards of LRTI 
following revaccination in elderly, but this was not seen for first vaccinations. 
We were able to differentiate those refusing vaccination from the rest of the non-
vaccinated control group (data not shown). Persons with underlying comorbidity 
listed as vaccine refusers were at lower risk of LRTI compared to the rest of the 
non-vaccinated persons with co-morbidity. Contrary, persons without comorbidity 
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Table 2: Association between influenza vaccination and lower respiratory tract infection during the period 1996-2002
First vaccination Revaccination
cases HR(± CI95%) cases HR(± CI95%)
Full period
 Total population 314 1.03 (0.90-1.19) 2208 1.08 (0.98-1.18)
Epidemic period
 Total population  79 0.86 (0.71-1.05)  567 0.94 (0.83-1.06)
 Without comorbidity  13 0.90 (0.56-1.45)   58 0.67 (0.48-0.92)
 With co-morbidity  66 0.83 (0.66-1.04)  509 0.95 (0.82-1.10)
 Chronic respiratory disease  27 0.77 (0.55-1.08)  269 0.94 (0.75-1.15)
Baseline age
 <70 years  20 0.91 (0.61-1.36)  162 1.27 (0.98-1.65)
 70-79 years  29 0.82 (0.60-1.12)  239 0.85 (0.70-1.04)
  ≥80 years  30 0.89 (0.64-1.24)  166 0.83 (0.67-1.01)
Summer period
 Total population  52 1.41 (0.99-2.01)  347 1.18 (0.92-1.52)
Abbreviations: CI, confidence interval; HR, hazard ratio.
Note: adjustment for gender, underlying chronic diseases (cardiovascular diseases, respiratory diseases, hypertension, malignancies, renal 
insufficiency, diabetes mellitus, and neurological diseases), smoking, number of antibiotic prescriptions and number of GP visits. 
Table 3: Association between influenza vaccination and pneumonia over the period 1996-2002
First vaccination Revaccination
cases HR ± CI95%) cases HR ± CI95%)
Full period
 Total population 93 0.84 (0.65-1.07) 839 0.96 (0.82-1.11)
Epidemic period
 Total population
 Hospitalised patients
26
 3
0.87 (0.55-1.36)
0.29 (0.10-0.96)
216
 70
0.89 (0.67-1.18)
0.82 (0.49-1.36)
 Without comorbidity  4 0.55 (0.19-1.61)  23 0.50 (0.27-0.93)
 With co-morbidity 22 0.95 (0.58-1.57) 193 0.97 (0.70-1.35)
 Chronic respiratory disease  8 0.65 (0.27-1.57) 107 1.03 (0.61-1.73)
Baseline age
 <70 years  7 0.95 (0.38-2.35)  55 1,31 (0.72-2.40)
 70-79 years  4 0.49 (0.18-1.30)  88 0.98 (0.60-1.60)
 ≥80 years 15 1.12 (0.60-2.08)  81 0.66 (0.43-1.02)
Summer period 
 Total population 19 1.14 (0.65-2.00) 144 1.00 (0.69-1.47)
Abbreviations: CI, confidence interval; HR, hazard ratio.
Note: adjustment for gender, underlying chronic diseases (cardiovascular diseases, respiratory diseases, hypertension, malignancies, renal 
insufficiency, diabetes mellitus, and neurological diseases), smoking, number of antibiotic prescriptions and number of GP visits. 
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listed as vaccine refusers, were at a significantly higher risk of LRTI than the rest of 
the non-vaccinated control group without comorbidity. 
Considering the full follow-up period, there was no benefit of first or revaccination 
on the risk of hospitalized and non-hospitalized pneumonia (table 3). During the 
epidemic period revaccination was associated with a 50% risk reduction of pneumo-
nia, but only in the subpopulation without comorbidity. A first influenza vaccination 
was associated with a 71% risk reduction (CI
95%
: 4-90%) of hospitalized pneumonia, 
but no significant association was seen for revaccination. 
Influenza vaccination was not associated with all LRTI or pneumonia during the 
summer period (tables 2, 3). 
Only in the seasons with mild to moderate epidemic activity revaccination was 
associated with a reduced risk of LRTI compared to a first vaccination (Figure 1). 
During seasons with mild or no epidemic activity, subjects with an first vaccination 
consistently had a lower risk of LRTI than revaccinated subjects. 
Figure 1. Association between influenza first or revaccination and lower respiratory tract infection during epidemic periods, stratified by year.
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Figure 1 – Association between influenza first or revaccination and lower respiratory 
tract infection during epidemic periods, stratified by year. 
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Note: adjustment for gender, underlying chronic diseases (cardiovascular diseases, respiratory diseases, hypertension, malignancies, renal 
insufficiency, diabetes mellitus, and neurological diseases), smoking, number of antibiotic prescriptions and number of GP visits. 
X-axis: 1st vaccination, any revaccination, revaccination vs. first vaccination all fully adjusted. 
Y-axis: hazard ratio indicates the risk of lower respiratory tract infection following first vaccination or revaccination vs. no vaccination, or 
following revaccination vs. first vaccination  
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Discussion
In the present study we showed that influenza vaccination reduces the risk of LRTI, 
but only in specific subgroups and during the epidemic period. The observed protec-
tion against hospitalization for pneumonia is in line with other studies [11-13]. In our 
study, revaccination was only beneficial in years with mild to moderate epidemic 
activity. This supports the necessity to analyse these morbidity outcomes by epi-
demic year. Others reported that the potential impact of influenza vaccination on 
the risk to develop pneumonia depends upon the individuals’ risk profile [14, 16, 
17]. With increasing age, a tendency towards a stronger effect of revaccination was 
noted in our study, although the estimates did not reach statistical significance. One 
explanation might be the gradual impairment of health status with age, resulting in 
a higher disease burden allowing for a stronger impact of vaccination. The tendency 
towards a reduced beneficial effect of a first vaccination, might reflect an impaired 
immune response in the elderly. Similar observations, although not distinguished 
between first vaccination and revaccination, led to the conclusion that the benefit of 
influenza vaccination in elderly was limited to those below 70 years [22]. 
Like all observational studies, also this study may suffer from selection bias, in-
formation bias and confounding. Selection bias was discarded as the data were 
obtained from computerized GP patient records that are population-based and in-
dependent of morbidity. Information bias may occur on exposure and outcome. 
Misclassification of the cumulative number of influenza vaccinations is possible but 
will be low since all data are recorded prospectively in the computer. The vaccina-
tion is supplied almost exclusively by the GP, and we only included practices with 
consistent vaccination coverage over the follow-up period. Misclassification of LRTI 
in a GP setting may be problem. To some extent, the validation process in free text 
is valuable to control for possible variations in the application of ICPC codes by GPs. 
However, to enhance sensitivity of the clinical criteria, microbiological confirmation 
is important [23]. Respiratory tract infections are caused by a variety of viruses and 
bacteria and are common in elderly, especially during winter months [23], but are 
often not confirmed [3]. Although influenza virus is the most commonly isolated 
specimen in respiratory infections in adults [24], other viruses (e.g. RSV, rhinoviruses, 
corona viruses) are more frequent in elderly [23]. Also clinical symptoms of LRTI can 
be misleading in community dwelling elderly [3]. Misclassification of LRTI may have 
been differential if GPs were less likely to diagnose LRTI in vaccinated persons in 
view of the assumed effectiveness. 
Another potential problem is confounding by indication. Although the national 
recommendation was to vaccinate all elderly of 65 years and older, generally healthy 
individuals do not always follow such advice [25]. On the contrary, critically ill 
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patients may refuse vaccination or may not be offered the vaccination any more in 
view of their poor prognosis. However, this appeared not to be the case in our study. 
Persons with underlying comorbidity listed as vaccine refusers appeared to be in a 
relatively better health than the rest of the non-vaccinated control group, whereas 
those without comorbidity appeared to be relatively less healthy. Apparently, how-
ever, vaccine refusers do not have a consistent risk profile.
We suspected potential confounding by indication since pre-existing chronic 
respiratory tract disease, cardiovascular tract disease, diabetes mellitus, malignancy, 
chronic renal insufficiency and neurological disease were independent risk factors 
for increased influenza associated morbidity. Therefore, we adjusted for these risk 
factors. However, residual confounding is possible, and may have led to an under-
estimation of the true effect of influenza vaccination [23]. 
The strength of this study is that the effect of repeated vaccinations on LRTI or 
pneumonia could be estimated in each of 6 consecutive seasons in which epidemic 
and vaccine strain characteristics varied. The possible influence of vaccine strain 
selection on effectiveness of vaccination in repeat vaccinees has already been re-
ported [26, 27]. Contrary to mortality, in the present study interruption and restart of 
the vaccination series had no obvious impact on vaccination effectiveness [21]. 
In summary, this study indicates that in a population of community dwelling elderly 
repeated influenza vaccination may reduce the risk to develop LRTI or pneumonia, 
in years with higher epidemic activity. Although the protective effect is modest 
influenza vaccination should be advised in view of the high background incidence 
of LRTI and because of the reduced mortality in elderly [21].
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Abstract
Introduction
As part of an annual relicensure requirement, marketing authorization holders (MAH) 
of trivalent inactivated influenza vaccines submit serological studies performed in 
healthy adults and elderly to the regulatory authorities of the European Union. 
Objective
The objective of the present study was to analyse the serological data submitted to 
the Dutch Medicines Evaluation Board (MEB) between 1992 and 2002, with respect 
to their ability to assess the immunogenic properties of the vaccines.
Methodology 
Serological data from immunogenicity trials for influenza vaccines submitted to 
the MEB as part of the annual relicensure dossier were analysed. This was done 
according to criteria described in the Committee of Human Medicinal Products Note 
for Guidance on harmonisation of requirements for influenza vaccines (CHMP NfG). 
These trials are typically uncontrolled and open label, and include 2 groups of at 
least 50 healthy adults and healthy elderly. 
Results
In 48 age-defined trials, 4,518 persons (2,510 adults, 2,008 elderly) satisfied the 
CHMP pre-requirements. All but three trials fulfilled the CHMP criteria. However, in 
many studies pre-vaccination antibody levels were already high and very important 
for the fulfilment of the CHMP seroprotection criterion. Moreover, the serological re-
sponse was age dependent. A history of previous influenza vaccinations significantly 
affected pre-, but not post-vaccination titres.
Conclusions
The CHMP criteria show serious methodological limitations, which affect their ability 
to identify influenza vaccines with low immunogenicity. The value and need of an-
nual serological trials for relicensure influenza vaccines in the European Union may 
be questioned.
Serological trials submitted for annual relicensure 81
Introduction
Many countries recommend annual influenza vaccination for elderly and individuals 
with specified high risk conditions, with the objective to induce protection against 
influenza infection in the upcoming season [1]. Annually, the World Health Organisa-
tion issues an updated recommendation for the vaccine composition for the next 
season, based upon the expected circulating strains. As, in general, the strain compo-
sition changes each year, influenza vaccines are relicensed annually. Ideally, clinical 
vaccine efficacy is established in experimental field trials [2], but for an annual 
relicensure procedure, this approach is unrealistic. 
Within the European Union, marketing authorization holders of influenza vaccines 
are required to provide clinical immunogenicity data to support the annual relicensure 
procedure, in addition to pre-clinical requirements addressing Good Manufacturing 
Practice, toxicity (e.g., endotoxin content), and antigenic content (i.e., potency as 
determined by the single radial immunodiffusion assay). The “Note for Guidance 
on Harmonisation of requirements for influenza vaccines” (CHMP/BWP/214/96) [3] 
describes the requirements and criteria for serological annual update trials. This pro-
cedure can only be followed if a first licensure, evaluating quality, immunogenicity 
and safety has been issued. 
The underlying rationale of the CHMP-criteria is to assess the immunogenicity of 
annual influenza vaccines (in case of new components) according to pre-specified 
response parameters as a proxy for clinical protection. Although these parameters 
provide objective criteria, and are age specific they do not account for heterogeneity 
in response that may be due to other factors. For instance, indivuals are exposed, 
by infection or vaccination, to many influenza virus (sub) types and strains during 
their lifetime, which results in highly variable pre-vaccination titres [4]. Also, ageing 
and health status may affect humoral responses to influenza viral antigens [5-12], 
although immune function may be preserved in those reaching advanced age in 
overall good health [13]. These population characteristics can influence the haemag-
glutinin inhibiting (HI) antibody response induced by vaccination, independent of 
the vaccine. The influence of such vaccine-unrelated population characteristics on 
the seroprotection rate is unwanted. To control for these confounding factors, the 
relicensure trials use age stratification and a requirement of good general health of 
the trial population. Moreover, to address pre-vaccination titre, titre increase and 
response rate are used in addition to seroprotection rate. However, it is not clear 
to what extent these measures result in a more reliable assessment of the vaccines’ 
immunogenicity [4]. 
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The objective of this study was to describe response rates and to explore the 
influence of certain population characteristics (prevaccination titres, age and vac-
cination history) on postvaccination titres.
Methods
Data collection
We derived serological data from 51 immunogenicity trials for eight different trivalent 
inactivated split virus and subunit influenza vaccines that were submitted to the 
Dutch Medicines Evaluation Board (MEB) as clinical part of the annual relicensure 
dossier during the period 1992-1993 to 2002-2003. These data are stored on micro-
fiche in the archives of the MEB. 
The marketing authorisation holders of inactivated influenza vaccines in the 
Netherlands approved the use of their serological data for this study, provided that 
all product identifiers were removed and no direct between-product comparisons 
were published. 
Inclusion criteria and CHMP criteria 
According to the CHMP Note for Guidance on harmonisation of requirements for 
influenza vaccines [3], the immunogenicity of an influenza vaccine should be studied 
in at least 50 healthy adults aged 18 to 60 years and in at least 50 healthy elderly 
of 61 years or older. Blood samples are to be taken before and ~3 weeks after one 
dose and tested (in 2-fold) for anti-haemagglutinin antibody by either the haemag-
glutination inhibition (HI) assay or the single radial haemolysis (SRH) assay. For 
the HI assay, three statistics are measured: first, the proportion of subjects equal to 
or exceeding a post-vaccination titre of 40 (seroprotection rate); second, the mean 
geometric increase (also called mean fold increase, MFI), i.e. the geometric mean of 
the quotients of post- and pre-vaccination titres; and third, the combined proportion 
of seroconversions (i.e., previously seronegative subjects exceeding a post-vaccina-
tion titre of 40) and the proportion of subjects with a significant increase (i.e. that 
of previously seropositive subjects with a ≥4-fold increase in GMT). Together, these 
latter parameters are referred to as response rate. The CHMP NfG defines assessment 
criteria for these parameters. For adults seroprotection should be achieved postvac-
cination in at least 70% of the vaccinees, the other 2 parameters should be achieved 
in at least 40% of the vaccinees. In elderly, the corresponding percentages are 60% 
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and 30%. For each virus strain and each age class, at least one out of 3 criteria should 
be met. 
Dataset 
For inclusion in the final database documentation of the subjects’ age, general health 
state and the complete set of pre- and post-vaccination titres was mandatory. We 
only regarded antibody titres determined by the HI assay, SRH results were excluded 
from the eligible population. From trials in adults, subjects <18 or >60 years-of-age 
were excluded, and from trials in elderly, subjects <61 years were excluded from the 
dataset. Trials, which covered both adult and elderly subjects, were stratified by age 
(either 18 to 60, or ≥61 years-of-age). A trial, which, after applying these selections, 
included less than 50 subjects, was removed.
Statistical methods
For database management and calculations, Microsoft® Excel 2002 and SPSS for 
Windows 10.0.1 1999 were used. Where appropriate, post-vaccination GMTs were 
adjusted for pre-vaccination GMTs by linear regression as described in Beyer et al. 
[4]. For comparisons between continuous sample statistics (e.g., GMT-values of sub-
jects with negative versus positive vaccination history), the ratio was used as effect 
measure. For comparisons between binominal statistics (e.g., seroprotection rates), 
the absolute rate difference was used. Ratios throughout trials were combined by 
the inverse variance-weighted method [14], and rate differences by the meta-analysis 
method of DerSimonian and Laird for binominal data [15]. Interval estimates were 
given as 95% confidence intervals (CI
95%
).
Results
Fifty-one studies including 7,126 subjects were gathered from the archives. Three 
studies with 382 subjects using the SRH assay were excluded. A number of studies 
covered both age groups and were each separated into two (age-defined) trials (18-
60, and >60 years). This resulted in a total of 71 strictly age-defined trials with 6,744 
subjects. Twenty-three (23) trials including 2,226 subjects were excluded as they 
did not meet the inclusion criteria (see table 1). Of the remaining 4,518 vaccinees, 
gender was reported in 4,407 (55.5% female). Figure 1 shows the age distribution. 
The median age for adults was 36 and for elderly 69 year. Over calendar time the 
median age decreased both in elderly (from 71 in 1992 to 66 in 2002) as well as in 
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Table 1: Exclusion of trials and subjects to satisfy the CHMP pre-requisites
No. trials No. subjects
Originally retrieved data 71 6,744
(1) experimental vaccines1    12
(2) no age reported  7   732
Exclusions
(3) In adult studies: subjects <18 and >60 
In elderly studies: subjects ≤ 60
   39
(4) no complete titre sets  1   275
(5) reported co-morbidity   473
(6) trial size <50 after exclusions 15   495
Final study population 48 4,518
(1) Study arms with experimental adjuvant vaccine.
Figure 1. Age distribution for adult (18-60 years) and elderly (>60 years) study populations
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adults (from 48 to 25 years) (figure 2). Before vaccination less than 40% of the 
adults and <21% of the elderly were seronegative for at least one of the strains 
(table 2). More than half of the elderly population was already seroprotected 
against one or more strains. In elderly the post-vaccination seroprotection crite-
rion of 60% for the B-strain was reached almost entirely pre-vaccination (table 2). 
Figure 2. Median age of the adult (18-60 years) and elderly (>60 years) study populations over the study period 1992 to 2002
Table 2: Baseline serology 
No. (%)
Adults Elderly
Prevaccination titre seronegative
(<10)
seroprotected
(≥40)
seronegative
(<10)
seroprotected
(≥40)
A/H3N2
A/H1N1
B
996
101
646
(39.7)
(40.4)
(26.3)
 729
 812
1031
(29.0)
(32.4)
(42.0)
399
426
265
(19.9)
(21.2)
(13.5)
1066
1019
1166
(53.1)
(50.7)
(59.6)
Seronegative (<10) indicates HI titre< 10 before vaccination
Seroprotected (≥ 40) indicates HI titre before vaccination.
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CHMP criteria in 48 age-defined trials
Table 3 presents the outcomes of the 48 trials. Single CHMP criteria were occasionally 
not met, most frequently the seroconversion criterion. Three times, a vaccine did not 
meet the CHMP criteria in the elderly, while it did in the corresponding adult trial: 
trial 32 (1994, corresponding adult trial: 8), trial 36 (1996, corresponding adult trial: 
17), and trial 47 (1997, corresponding adult trial: 25).
The influence of pre-vaccination antibody titre on the seroresponse
In Figure 3a-c, pre- and post-vaccination seroprotection rates are shown for all indi-
vidual trials, sorted by age class and pre-vaccination protection rates. A substantial 
number of trials had high prevaccination seroprotection rates. In some trials, prevac-
cination seroprotection rates exceeded the CHMP post-vaccination criterion. The 
trials, that failed to reach the post-vaccination threshold, had virtually all a low pre-
vaccination GMT. The combined prevaccination seroprotection rates were higher 
in elderly than in adults (see also table 2), whereas the combined postvaccination 
Figure 3a-c.  Pre- and post-vaccination protection rates (defined as HI-titre≥40) for the individual trials and the combined ratio throughout 
 the trials, stratified for age class (a) A-H3N2 strain, (b) A-H1N1 strain, and (c) B strain.
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Figure 2 Median age of the adult (18-60 years) and elderly (>60 years) study 
populations over the study period 1992 to 2002 
 
 
Figure 3 -c:  Pre- and post-vaccination pr tection rates (defined as HI-titre≥40) for the 
individual trials and the combined ratio throughout the trials, stratified for age 
class (a) A-H3N2 strain, (b) A-H1N1 strain, and (c) B strain. 
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Pre = proportion of subjects reaching the seroprotection limit of 40 measured by HI-assay prevaccination.
Post =  proportion of subjects reaching the seroprotection limit of 40 measured by HI-assay postvaccination.
CHMP  threshold is defined as the proportion of seroprotected (titres>40) subjects postvaccination, for adults ≥70%, for elderly ≥ 60%.
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seroprotection rates were slightly lower in the elderly. In trial specific linear regres-
sion models pre-vaccination titres were a predictor of post-vaccination titres in 70% 
of the trials. 
The influence of age on pre- and post-vaccination titres in adults and elderly 
Figure 4 shows age-specific pre- and post-vaccination GMT-values, and the post-
vaccination GMT-values corrected for pre-vaccination titres. The adult group was 
divided into 7 five-year age bands (18-23 years to 54-59 years), and the elderly age 
class into 6 five-year age bands (61-66 years to 91-96 years). 
Pre-vaccination GMT-titres were higher in the elderly than in the adults, but 
did not show a clear trend. Post-vaccination GMT-titres decreased with age in 
adults and elderly for all three subtypes (up to 4-fold for the A/H1N1 subtype in 
adults). This pattern was even clearer for pre-vaccination corrected GMT-values. 
In terms of GMT increase, persons of ≥80 years responded poorly to vaccination. 
Figure 4. Geometric mean titres within 5-year band age classes. 
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Figure 4: Geometric mean titres within 5-year band age classes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations:  HI: haemagglutinin inhibition; GMT: geometric mean titre
Pre   = prevaccination geometric mean titre of the A/H3N2, a/H1N1 or B strain presented for the different age categories.
Post  =  postvaccination geometric mean titre of the A/H3N2, a/H1N1 or B strain presented for the different age categories.
Corr.  =  corrected GMT = postvaccination GMT corrected for prevaccination GMT by linear regression.
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Figure 5. Pre- and post-vaccination seroprotection titres for A/H3N2 subtype of 18 individual trials for which vaccination history data were 
available.
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Figure 5:  Pre- and post-vaccination seroprotection titres for A-H3N2 subtype of 18 
individual trials for which vaccination history data were available. 
 
 
Abbreviations : F: first vaccination group; M, multiple vaccinations group; 
  pre: prevaccination; post: postvaccination.
The influence of previous vaccinations on post-vaccination titres
Vaccination history (influenza vaccination in the year(s) before the trial) was re-
corded in 22 trials. In 4 trials the number of subjects with previous vaccination 
was smaller than 5; these trials were excluded because of statistical reasons. The 
remaining 18 trials included 1,614 subjects. Subjects were either never previously 
vaccinated (single vaccination group), or vaccinated in the year prior to the trial, or 
previously vaccinated but not in the year prior to the trial. Since there was no statisti-
cally significant difference between the latter two groups (not shown), they were 
combined (multiple vaccination group). In a meta-analysis (DerSimonian & Laird, see 
Methods) the pre-vaccination seroprotection rate was 22.6% (CI
95%
: 17.0% - 28.2%) 
higher in those with multiple vaccinations as compared to those with no history 
of vaccination. No difference in postvaccination seroprotection rates was observed 
(1.1%; CI
95%
:-1.7% - 4.0%). Similar patterns were found for pre- and post-vaccination 
GMT (combined by the inverse variance-weighted method), and for A/H1N1 and B 
(not shown).
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Discussion
This study indicates that for serological annual update trials of inactivated influenza 
vaccines the influence of population characteristics on the outcomes precludes any 
assessment of the immunogenic potential of the vaccine. All but 3 trials fulfilled at 
least one CHMP criterion for all 3 strains [3]. 
In an effort to adjust for confounding population factors, seroresponse was in-
troduced in the CHMP NfG in addition to seroprotection rate. Furthermore, studies 
were stratified into 2 age classes and inclusion of only healthy individuals should 
preclude an impact of underlying disease on the immune responsiveness. In our 
study, we strictly applied the CHMP criteria, which may not have been the case for 
the original studies. For the purpose of annual relicensure it is thus possible that 
different conclusions were drawn. 
It is doubtful whether these measures were sufficient to control for confounding 
factors. First, in persons with high pre-vaccination titres only a small amount of 
newly induced antibody is enough to reach the required post-vaccination antibody 
titres. This precludes a reliable assessment of the antibody-inducing potency of a 
vaccine. Although the quotient of post- and pre-vaccination titre should correct for 
the pre-vaccination titre, it has been shown to be insufficient since the mean fold 
increase and response rate remain dependent on pre-vaccination titre [4]. Stratifica-
tion in only two age groups was insufficient to control for the age dependency of 
the antibody response. 
Furthermore, the CHMP inclusion criterion of being ‘healthy’ is vague and may 
not exclude unapparent pathological conditions. Our data were not detailed enough 
to assess this possibility. Although we adjusted for health status by excluding every 
individual with recorded comorbidity, we cannot exclude residual comorbidity. Co-
morbidity of individual subjects was recorded in a minority of the trials, and in none 
of the trials conducted prior to 1995. 
The CHMP NfG does not consider other possibly relevant population characteristics 
such as previous vaccinations and genetic variation between individuals. We found 
no clear influence of vaccination history on post-vaccination titres for the combined 
trials. This is in accordance with earlier observations [16]. However, for a single trial 
it does not exclude unwanted large variation by its strong positive influence on the 
pre-vaccination state. 
It should be emphasised that all the summarised population characteristics are cor-
related. For example, pre-vaccination titre, co-morbidity and previous vaccinations 
may themselves be dependent on age, and again pre-vaccination titres on previous 
vaccinations, resulting in a complex pattern of interactions (figure 6). Interpreta-
tion is further complicated by the fact that correlations between vaccine strains and 
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Figure 6. Possible population characteristics that may influence postvaccination immune response to influenza vaccination
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Figure 6:  Possible population characteristics that may influence postvaccination 
immune response to influenza vaccination 
 
 
 
circulating strains might play a more profound role in clinical performance of influ-
enza vaccines than previously assumed, especially in those annually revaccinated 
[17, 18].
Immunogenicity of influenza vaccines is determined each year in open label un-
controlled trials of limited size. Due to lack of a comparator group and lack of 
random treatment assignment the immunogenic properties of the vaccines cannot be 
assessed unbiased. Stratification and restrictions are measures to reduce confounding 
but within strata residual confounding may occur. 
In a time which is characterized by a need for evidence-based medicine, and 
in view of the serious limitations of these trials, the final question is “what do we 
expect from an annual update trial?” 
Each influenza vaccine qualifying for annual relicensure has to proof its quality, 
immunogenicity and safety in a sufficiently large dataset. The subsequent annual up-
date trials are no more than a model to address consistency of immunogenicity. The 
selected population in such a study is of major importance, as it has to be the most 
optimal for the desired outcome, through minimal interference of disturbing popula-
tion characteristics. For influenza vaccines this means a relatively naïve healthy indi-
vidual, e.g., a never influenza vaccinated healthy young adult. In this perspective, the 
observed reduction of the median age of the study populations in the more recent 
years could be interpreted as an improvement to address the objectives.
It is noted that the EU is the only region in which annual update trials are presently 
requested. Other regulatory authorities only require assessment of the potency of 
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the annually produced influenza vaccines by in vitro tests using a standardised SRH 
assay [3], which is also required in the CHMP NfG and, which in several studies is 
validated for protection [19-21].
In conclusion, the need and design of annual update trials of inactivated influenza 
vaccines may be questioned and should be rediscussed. The present practice of fol-
low-up of the CHMP NfG criteria inhibits progress for inactivated influenza vaccines, 
as it does not encourage companies and investigators to explore other possibly 
relevant immunological parameters to support new applications or specific clinical 
claims [22, 23]. 
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Abstract
Context
Efficacy of strain variations in influenza vaccines is measured by serological para-
meters. Little is known about their validity as correlate for clinical protection in 
elderly individuals, especially when administered annually. 
Objective 
The objective of this review was to investigate the impact of annual vaccination on 
serological and clinical parameters, and the relevance of using serological outcomes 
as proxy for clinical protection. 
Methods 
Publications of studies based upon use of inactivated trivalent influenza vaccines in 
elderly subjects and relevant reviews were selected from a MEDLINE search until 
2005. For this purpose, publications needed to describe total number of subjects and 
those with the outcome of interest for the exposed and non-exposed group. 
Results
In 23 serology publications no correlations were found between postvaccination 
seroprotection rate and seroresponse. The response rates in uncontrolled trials ap-
peared less heterogeneous than in controlled trials. Thirty publications addressing 
clinical outcomes showed a significant protective effect with regard to death, pneu-
monia and influenza. In the presence of a vaccination history, serological responses 
did not adequately predict clinical response. There were only a few studies which 
addressed both serological and clinical parameters. None of these confirmed the 
validity of the serological parameter as a correlate for clinical protection.
Conclusions
This review supports the clinical benefit of annual influenza vaccination in elderly, 
but does not support the use of serological data as a proxy for clinical outcomes.
Do outcomes of serological studies with influenza vaccines in elderly predict clinical protection? 99
Introduction 
Annual influenza epidemics are associated with substantial morbidity and mortality, 
especially in elderly and in those with underlying diseases [1-4]. Among older com-
munity dwelling and institutionalised individuals, respiratory virus infections are 
common. A substantial proportion of these are caused by influenza and associated 
with respiratory complications, hospitalisations and excess deaths [5-13]. 
Influenza vaccination programs focus on elderly persons and on those with risk fac-
tors. Intramuscularly administered inactivated influenza vaccines primarily stimulate 
production of immunoglobulin G (IgG) antibodies. Age-related decline in antibody 
response, or immunosenescence, has been reported in several publications [14-20], 
but not in all [21-24]. Contrary to the humoral immunity which is strain-specific, 
T cell mediated immunity is cross-reactive with many other strains of influenza A 
and B. This is supposed to offer protection against many influenza virus strains. Age, 
lifestyle and health status may affect T cell function and thus humoral responses to 
influenza viral antigens [21, 25-36], although preserved immune function is reported 
in those reaching advanced age in overall good health [37].
Strategies to improve age-related decreases in vaccine efficacy include annual re-
vaccination [20, 38, 39], increased antigenic content of the vaccines [40-43], use of 
whole cell vaccines [44], use of booster doses [43, 45-49], intranasal administration 
[50], use of adjuvants [51, 52] and other immunomodulators [53, 54], live attenuation 
of the virus [46, 55, 56], and alternative routes of administration [57]. However, up till 
now, only annual revaccination appears to be an effective strategy, although this is 
not generally accepted [53, 58]. 
Trials performed for annual relicensure of the inactivated influenza vaccines 
are based upon predefined serological criteria described in the so-called “CHMP 
(Committee of Human Medicinal Products) Note for Guidance on harmonisation 
of requirements for influenza vaccines” [59]. Most trials seem to meet these criteria 
[20, 39, 51, 60]. However, their clinical relevance is not always obvious [23, 61, 62]. 
Serological data are only incidentally supplemented by data on clinical protection 
[51, 55, 56, 63-68]. A meta-analysis of single versus multiple vaccination indicated no 
specific benefit of revaccination according to serological parameters [23]. But despite 
their limitations, CHMP criteria are often used in experimental trials as a proxy for 
clinical protection.
Early observational studies in institutionalised and community dwelling elderly sup-
ported the benefit of annual mass influenza vaccination [63, 69-73]. A large number 
of observational studies report a variety in protective effects of influenza vaccination 
on clinically relevant endpoints, such as influenza like illness, (hospitalisations for) 
pneumonia, cardiovascular diseases and mortality [55, 56, 68, 70, 73-96]. Meta-analy-
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ses that included a limited number of studies showed an overall benefit on mortality 
and hospitalisations for pneumonia and other respiratory infections [97-100]. 
The serological responses in trials are generally used as a correlate for clinical 
protection [33, 56]. However, they are not unambiguous [19, 101]. Out of a number 
of studies and one meta-analysis addressing both clinical outcomes and serological 
responses, [23, 33, 56, 63-65, 76, 102] only one study reported a positive correlation 
[56]. Antigenic variations of vaccine strains and circulating influenza strains and the 
individuals’ vaccination and infection history are confounding factors in interpreting 
the validity of serological data as a correlate for clinical protection [53, 74, 75, 103-
105].
The objective of this review is to investigate the impact of annual vaccination on 
serological and clinical parameters and the validity of using serological endpoints as 
a surrogate parameter. 
Selection of publications
A Medline search was performed using one or more of the following terms in as-
sociation with “influenza”: “vaccine”, “vaccination”, “clinical”, “Influenza Like Ill-
ness”, “pneumonia”, “hospitalisation”, “mortality”, “death”, “serology”, “serological”, 
“elderly” and “correlation”. Publications of studies on use of inactivated trivalent 
influenza vaccines in elderly subjects as well as relevant reviews were selected. Their 
reference lists were further investigated for additional publications.
Relevant publications with quantitative data are listed in table 1 when it concerned 
serological studies and tables 2-4 when the publications had clinical outcomes. To 
be considered for inclusion in these tables, a publication needed to describe abso-
lute numbers of vaccinated and non-vaccinated subjects and the number with the 
outcome of interest. For serological studies this was postvaccination response rate, 
defined as a ≥4 fold increase in geometric mean titre (GMT) and postvaccination 
seroprotection rate, defined as postvaccination GMT ≥40 by Haemagglutination Inhi-
bition (HI) assay. Clinical endpoints were death, pneumonia or confirmed influenza 
associated respiratory infections. 
Seroprotection and seroresponse
The CHMP criteria require a post vaccination seroprotection rate of 60% or more 
in elderly aged 61 years or older [59]. However, this is not always achieved [20, 25, 
26, 38, 41, 52, 55, 56, 107] . A randomised placebo controlled trial in elderly general 
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practioner’s patients showed relatively low seroprotection rates following vaccina-
tion, ranging from 43-68%. In patients not previously vaccinated, seroprotection rates 
varied between 46-69% whereas in those with a vaccination history this was only 
19-52% [64] (table 1). Others found seroprotection rates well above the predefined 
CHMP limit of 60% [19, 45, 47, 49-51, 53, 60, 68, 96, 108]. 
Efforts to improve the seroprotection rate were generally not successful. In a re-
view summarising dose response studies only 3/26 study groups showed a signifi-
cant positive dose response relationship [42]. Also other strategies, such as adjuvants 
[51], booster doses [45, 47, 49, 68], live attenuation of the virus [56] did not lead to 
significant increases in seroprotection rates. However, the use of higher vaccine 
dosages and adjuvants was again proposed as a possibility to improve vaccine-
induced immune responses in the elderly [109].
According to the CHMP criteria, seroresponse rate should exceed 30% in elderly. In 
several studies the response rate is inversely related to the prevaccination antibody 
titre. Individuals with low prevaccination titres tend to have a higher postvaccina-
tion titre, and thus a higher response rate [46]. Also response rate has shown to be 
highly variable between studies (see table 1). Non-response to all 3 strains has been 
reported to occur in up to 46% of the vaccinees [16]. 
In the 23 publications summarised in table 1, we identified 42 different mutually ex-
clusive treatment periods and/or subgroups. Logistic regression analyses performed 
on the outcomes indicated that there was no correlation between postvaccination 
seroprotection rate and response rate for the A/H3N2, A/H1N1 and B strain. 
Clinical protection
Several studies addressed confirmed influenza infections during an influenza epi-
demic period in community dwelling elderly (table 2). In a randomised controlled 
trial, influenza vaccination resulted in a 50% reduction of serologically confirmed 
influenza infections (CI
95%
: 39-65%). In 3 other studies, influenza vaccination was 
as effective in reducing confirmed influenza infections [87, 91, 110]. The use of 
live attenuated vaccine with or without simultaneous inactivated influenza vaccine 
administration resulted in similar incidences of serologically confirmed influenza 
infections in elderly COPD patients [56]. As clinical detection of influenza like illness 
alone often fails to show a significant benefit from vaccination [9, 65, 69, 90, 91, 102, 
112], the use of serological or virological methods to ascertain influenza infection is 
advised to increase diagnostic sensitivity [110, 113, 114].
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Most data in elderly, however, concern the effect of influenza vaccines on mortality 
or influenza associated respiratory complications (see tables 3 & 4). Some studies 
focus on specific patient populations [55, 56, 68, 94-96].
Large cohort studies have been performed using computerized datasets from 
managed care organizations [11, 70, 73, 77-84] , insurance companies [85], primary care 
settings [87-93, 115], and through media campaigns [86]. The sample sizes achieved 
with these studies are reflected in the higher precision of the outcomes (see tables 3 & 
4). Several large cohort studies report a protective efficacy (i.e., 1-relative risk) of in-
fluenza vaccination against (hospitalisations for) pneumonia with or without influenza 
in elderly persons, which is generally lower in persons with predefined comorbidity 
compared to the “healthy“ elderly [77-79, 82, 85, 88, 90, 116] . But a stronger benefit 
for elderly with comorbidity has been reported as well [73, 81]. The studies included 
in table 3 showed an overall protective benefit of influenza vaccination against pneu-
monia, which appeared to be stronger in healthy elderly (OR, 0.35, CI
95%
: 0.32-0.39) 
than in those with comorbidity (OR, 0.74; CI
95%
: 0.70-0.78). In a population receiving 
both influenza vaccine and polysaccharide pneumococcal vaccine, the unadjusted 
reduction in hospitalisation was 29% (CI
95%
: 24-34%) for pneumonia and 46% (CI
95%
: 
34-56%) for influenza with or without pneumonia [86]. In institutionalised elderly, 
whose health status is less favourable, the benefit of influenza vaccination has been 
positively associated with vaccination coverage, revaccination status, and/or antigenic 
match between circulating strain and vaccine strain [69, 71, 74, 117, 118]. A booster 
dose had no significant clinical benefit over a single dose [111]. 
Table 2: Overview and descriptive confirmed influenza infection results from selected clinical studies
Influenza
season health mean age vaccine control
Ref. Author Design status vaccine control yes no yes no
Crude OR 
(± CI95%)
GP practice or outpatient setting
[65] Govaert ’91-‘92 RCT Mixed 67.3   67  41   886  80    831 0.50 (0.35-0.73)
[87] Nicholson ’93-‘94 Cohort Mixed >65   1   440  19    420 0.05 (0.01-0.39)
[91] Carrat ’95-‘96 CC Mixed  13   155  33    133 0.39 (0.21-0.71)
Hospitalised or institutionalised patients
[61] Nicholson ’88-‘89 CC Comor 85.3 85.3   1    72   5     31 0.10 (0.01-0.81)
[74] Dindenaud ’89-‘90 Cohort Mixed 66.8  12    69   2     32 2.52 (0.60-10.7)
[86] Christenson ’98-‘99 Cohort Mixed 75.2 75.8  36 23188 386 159000 0.64 (0.46-0.90)
[111] Deguchi ’98-‘99 Cohort Mixed   82 256 10483 694  11029 0.40 (0.35-0.46)
Abbreviations: REF.: reference; GP: general practitioner; RCT:  
randomised controlled trial; CC: case control; OR: odds ratio
Fixed model / random model according to DerSimonian and Laird[106]
Influenza fixed 0.42 (0.37-0.48)
Influenza random 0.45 (0.31-0.65)
heterogeneity p=0.003
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Table 3: Overview and descriptive pneumonia results from selected clinical studies 
pneumonia
health mean age vaccine control
Ref. Author season Design status vaccine control yes no yes no
Crude OR 
(± CI95%)
Data from GP practice or outpatient setting
[90] Voordouw ’96-‘97 Cohort Healthy  74.7  74.7   28 5321 54 5996 0.59 (0.37-0.92)
[90] Voordouw ’96-‘97 Cohort Comor.  74.7  74.7   44 3518 29 2832 1.22 (0.76-1.94)
[9] Connolly ’89-‘90 CC Mixed    8 334 7 335 1.14 (0.42-3.12)
[112] Allsup ’99-‘00 RCT Mixed  68.9  69.1    0 552 0 177 -
Hospital data or institutionalised patients
[73] Barker ’68-‘69 Cohort Healthy  71.3  71.2    3 957 13 4847 1.17 (0.33-4.09)
[73] Barker ’72-‘73 Cohort Healthy  72.4  71.5    0 740 13 5187 -
[82] Mullooly ’80-‘89 CC Healthy > 65 > 65  128 31620 2291 116674 0.21 (0.18-0.25)
[94] Nichol ’93-‘96 Cohort Healthy  73.5  532   56 1310 29 503 0.75 (0.49-1.16)
[81] Hak ’96-‘97 Cohort Healthy  74.2    74  201 37492 254 30589 0.65 (0.54-0.78)
[81] Hak ’97-‘98 Cohort Healthy  74.3  73.9  164 33991 267 32222 0.58 (0.48-0.71)
[73] Barker ’68-‘69 Cohort Comor.  72.2    73    4 1116 15 2805 0.67 (0.22-2.02)
[73] Barker ’72-‘73 Cohort Comor.  74.4  74.1    2 1098 24 3676 0.28 (0.07-1.18)
[82] Mullooly ’80-‘89 CC Comor. > 65 > 65  734 36783 1474 61330 0.83 (0.76-0.91)
[81] Hak ’96-‘97 Cohort Comor.  74.2    74  695 32617 811 20315 0.54 (0.49-0.60)
[81] Hak ’97-‘98 Cohort Comor.  74.3  73.9 1129 56717 995 32969 0.67 (0.61-0.73)
[63] Howells ’71-‘72 Cohort Mixed   80.1  76.9    2 132 18 338 0.30 (0.07-1.26)
[63] Howells ’72-‘73 Cohort Mixed  78.7  79.8    3 120 28 239 0.23 (0.07-0.75)
[63] Howells ’73-‘74 Cohort Mixed  78.7  78.8    0 183 11 276 -
[71] Saah ’79-‘80 Cohort Mixed    84    83   11 208 20 214 0.59 (0.29-1.20)
[71] Saah ’80-‘81 Cohort Mixed    83    84   12 232 11 203 0.96 (0.43-2.12)
[71] Saah ’81-‘82 Cohort Mixed    83    85    9 216 16 210 0.57 (0.26-1.25)
[69] Patriarca ’82-‘83 Cohort Mixed  82.3  80.4   22 526 45 425 0.42 (0.26-0.69)
[84] Fedson ’82-‘83 CC Mixed  69.8  68.2  283 2336 754 7098 1.13 (0.99-1.28)
[84] Fedson ’85-‘86 CC Mixed 71.1  71.1  370 2047 1008 6241 1.10 (0.99-1.23)
[70] Foster ’89-‘90 CC Mixed  78.5  135 188 524 718 0.99 (0.86-1.14)
[93] Mangtani ’90-‘99 Cohort Mixed > 65 1993 143713 3177 270865 1.18 (1.12-1.25)
[78] Nichol ’90-‘93 Cohort Mixed    72  72.5  166 41252 297 36812 0.50 (0.41-0.61)
[77] Nichol ’90-‘91 Cohort Mixed    72  72.1   29 11454 81 13968 0.44 (0.29-0.67)
[77] Nichol ’91-‘92 Cohort Mixed    72  72.5   83 15205 124 10957 0.49 (0.37-0.64)
[77] Nichol ’92-‘93 Cohort Mixed  72.4  72.5   63 14584 99 11880 0.52 (0.38-0.71)
[116] Puig ’94-‘95 CC Mixed  76.3  76.4   47 36 102 64 0.92 (0.74-1.15)
[68] Wonsurakiat ’97-‘98 RCT Mixed  67.6  69.1    2 60 12 51 0.17 (0.04-0.73)
[86] Christenson ’98-‘99 Cohort Mixed  75.2  75.8  335 22889 2468 156918 0.93 (0.83-1.04
[111] Deguchi ’98-‘99 Cohort Mixed    82   32 10707 150 11573 0.23 (0.16-0.34)
[79] Nichol ’98-‘99 Cohort Mixed  74.2  73.7  495 77243 581 61736 0.68 (0.61-0.77)
[79] Nichol ’98-‘99 Cohort Mixed  74.2  73.4  589 86768 501 58470 0.79 (0.71-0.89)
Abbreviations: REF.: reference; GP: general practitioner; RCT:  
randomised controlled trial; CC: case control; OR: odds ratio
Fixed model / random model according to DerSimonian and Laird[106]
Pneumonia fixed model 0.80 (0.78-0.83)
Pneumonia random model 0.63 (0.53-0.74)
heterogeneity p<0.0001
106
Ch
ap
te
r 7
Table 4: Overview and descriptive of mortality results from selected clinical studies 
mortality
health mean age vaccine control
Ref. Author season Design status vaccine control yes no yes no crude OR(± CI95%)
Data from GP practice or outpatient setting
[90] Voordouw ’96-‘97 Cohort Healthy 74.7 74.7 68 5281 88 5962 0.87 (0.64-1.20)
[90] Voordouw ’96-‘97 Cohort Comorb. 74.7 74.7 75 3487 76 2785 0.79 (0.58-1.09)
[89] Voordouw ’96-‘02 Cohort Mixed 73.1 2225 60251 1260 25252 0.75 (0.70-0.80)
[92] Fleming ’89-‘90 Cohort Mixed 71.3 69.1 3 596 84 7848 0.47 (0.15-1.49)
[119] Ahmed ’89-‘90 CC Mixed 82.4 83.1 57 258 178 599 0.74 (0.53-1.04)
[65] Govaert ’91-‘92 RCT Mixed 67.3 67 6 921 3 908 1.97 (0.49-7.91)
[112] Allsup ’99-‘00 RCT Mixed 68.9 69.1 3 549 1 176 0.96 (0.10-9.31)
[129] Landi ’99-‘00 Cohort Mixed 78.8 80.1 167 917 192 806 0.77 (0.61-0.96)
Hospital data or institutionalised patients
[73] Barker ’68-‘69 Cohort Healthy 72.2 73 0 960 1 4859 -
[73] Barker ’72-‘73 Cohort Healthy 74.4 74.1 0 740 3 5197 -
[82] Mullooly ’80-‘89 CC Healthy > 65 > 65 7 31741 2292 116673 0.01 (0.01-0.02)
[73] Barker ’68-‘69 Cohort Comorb. 71.3 71.2 3 1117 8 2812 0.94 (0.25-3.57)
[73] Barker ’72-‘73 Cohort Comorb. 72.4 71.5 0 1100 13 3687 -
[82] Mullooly ’80-‘89 CC Comorb. > 65 > 65 106 37411 1476 61328 0.12 (0.10-0.14)
[63] Howells ’71-‘72 Cohort Mixed 80.1 76.9 1 133 15 341 0.17 (0.02-1.31)
[63] Howells ’72-‘73 Cohort Mixed 78.7 79.8 3 120 22 245 0.28 (0.08-0.95)
[63] Howells ’73-‘74 Cohort Mixed 78.7 78.8 0 183 11 276 -
[71] Saah ’79-‘80 Cohort Mixed 84 83 2 217 12 222 0.17 (0.04-0.77)
[71] Saah ’80-‘81 Cohort Mixed 83 84 3 241 8 206 0.32 (0.08-1.22)
[71] Saah ’81-‘82 Cohort Mixed 83 85 3 222 5 221 0.60 (0.14 -2.53)
[69] Patriarca ’82-‘83 Cohort Mixed 82.3 80.4 6 542 21 449 0.24 (0.10-0.59)
[33] Provinciali ’89-‘90 RCT Mixed 81.3 81.3 29 244 3 35 1.39 (0.40-4.79)
[111] Deguchi ’98-‘99 Cohort Mixed 82 1 10738 5 11718 0.22 (0.03-1.87)
[79] Nichol ’98-‘99 Cohort Mixed 74.2 73.7 943 76795 1361 60956 0.55 (0.51-0.60)
[79] Nichol ’99-‘00 Cohort Mixed 74.2 73.4 1019 86338 1026 57945 0.67 (0.61-0.73)
Abbreviations: REF.: reference; GP: general practitioner; RCT:  
randomised controlled trial; CC: case control; OR: odds ratio
Fixed model / random model according to DerSimonian and Laird[106] 
Mortality fixed model 0.58 (0.56-0.61)
Mortality random model 0.42 (0.29-0.60)
heterogeneity p<0.0001
Do outcomes of serological studies with influenza vaccines in elderly predict clinical protection? 107
Overall, the studies summarised in table 4 underline the protective efficacy of 
influenza vaccination on mortality (OR, 0.42; CI
95%
: 0.29-0.60) (method by derSimo-
nian and Laird) [106]. In a cohort study covering 1996-2000, (unadjusted) influenza 
attributable deaths were prevented in 83% [88]. On some occasions, a protective 
effect was seen in one season but not in the other [63, 71, 84] , in the subgroup with 
comorbidity but not in the subgroup without [90] and after revaccination but not 
after first vaccination [89]. In 2 studies the protective benefit of vaccination did not 
sustain when vaccination was interrupted for a year [89, 92].
Several large scale cohort studies also addressed other outcomes, such as hospitali-
sations for acute or chronic respiratory conditions, congestive heart failure, cerebral 
disease, diabetes mellitus and health care utilisation [78-80, 85, 94, 95]. 
The influence of vaccination history on serological response and clinical 
protection
Vaccination history is often recorded, but is not necessarily used as a factor in the 
determination of clinical effectiveness [63, 65, 68-71, 73, 79, 89-93, 119]. Although 
most serological studies summarised in this review addressed the vaccination status, 
only 4 studies distinguished between first vaccination and revaccination [19, 20, 53, 
64]. In 3 studies, seroprotection rate following revaccination was lower than after 
first vaccination [20, 53, 64]. Based on this finding, one of the authors concluded that 
repeated vaccination should be avoided [53]. Similar conclusions were drawn in an 
early study upon impaired clinical protection of boys in a boarding school [58]. In 
nursing home residents, vaccination history did not result in impaired seroprotec-
tion [19]. In general, vaccination history has not shown to have a major impact on 
postvaccination seroprotection rate. In a cohort study covering 3 epidemic seasons, 
seroprotection rates tended to decrease from the individuals’ first vaccination to 
subsequent revaccinations [39]. In another cohort study, results were more variable 
[20]. It was concluded that vaccination history should always be addressed as an 
independent factor in serological studies [39].
Another serological parameter, seroresponse rate, seems to be inversely corre-
lated to the prevaccination antibody titre [46, 62], and higher prevaccination titres 
are almost exclusively observed in previously vaccinated individuals. But lower 
seroresponse (and seroprotection) rate is not always observed in elderly with high 
prevaccination antibodies. Especially in institutionalised populations, unexpected 
high seroresponse has been reported [19, 102, 107]. In one of these studies, also 
unexpectedly high clinical responses were seen [102].
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In the randomised controlled trial in elderly GP practice patients, revaccination 
further decreased serologically confirmed influenza by 50% in first time vaccinees to 
a decrease by 89% in those with a vaccination history (CI
95%
: 17-99%) [65]. In adults, 
annual influenza vaccination did not further decrease the risk of clinically diag-
nosed influenza like illness [120, 121]. In a case control study revaccination reduced 
mortality significantly, whereas a first vaccination did not [119]. In an earlier cohort 
study, influenza vaccine administered directly prior to the epidemic was highly ef-
fective in reducing mortality risk in GP patients, including those with comorbidity 
[92, 95]. However, persons vaccinated in the year before but not directly prior to the 
epidemic season under study had no benefit from their previous vaccination [92]. 
The importance of compliance to the annual vaccination to sustain mortality risk 
reduction was recently reported in a cohort study covering 6 epidemic years [89]. 
The predictive value of serological response for clinical protection
The relationship between serological and clinical response variables is an issue of 
continuing debate. Early studies showed an inverse relationship between initial se-
rum haemagglutinin inhibition (HI) titre (by natural infection or vaccination) and 
postvaccination seroresponse [101] or susceptibility to infection [122], leading to the 
assumption of a correlate for protection. 
Only a few studies addressed serological and clinical parameters [23, 33, 56, 63-
65, 76, 102]. Of these studies, only one has shown a positive correlation between 
postvaccination serum antibody titres and the occurrence of laboratory confirmed 
influenza infections in elderly COPD patients [56]. Low seroprotection rates did not 
always correspond to a low clinical protection [64, 65, 76, 102] and revaccination has 
shown to increase the protection achieved by influenza vaccination [63, 65, 89, 92, 
95]. Also in institutionalised elderly, despite a variable and sometimes limited sero-
responsiveness, annual vaccination resulted in low numbers of symptomatic infec-
tions [61, 102]. In contrast, in 2 other studies in nursing home residents, vaccination 
did not exert a significant protection against influenza like illness [74] or mortality [33] 
during an aggressive and mismatched epidemic (1989-1990), despite seroprotective 
titres. As in the latter study [33] the non-vaccinated controls also showed a significant 
increase in seroprotection rates, one can not exclude re-infection by circulating wild 
virus in this institutionalised population. 
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Comment
The value of serological endpoints as a surrogate variable for clinical protection 
remains undetermined due to a surprising lack of studies correlating both serological 
and clinical endpoints. The main question that remains is why clinical protection 
sustains and apparently improves in elderly with compliance to annual vaccination 
when it is not reflected in seroresponse following repeated vaccination. The studies 
reviewed here do not support a straightforward correlation between serological para-
meters and clinical parameters. 
First, there is the interpretation of the immune response following vaccination. 
The heterogeneity observed between the studies might very well reflect their in-
trinsic variability due to differences in study populations, and / or differences in 
responsiveness of individual strains [41], and also between laboratory variability of 
the haemagglutination inhibition (HI) assay [124]. The use of other methods to detect 
antibodies, or to characterise the immunity to influenza virus epitopes (from vaccine 
or infection) may be more sensitive than the classic HI assay [46, 56].
Revaccination appears to have a detrimental effect on seroresponse, but not on 
clinical protection, which might be a result of improved cellular immunity. Age-
associated immune senescence has been promoted as a reason for revaccination 
[125]. Expanding T cell repertoire recognition for heterologous influenza strains as a 
result of revaccination might be essential for sustained protection against influenza 
in elderly. Specific cellular immunological parameters might, for example, provide 
useful information with regard to defining “risk categories” for impaired immune 
responsiveness [16, 126]. More detailed immune characterisation following influenza 
vaccination might allow for an understanding of clinical unpredictability of influenza 
epidemics, which may lead to negative results in one year but positive results in the 
other year [73, 82, 83], possibly by inhibiting interactions between vaccine strains 
and circulating strains [103, 104, 127]. More insight into these mechanisms may also 
lead to new design options for annual strain selection [105]. 
The conduct of outcome studies in large computerised databases allows for in-
creasingly valid data over a wide variety of clinically important outcomes and cover-
ing several epidemic seasons [77-79, 81-83, 88, 89]. 
In conclusion, as clinical and serological outcomes following repeated exposure 
to influenza vaccine appear to diverge, it seems necessary to search for other, more 
reliable surrogate parameters. A decreased number of B lymphocytes in elderly, 
impairment of expansion [19, 53], inability to respond to new epitopes in presence 
of high baseline HI titres [16, 103] and age related differences in IgG subclass re-
sponses [32] have been reported as cause of the inability to mount adequate humoral 
responses after revaccination. 
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The importance of knowing how protection against influenza is induced by different 
components of the immune system, including immunological factors responsible for 
heterotypic and heterosubtypic protection and specifically the role of (cytotoxic) 
cellular immunity was recently reported [109]. The recommendations of this meeting 
support the view that claims with regard to clinical benefit on serological trials only 
are insufficient [52, 128].
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1 Background
Epidemics caused by influenza viruses are associated with considerable morbidity 
and mortality which increases with age, especially in patients with high-risk condi-
tions [1, 2]. Therefore, many countries recommend annual influenza vaccination of 
elderly individuals and of adults and children with specific high risk conditions [3]. 
The composition of the influenza vaccine is determined yearly following recom-
mendation by the World Health Organisation. 
As in general the strain composition changes each year, influenza vaccines are 
relicensed annually, after having obtained an initial licensure based on a full preclini-
cal and clinical dossier. Within the European Union, the annual relicensure requires 
some proof of immunogenicity and acceptable reactogenicity following vaccination. 
For this purpose, the marketing authorization holders perform small scale open label 
trials in a selected population of healthy adults and elderly. The requirements for 
these trials are described in the “Note for Guidance on Harmonisation of require-
ments for influenza vaccines” (CHMP/BWP/214/96) [4]. The objective of these trials 
is mainly to assess the immunogenicity of annual influenza vaccines (in case of new 
components) as a proxy for clinical protective efficacy. However, individuals are ex-
posed, by infection or vaccination, to different influenza virus (sub)types and strains 
during their lifetime [5]. Moreover, ageing and health status may affect humoral 
responses to influenza viral antigens [6-14]. Consequently, it is questionable whether 
these annual update trials are adequate to answer this objective. 
Clinical outcomes following influenza vaccination are mainly investigated in ob-
servational studies. The ability to detect a clinical benefit of vaccination with regard 
to the risk to develop influenza like illness also depends upon the availability of 
serological or virological methods to ascertain influenza infection [15-17]. The most 
common complication following influenza infection is acute bronchitis, which risk 
increases in elderly and in individuals with underlying chronic conditions [18]. Hospi-
talisation rates for pneumonia and influenza, acute bronchitis and chronic respiratory 
disease are significantly higher during influenza periods [19, 20]. In several studies 
the impact of vaccination on influenza, pneumonia or acute respiratory infections 
has been addressed. Generally, it seems that in individuals with underlying chronic 
disease vaccination is less effective than in individuals without such conditions [21-
28]. 
The ability of influenza vaccination to reduce mortality risk has been reported 
quite consistently in community dwelling elderly [21, 23, 24, 29-32]. More than 80% 
of all pneumonia and influenza related deaths are reported to occur in elderly aged 
≥65 years [33]. 
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According to the Statistics Netherlands (CBS), influenza causes an excess mortality 
of more than 2000 persons per year. In the 2004-2005 season, 800 excess deaths 
were calculated despite a relatively mild epidemic activity [34].
This estimated impact of annual influenza epidemics on morbidity and mortality 
in elderly, and the assumed (cost-) effectiveness of influenza vaccination, has been 
the basis for implementing nationwide influenza vaccination programs for elderly 
[3]. Annual revaccination has been proposed as a strategy to compensate for the 
decrease in effectiveness in high risk individuals [6,25, 31, 35-39]. Although in a 
meta-analysis no specific advantage of revaccination over single vaccination was 
observed in the pooled analysis, 7 out of 10 field trials supported sustained protec-
tion against laboratory confirmed influenza like illness upon revaccination [40]. In 
institutionalised elderly, a positive association between vaccination coverage, revac-
cination status, and/or antigenic match between circulating strain and vaccine strain 
and vaccine effectiveness was observed [41-45]. 
But, although seasonal epidemiological surveillance of influenza infections is stan-
dard practice, and it is recommended to vaccinate all elderly of 65 years and older, 
effectiveness of annual influenza vaccination in relation to vaccination history and 
health status of community dwelling elderly has not systematically been evaluated.
This chapter summarises the most important findings from the studies performed 
to address the question of the benefit of annual revaccination against influenza in 
community dwelling elderly. The methodological considerations underlying these 
studies are discussed. Finally, some ideas and suggestions are given for future re-
search to further clarify the impact of influenza revaccination. Also, some alterna-
tives are suggested for the present practice of serological update trials for annual 
relicensure of influenza vaccines. 
2 Main findings
2.1 Impact of influenza vaccination on mortality, pneumonia and influenza like 
illness
The influenza season of 1996-1997 was of mild to moderate severity, with a peak 
activity of influenza like illness of 28.8 per 10,000 persons observed in week 4 
of 1997 and a distribution in elderly similar to the general population [25]. There 
was a good match between vaccine strain and the predominant circulating strainA/
H3N2/Nanchang/933/95. In this epidemic period, we investigated the effectiveness 
of influenza vaccination in a cohort of community dwelling elderly aged 65 years or 
older using the IPCI database [25]. 
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Influenza vaccination effectively prevented mortality and morbidity (RR, 0.72; CI
95%
: 
0.60-0.87), although in individuals with co-morbidity, influenza vaccination failed to 
show a protective effect against pneumonia. Influenza infections were identified by 
the ICPC-code R80.0 (“proven infection without pneumonia”). Influenza infections 
decreased by 52% in the vaccinated population (CI
95%
: 9-74%), although this figure 
was based upon 48 cases only (16 in the vaccinated cohort and 32 in the control 
cohort). Most of excess mortality due to influenza and/or pneumonia is attributed 
to elderly with high-risk conditions [46]. In our study, influenza vaccination reduced 
mortality risk by 24% (CI
95%
: 3-40%) in the total population. This risk reduction was 
33% (CI
95%
: 6-54%) in elderly with co-morbidity. On the contrary, however, influenza 
vaccination had no significant benefit with regard to pneumonia in the total popula-
tion (RR, 0.77, CI
95%
: 0.55-1.07]). However, in the population without co-morbidity 
vaccination significantly reduced the risk by 44% (CI
95%
: 11-65%). We made a similar 
observation in the revaccination study described in chapter 5. 
We concluded that it might be possible that the failure to detect a benefit of vac-
cination in elderly with chronic underlying disease may result from the fact that the 
subjects die before developing clinical pneumonia, or that the pneumonia is not 
recognized, because symptoms are less prominent. 
2.2 Revaccination and mortality risk 
In this first study, we did a preliminary assessment of annual revaccination. In the 
population with a vaccination history the impact of vaccination on mortality risk 
was more prominent. But numbers were too small in the different subpopulations to 
allow for appropriate conclusions.
Following the first study, the issue of revaccination was further explored. Although 
annual influenza revaccination has been described in the literature as a strategy to 
increase vaccination effectiveness [6, 31, 38, 39], the benefit was not always obvious 
from clinical studies. In institutionalised elderly, annual revaccination as well as vac-
cination coverage showed to be the most consistent contributors to survival [42, 44]. 
But there were no such data for community dwelling elderly. With regard to serologi-
cally or virologically confirmed influenza, revaccination had no additional impact on 
the risk in both community dwelling elderly [35] and in healthy adults (aged 30 to 60) 
[47, 48]. However, in both cases, first vaccination and revaccination resulted in better 
protection against influenza virus infection compared to placebo. These findings 
were confirmed in a meta-analysis [38]. The possible association between mortality 
and revaccination status in elderly was studied in only one case-control study [31]. 
This study indeed showed that a previous vaccination significantly increased vaccine 
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effectiveness in the next season. However, the population included both community 
dwelling and institutionalised individuals. 
From the first study we knew that it was possible to obtain detailed information on 
vaccination status for each individual. This gave the opportunity to assess the overall 
and epidemic effectiveness of annual influenza vaccinations, including the effect 
of individual revaccinations. However, a greater sample size was required to allow 
valid conclusions. Therefore, the effect of annual revaccination on all cause mortality 
was investigated over the period 1996-2002. 
The most important finding was that revaccination was associated with a signifi-
cantly reduced mortality risk compared to both the non-vaccinated reference group 
but also compared to subjects who had received only one vaccination. During the 
epidemic periods, the apparent benefit of revaccination compared to a first vaccina-
tion was even stronger. The effect was apparent in both healthy elderly and in those 
with underlying chronic disease. Remarkable was the finding that revaccination 
mainly resulted in a significant mortality reduction among those aged 70 years and 
older, which seemed to reflect differences in age related causes of death, and a lower 
baseline risk to die at younger age. And indeed the subjects for whom the cause of 
death was classified as “infections” or “natural causes” had the highest mean age. For 
these 2 causes of death the effect of vaccination was strongest. 
Another main finding was the fact that interruption of yearly influenza vaccination 
was associated with a significantly increased mortality, but after restarting vaccination 
mortality risk reduced again to a revaccination status level. Absence of sustained pro-
tection from vaccination was studied as explanation for the observed risk increase. 
We observed that in subjects who interrupted vaccination for 2 or more consecutive 
years mortality risk seemed to increase even more. Although epidemiological studies 
do not allow for assessment of causal relations, one can not exclude that these 
finding support the relevance of complying to annual revaccination, especially at 
older age. 
To compensate for the age-related decline in antibody response, or immunose-
nescence, [10, 39, 49-53], the maintenance of cross-reactive immunity conferred by 
T cell may be especially important. As cellular immunity is also affected by age [6-12, 
54-56], annual revaccination might provide the “boosting” effect necessary to sustain 
clinical protection and to reduce variations in protective efficacy. From studies in 
nursing homes, we already learned that herd immunity was associated with a lower 
dependency on the antigenic match between vaccine and virus [14-16]. In these 
settings, most individuals are also vaccinated each year. 
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2.3 Revaccination and sudden cardiac death 
Cardiovascular morbidity and mortality, particularly acute myocardial infarction, 
stroke and sudden cardiac death show seasonal variation, with peak incidences in 
winter months [23, 37, 57-59]. Influenza activity has been suggested as an explanation 
for the winter peak of myocardial infarction [60] and it was suggested that Sudden 
Cardiac Death (SCD) may be a complication following influenza virus infection [57, 
61, 62]. Consequently, it might be hypothesized that influenza vaccination protects 
against SCD.
Indeed, in our study revaccination was associated with a decreased risk of sudden 
cardiac death. However, a first vaccination showed a tendency towards an increased 
higher risk (HR, 1.50, CI
95%
: 0.98-2.32), which became significant for the subpopula-
tion without co-morbidity (HR, 2.44, CI
95%
:1.00-5.98). However, precision was low. 
Recent findings did not show an association between vaccination and an increased 
risk of SCD [63], and it is not clear how the influenza vaccination could increase the 
risk of SCD after a first vaccination, but not after revaccination. 
A remarkable finding was the important association between those refusing vac-
cination and the outcome. In the overall population, those refusing vaccination were 
at a 52% (CI
95%
: 19-74%) lower risk of SCD compared to the overall non-vaccinated 
reference group. The belief to be in good health is an already reported reason for 
vaccination refusal [3]. 
2.4 Revaccination and the risk of lower respiratory tract infections 
As mentioned in paragraph 2.1, the benefit of revaccination is most obvious in its 
association with reduction of mortality. For serologically or virologically confirmed 
influenza infection, no additional impact of revaccination was observed in both com-
munity dwelling elderly [35] and in healthy adults (aged 30 to 60) [47, 48]. However, 
during winter periods, up to 30% of elderly may experience acute respiratory infec-
tions of which up to 20% are attributed to influenza virus [16, 64-66].
Respiratory complications following influenza infection include acute bronchitis, 
pneumonia and exacerbations of chronic bronchitis or asthma [67]. In general prac-
tice, acute bronchitis following influenza infection is the most common complication 
and the risk increases in elderly and in those with underlying conditions [18].
We found no published data on the effectiveness of influenza vaccination against 
LRTI in community dwelling elderly. Therefore, we investigated the risk of lower 
respiratory tract infections (LRTI) following annual revaccination in our cohort of 
community dwelling elderly [24]. 
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In the overall population, the study did support a benefit of annual influenza 
vaccination for clinically established LRTI or pneumonia, when analysed for the 
epidemic period, but only for those without recorded comorbidity. For patients 
hospitalised with pneumonia, influenza vaccination was already associated with a 
significant protection [21, 68-70].
Also in this study it was apparent that adjustment for known risk factors did not 
fully appreciate other population factors underlying the risks to develop LRTI or 
pneumonia. 
Previous studies that addressed health status as a factor in establishing vaccine 
effectiveness in LRTI or pneumonia, also reported a stronger benefit of the relatively 
healthier subpopulation [26, 71], although a stronger benefit for the population with 
underlying disease has also been reported [36].
A final interesting finding in this study was the importance of the characteristics 
of the epidemics. Only in years with moderate epidemic activity revaccination was 
associated with a substantially lower risk of LRTI or pneumonia compared to a 
first vaccination. Possibly the attack rates during the epidemic seasons 1996-1997 
and 1999-2000 were just sufficient to observe an impact of revaccination. Epidemic 
characteristics are described in many studies but not often do the data allow for 
epidemic specific subanalyses. 
2.5 Immunogenicity of influenza vaccines 
Within the European Union, influenza vaccines are relicensed annually following 
determination of their composition by the World Health Organisation. This relicen-
sure requires some clinical data to support the immunogenicity and reactogenicity 
of the vaccine to be administered in the upcoming season. These requirements are 
laid down in the “Note for Guidance on Harmonisation of requirements for influenza 
vaccines” (CHMP/BWP/214/96) [4]. 
The annual update trials are analysed for seroprotection rate and seroresponse 
rate. In adults, the defined threshold titre for protection of 40 measured by haemag-
glutination inhibition (HI) assay may be a fair assumption [72], but it is not clear 
whether this also applies for elderly and it is never studied in children. Older studies 
indicated a threshold of 120 in elderly to protect against more severe outcomes such 
as pneumonia [39, 73]. 
The annual update trials are meant to evaluate the immunogenicity of annual 
influenza vaccines. Therefore it is important to assure that the responses which are 
measured indeed reflect the immunogenicity of the vaccine and not population 
characteristics such as age, health status and a widely variable exposition, by infec-
tion or vaccination, to different influenza viruses during ones’ lifetime [5]. 
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In 48 age-defined trials, which we controlled for health status, age and prevac-
cination titre, we observed that increasing pre-vaccination antibody levels signifi-
cantly contributed to seroprotection. Furthermore, post-vaccination parameters were 
strongly dependent on age. However, adjustment for these factors may not be suf-
ficient as it does not take into account that these population characteristics may be 
correlated. In addition to pre-vaccination titre and (unapparent) co-morbidity, the 
previous vaccinations may be dependent on age. But pre-vaccination titres also 
depend on previous vaccinations, health status etc. resulting in a complex pattern of 
interactions. Another complicating factor might be the observation that correlations 
between vaccine strains and circulating strains apparently play a more profound role 
in clinical performance of influenza vaccines than previously assumed, especially in 
those annually revaccinated [74, 75].
Also in our analysis, previous influenza vaccinations significantly affected pre-, 
but not post-vaccination titres. Impaired postvaccination seroprotection rate or se-
roresponse rate is inevitable in the presence of high baseline titres, and is mainly 
observed in those with a vaccination history. Several authors have hypothesized 
about this issue, including suggestions about a decreased pool of B lymphocytes 
and thus an impaired ability to expand [52, 76], inability to respond to new epitopes 
in presence of high baseline HI titres [49, 74], and age related differences in IgG 
subclass responses [56]. 
It is questionable whether for an inactivated vaccine with a mainly humoral driven 
response, serological data in elderly individuals, who are exposed to a wide variety 
of influenza strains during their life time, are likely to provide any reliable informa-
tion with regard to clinical protection. Even with low postvaccination seroprotection 
rates in an elderly GP patient population, stronger clinical protection was achieved 
for those patients with a vaccination history [35]. As humoral driven responses do 
not necessary show a booster effect, it may indeed be more relevant to focus on 
the possible positive role of cellular immunity [35], as it may decrease variations in 
protective potential of a vaccine through sustained cross-protection [77]. 
2.6 Serological responses as correlate for clinical protection
Trying to understand serological trials and clinical responses in elderly individuals 
the main issue is why clinical protection seems to improve with annual revaccination 
whereas it is not reflected in seroresponsiveness. There is obviously no support for 
a straightforward correlation between serological and clinical parameters. The high 
baseline titres resulting in blurred post vaccination responses are not predictive of an 
impaired immune response. On the contrary, high baseline titres are usually found in 
128
Ch
ap
te
r 8
individuals with a vaccination history [5], and the presence of a vaccination history 
is associated with increased protection [24, 31]. 
A decline in humoral immunity does not necessarily imply a decline in cellular 
immunity and vice versa [10, 78]. Apparently a long history of exposure to influenza 
virus and./or vaccine leads to blurring of the humoral response, but not necessarily 
to an impaired protection. The efficacy of annual variations in influenza vaccines is 
measured by serological parameters and clinical outcomes are measured in observa-
tional studies. These different settings make it complex and studies addressing both 
clinical and serological parameters did not correlate the 2 outcomes. In the literature 
we found only 2 studies which presented both evaluable clinical and serological 
parameters [35, 79, 80]. 
Given the highly variable influenza history of elderly persons one should question 
the relevance of pursuing on serological studies following influenza vaccination 
without additional confirmation of other immunological or clinical parameters. It 
might be more useful to focus on cellular immune response as a proxy for (sus-
tained) clinical protection following revaccination [49, 77, 81]. Further immunologi-
cal characterisation following influenza vaccination, and modelling could also allow 
for an understanding of clinical unpredictability of influenza epidemics, which may 
lead to negative results in one year but not in another [26, 70, 82]. The availability of 
large computerised databases allow for increasingly valid research on a wide variety 
of clinically important outcomes over several epidemic seasons [21, 23-26, 30, 36, 
42, 82, 83]. 
More insight into the relevant immunological parameters [49, 81] and virus to vac-
cine interactions [74, 75, 84] is necessary to improve the validity of the observational 
studies, which may result in better defined risk factors. The need for this has already 
been expressed, but was focussed on clinical parameters only [85, 86]. In addition 
to better defined case definitions, this may also contribute to more specific and valid 
outcomes [87]. This is not only important to better quantify effects of influenza revac-
cination in elderly, but also in adults and children with chronic underlying disease.
3 Methodological considerations
3.1 Validity
Whereas in experimental trials randomisation and blinding procedures often guar-
antee valid study results, the validity of the results in observational studies might be 
endangered by selection bias, information bias and confounding. 
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Selection bias
Selection bias is mainly an issue when inclusion of cases and controls depends to 
some extent on the exposure of interest. In this respect selection bias is most impor-
tant in case control studies. However, also cohort studies may suffer from selection 
bias, if the exposure status depends upon the outcome of interest. In the cohort 
studies described in chapters 2-5, selection bias was considered unlikely, as in the 
Dutch health care system all individuals are designated to their own GP. Hence, all 
morbidity and mortality comes to the attention of the GP. As the computerized data 
collection is complete for all patients who consult their doctor, the chance of selec-
tion bias in these studies is negligible. 
In the serology trials selection bias is possibly a more serious issue. These open 
label uncontrolled trials are especially prone to selection bias, e.g., for age to en-
hance the possibility of a positive outcome of interest. In the study described in 
chapter 6, we showed that over the follow up period the median age of the younger 
age category decreased substantially. The median age of the elderly trial population 
was relatively low throughout the study period.
Information bias
Information bias is a potential source of major error in cohort studies, as it depends 
upon the validity by which subjects are classified to their exposure and outcome 
[88].
In cohort studies, information bias may have occurred if the vaccination was not 
recorded or a (re)vaccination status was assigned to the wrong follow up period. 
However, it is likely that such misclassification is random because exposure is pro-
spectively recorded without prior knowledge of the research hypothesis and before 
the outcome of interest occurred. A consequence of such random misclassification 
would be that our estimates were a conservative one and that the real protective 
effect might even be higher. 
Misclassification of death as studied in chapters 2-4 is probably minimal since 
death rates in IPCI are in line with national data on mortality. Moreover, death is 
usually adequately registered at GP practices. Misclassification of lower respiratory 
tract infections as studied in chapter 5, may be a problem. Despite the fact that the 
availability of free text is a valuable tool in the validation process as it allows for con-
trolling possible non-uniform application of ICPC codes by GPs, it does not enhance 
sensitivity of the used clinical criteria. Microbiological confirmation is important [16, 
89] as respiratory tract infections are common in elderly, especially during winter 
months [89]. Causative organisms are identified in only a limited number of specimen 
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[66], and in elderly other viruses than influenza virus (e.g. RSV, rhinoviruses, corona 
viruses) are responsible [64, 89]. Also clinical symptoms of LRTI can be very variable 
in community dwelling elderly [66].
Misclassification of pneumonia, studied in chapters 2 and 5, might be a less im-
portant issue as all cases were confirmed radiologically and/or microbiologically. 
However, also for pneumonia, especially in elderly with an impaired clinical condi-
tion one can not exclude underreporting of pneumonia, because the patient died 
before developing a clinical picture of pneumonia, or pneumonia is not recognised, 
because as for LRTI, symptoms in elderly may be less prominent. It is possible that 
influenza infection, studied in chapter 2, was underestimated in the vaccine cohort 
because doctors were aware of the vaccination status of their patients.
Confounding
Confounding is a potential serious problem for all observational studies. In con-
founding the effect of the exposure under study on the outcome is mixed with a 
third factor. This third factor may cause the disease, but is also associated with the 
exposure, without being an intermediate step between exposure and outcome [90]. 
Important here is that the variable is also a risk factor for the disease in the non-ex-
posed and is also associated with the exposure in the non-diseased. Adjustment for 
confounding is possible through restriction, matching, stratification and multivariate 
techniques. For influenza vaccine studies, confounding factors include age, vaccina-
tion history and underlying disease.
In the cohort studies described in chapters 2-5 confounding by indication was ad-
dressed in detail. In all cohort studies, we assumed confounding by indication since 
pre-existing chronic respiratory tract disease, cardiovascular tract disease, diabetes 
mellitus, malignancies (excluded in the SCD study) and chronic renal insufficiencies 
have an increased risk of death and are strongly advised to have an influenza vac-
cination. 
With regard to health status, a perceived good health may be a reason for non-
compliance to the influenza vaccination program [3]. Also in our studies, a substantial 
proportion refused vaccination for one or more years. But the differential effect of 
refusers on the outcome may well have been a result of residual confounding. In the 
revaccination study discussed in chapter 3, study subjects listed as vaccine refusers 
showed a more or less similar mortality risk as those receiving a first vaccination; 
however, they were at a significantly increased risk compared to the remaining refer-
ence group. For the outcomes SCD and LRTI, studied in chapter 4 and 5 respectively, 
the health status (health beliefs) of those refusing vaccination did have a substantial 
impact on the outcome. Especially in the LRTI study residual confounding is likely, 
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and has probably led to an underestimation of the true effect of influenza vaccina-
tion, which included acute exacerbation of chronic bronchitis. Other factors may 
have contributed even more significantly to the risk to develop LRTI, such as pollu-
tion, self treatment and the delivery of pneumococcal vaccination [89].
However, as residual confounding cannot be excluded, a poorer prognosis in sub-
jects who were vaccinated means that we underestimated rather than overestimated 
the protective effect of annual revaccination. 
Confounding factors in the serology trials are also age, vaccination history and 
health status. To adjust for age and vaccination history we used restriction and strati-
fication. To adjust for health status we use restriction, by excluding all individuals 
for whom any comorbidity known to be associated with both an indication for vac-
cination and an outcome of interest was registered. However, this does mean that all 
vaccinated subjects were in good health. Only a limited number of studies reported 
individual data on comorbidity, none of these studies was performed before 1995.
3.2 Generalisability
The generalisability is important to extrapolate the results to the general population. 
This is an advantage of epidemiological research and a limitation of experimental 
trials. 
The demographic characteristics in the IPCI database are in accordance with the 
formal national registry CBS (Statistics Netherlands). The vaccination coverage for 
IPCI is also in agreement with CBS figures. The vaccination coverage in IPCI varied 
between 64-74%. According to CBS in 2002 the vaccination coverage in elderly aged 
≥ 65 years was 73.6%. 
Also the IPCI database complies with EC guidelines on the use of data for medical 
research [91].
4 Conclusions and future research
Despite the fact that the first inactivated influenza vaccines were licensed in 1945 
[92], today there are still a number of unsolved questions. These questions relate to 
the immunological sequelae following vaccination and their correlation to clinical 
protection. Research activities in this respect might take into consideration the fol-
lowing views.
1. Serological parameters do not simply correlate with clinical protection, es-
pecially since each vaccinated individual carries his or her personal infection and 
vaccination history. It is likely that annual revaccination is especially important to 
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maintain cellular immunity, which is necessary for cross-reactive immunity, thus 
reducing the risks associated with antigenic drift. The need for research in this direc-
tion was recently expressed at an expert meeting [77].
2. Evidence of the benefit of annual revaccination is not unambiguous. Observed 
variability of clinical effectiveness following revaccination has been explained by 
antigenic differences among the vaccine and epidemic strains [74, 75] or differential 
epitope susceptibility to new influenza antigens as a result of previous exposure to 
influenza antigens [84]. The availability of large computerised databases such as the 
IPCI or the GPRD database allow for prospectively generated extensive information 
on influenza vaccination and outcomes. Defining how to incorporate vaccination 
and /or infection history (i.e. “antigenic- history”) into the risk adjustment of these 
observational datasets, might further clarify the issue of observed variability in clini-
cal outcomes in different epidemic seasons. Ultimately, the result of such research 
might be a different attitude towards annual strain selection.
3. It seems that the time has come to reconsider the CHMP criteria and to study 
alternatives for annual update trials. For the purpose of such trials, a homogenous 
population should be selected in which the impact of disturbing population factors 
is minimal. The assessment criteria for such studies should be redefined. On the 
other hand, one might also conclude that with the availability of large computerised 
databases and more insight into the immunology, assessment of the in vitro potency 
is sufficient for annual strain variations. This assessment of in vitro potency is already 
common practice elsewhere.
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1 Summary
Since the last 400 years, recurrent epidemics and incidental pandemics caused by 
influenza viruses are documented. However, an influenza virus was not identified 
until 1933 and the first influenza vaccine was licensed in 1945 [1]. Influenza viruses 
circulate throughout the year, however in the northern hemisphere, influenza epi-
demic activity is mainly confined to winter months. In the Netherlands, an influenza 
epidemic is declared when at least 15 per 10,000 inhabitants report symptoms of 
influenza like illness (i.e., the epidemic threshold) [2]. 
Especially in the elderly and in persons with chronic underlying diseases, influ-
enza infections are associated with morbidity and mortality. In the Netherlands, the 
influenza epidemics have been of mild to moderate severity in the last decade. 
Annual vaccination programs aim to reduce the burden of disease associated with 
influenza infections, especially in elderly and in those with chronic underlying dis-
ease. However, despite recommendations to annually vaccinate all those who fulfil 
the inclusion criteria for participation in these programs, little is known about the 
effectiveness of influenza vaccines when administered annually. 
The first aim of this thesis was to get better insight into this effectiveness of influ-
enza vaccination in community dwelling elderly who were immunised as part of the 
national influenza vaccination program. To investigate this, 4 observational studies 
were conducted which are described in this thesis (chapters 2-5).
Since strains of influenza viruses may change, the composition of influenza vac-
cines is reassessed each year. The composition is based on recommendation of the 
World Health Organisation. Influenza vaccines need to be licensed for a first time 
and when the antigenic composition changes the vaccine needs to be relicensed. 
For this procedure the regulatory authorities within the European Union request an 
immunogenicity trial in a predefined number of healthy adults and elderly. A second 
aim of this thesis was to describe the outcomes of these serological trials and to in-
vestigate the influence of population characteristics on these outcomes (chapter 6).
Immunogenicity data are called “surrogate” parameters, which may be used as 
a proxy for clinical efficacy (i.e., the correlate for protection), provided that it is 
validated against the relevant clinical outcome. Since influenza vaccines were first 
licensed 60 years ago, clinical trials addressing both serological and clinical outcomes 
are generally not performed. Immunogenicity data are usually gathered in serological 
trials, whereas clinical outcomes are mostly investigated in observational studies. 
A final aim of this thesis was to investigate the impact of influenza vaccination on 
immunological and clinical outcomes, and the substantiation of using serological 
parameters as a correlate for clinical protection. For this purpose, we performed a 
review which is described in chapter 7.
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Chapter 1 describes the background of this thesis. In this chapter a short historic 
overview is given, followed by a summary of the epidemiology of influenza infec-
tions, symptomatology of influenza, the goals of influenza vaccination and how the 
vaccination program in the Netherlands is designed. Furthermore, this chapter shortly 
summarises what is known from the literature with respect to the immune response 
and clinical protection to influenza vaccines, especially in elderly. And finally the 
criteria for annual relicensure of influenza vaccines are shortly discussed.
Chapter 2 describes the first cohort study we performed in the Integrated Primary 
Care Information (IPCI) database with the objective to investigate the effectiveness of 
influenza vaccination in community dwelling elderly. For this study, we selected an 
eligible elderly population during the 1996-1997 influenza epidemic. Eligibility was 
defined as an age of 65 years or older on January 1st of 1996 and a permanent status 
in a practice in the IPCI source population. Two cohorts were defined on the basis 
of vaccination status. We estimated and compared all cause mortality, pneumonia 
and clinical influenza infection risk between the cohorts. This study was conducted 
in a season of mild-moderate influenza activity and good antigenic match between 
vaccine strains and circulating strains and influenza vaccination was associated with 
decreased mortality and influenza infections in community dwelling elderly. 
Chapter 3 focused on revaccination since most large scale cohort studying effec-
tiveness of influenza vaccination did not systematically address the clinical benefit 
of annual revaccinations. The aim of the study was to investigate the effect of an-
nual influenza revaccination on mortality in community dwelling elderly. In this 
population-based cohort study the eligible elderly population was selected during 
the period 1996 through 2002. For each year, the individual cumulative exposure 
to influenza vaccination since study entry was computed. Eligibility was defined as 
an age of 65 years or older on January 1st of the year of study entry. In this study, 
the association between the number of consecutive influenza vaccinations and all 
cause mortality was compared to no vaccination using a time-varying multivariate 
Cox-proportional hazard model, adjusted for age, gender, chronic respiratory and 
cardiovascular disease, hypertension, diabetes mellitus, renal failure, and cancer. 
The study population included 26,071 subjects of whom 3,485 died during follow-
up. Overall, a first vaccination was associated with a non-significant annual reduc-
tion of mortality risk of 10% (CI
95%
: -3%- 22%), revaccination reduced mortality risk 
by 24% (CI
95%
: 17-30%). Compared to a first vaccination, revaccination was associated 
with a reduced annual mortality risk of 15% (CI
95%
: 4-25%). During the epidemic 
periods this reduction was 28% (CI
95%
: 4-47%). Similar estimates were obtained for 
subjects with and without chronic comorbidity and those aged 70 years or older at 
baseline. Overall, influenza vaccination prevented one death for every 302 vaccinees 
at a vaccination coverage that varied between 64% and 74%. This was the first study 
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in which we showed that annual influenza vaccination was associated with a reduc-
tion in all cause mortality risk in a population of community dwelling elderly, also 
in those at higher age. 
In chapter 4 we further explored the possible benefit of annual revaccination 
on the risk of sudden cardiac death. Influenza infections are associated with an 
increased risk of acute cardiac events. Although a protective effect of influenza 
vaccination on the risk of sudden cardiac death (SCD) has been suggested, it has 
not been systematically studied. The cohort study was performed in the same study 
population as described in chapter 3, with the exclusion of those persons in whom 
a malignancy was diagnosed. In this study, the risk of SCD after a first vaccination 
or a revaccination was compared to no vaccination using a time-varying multivariate 
Cox-proportional hazard model, adjusted for age, gender, smoking and underlying 
chronic disease. Overall, any influenza vaccination or revaccination was associated 
with a non-significant risk reduction of SCD. An increased risk following a first 
vaccination was observed, which reached statistical significance in subjects without 
comorbidity and in those with baseline age<70 years. Despite modest results, the 
study supports the practice of annual vaccination The observed increased risk fol-
lowing a first vaccination needs further attention. 
Chapter 5 describes a cohort study in which the effect of annual influenza vac-
cination on the occurrence of lower respiratory tract infections, defined as acute 
bronchitis, acute exacerbation of chronic bronchitis and pneumonia (LRTI) in com-
munity dwelling elderly was investigated. Acute bronchitis is the most common 
complication following influenza infection and the risk increases in elderly and in 
those with underlying chronic conditions. However, little is known about the effec-
tiveness of influenza vaccination in reducing the risk, and no studies were performed 
addressing the effect of revaccination on LRTI. In our study, a first vaccination was 
not associated with a reduced LRTI risk. During epidemic periods, revaccination 
reduced LRTI risk by 33% (CI
95%
: 8-52%), in individuals without comorbidity. 
Chapter 6 describes serological data from a large number of trials that were sub-
mitted to the Dutch Medicines Evaluation Board between 1992 and 2002, as part 
of an annual relicensure requirement. The trials were analysed according to the 
requirements and criteria described in the so-called Committee of Human Medicinal 
Products Note for Guidance on harmonisation of requirements for influenza vac-
cines (CHMP NfG). This guidance document is meant to assist marketing authorisa-
tion holders in the planning, conduct and evaluation of the preclinical and clinical 
studies for their regulatory annual relicensure dossier. Of the 48 age-defined trials, 
all but three trials fulfilled the CHMP criteria. Increasing pre-vaccination antibody 
levels significantly contributed to the fulfilment of the seroprotection criterion and 
post-vaccination parameters were strongly dependent on age. Trials with “younger” 
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vaccinees appeared to have better chances to meet all criteria. History of previous 
influenza vaccinations significantly affected pre-, but not post-vaccination levels. 
The CHMP criteria showed serious methodological limitations, which affected their 
ability to answer their objective, i.e., determination of the immunogenic potential of 
the individual trivalent inactivated influenza vaccine. The value and need of these 
trials for annual relicensure purposes may be questioned. 
Chapter 7 is a review to investigate the impact of annual revaccination on serologi-
cal and clinical outcomes, and the validity of serological parameters as a proxy for 
clinical protection. Efficacy of annual variations in influenza vaccines is measured by 
serological parameters, and little is known about their correlation with clinical pro-
tection, especially when administered annually and particularly in elderly individu-
als. Following an ongoing Medline search, publications of studies based upon use 
of inactivated trivalent influenza vaccines in elderly subjects and relevant reviews 
were selected. In 23 serology publications no correlations were found between 
postvaccination seroprotection rate and seroresponse. In 30 publications addressing 
clinical outcomes a significant protective effect with regard to death, pneumonia or 
influenza was found. This review supports the clinical benefit of annual influenza 
vaccination in elderly, but does not support the use of serological data as proxy 
for clinical outcomes. The value of serological endpoints as correlate for clinical 
protection remains undetermined also due to a surprising lack of studies correlating 
these outcomes. The main question that remains is why clinical protection sustains 
with compliance to annual revaccination when seroresponsiveness decreases with 
increasing age and following repeated vaccination.
Chapter 8 is the general discussion of the thesis. In this chapter, the main findings 
of different studies are summarised and put in the context of other published re-
search. This chapter also discussed some of the methodological issues. This chapter 
concludes with some ideas for further research and regulatory guidance for annual 
relicensure of influenza vaccines.
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2 Samenvatting
Gedurende de laatste 400 jaar zijn influenza epidemieën regelmatig en pandemieën 
incidenteel gedocumenteerd. Het influenza virus werd echter pas voor het eerst in 
1933 geïdentificeerd en het eerste influenza vaccin kwam in 1945 beschikbaar [1]. 
Het hele jaar is er circulatie van influenza virussen, maar op het noordelijk halfrond 
zien we influenza epidemieën eigenlijk alleen in de wintermaanden. In Nederland 
wordt een influenza epidemie vastgesteld wanneer tenminste 15 van de 10.000 in-
woners symptomen van een influenza-achtig ziektebeeld hebben. Dit noemen we 
de epidemische drempel [2]. 
Vooral ouderen en personen met chronisch onderliggend lijden hebben een 
verhoogd risico op complicaties of overlijden ten gevolge van influenza infecties. 
De laatste 10 jaar hebben we in Nederland geen grote influenza epidemieën meer 
gehad. 
Het doel van de jaarlijkse influenza vaccinatie campagne is om ziektelast ten ge-
volge van influenza infecties te verminderen, vooral bij oudere personen en perso-
nen met chronische ziekten. Er is echter weinig bekend over de effectiviteit van het 
jaarlijks vaccineren tegen influenza. 
Het eerste doel van het onderzoek beschreven in dit proefschrift was om een 
beter inzicht te krijgen in de effectiviteit van influenza vaccinatie bij zelfstandig 
wonende oudere personen die jaarlijks worden gevaccineerd in het kader van het 
nationaal influenza vaccinatie programma. In totaal werden 4 observationele studies 
uitgevoerd. Deze zijn beschreven in de hoofdstukken 2-5. 
Omdat de circulerende influenzavirussen kunnen veranderen, wordt de samenstel-
ling van influenzavaccins jaarlijks opnieuw beoordeeld door de Wereld Gezond-
heid Organisatie. Een nieuw influenzavaccin wordt eenmaal volledig beoordeeld 
bij een eerste registratie, waarna jaarlijks uitsluitend de veranderde samenstelling 
wordt beoordeeld en opnieuw geregistreerd. De Europese registratie autoriteiten 
vereisen voor deze jaarlijkse herregistratie een zogenaamde immunogeniciteitstudie 
bij tenminste 50 gezonde volwassen en tenminste 50 gezonde oudere personen. Het 
tweede doel van het onderzoek was om de resultaten van deze serologie studies te 
beschrijven en om de mogelijke invloed van populatie factoren op de uitkomsten te 
onderzoeken (hoofdstuk 6). 
Immunogeniciteit of serologische parameters worden als “surrogaat” parameters 
beschouwd voor klinische werkzaamheid, op voorwaarde dat deze gevalideerd zijn 
voor een relevante klinische uitkomst. Influenza vaccins zijn echter 60 jaar geleden 
voor het eerst geregistreerd. Daarom zijn er nauwelijks experimentele klinische stu-
dies waarbij serologische en klinische uitkomsten beiden zijn onderzocht. De data 
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met betrekking tot immunogeniciteit komen in de regel uit serologie studies en de 
klinische uitkomsten uit observationeel onderzoek. 
Het laatste doel van het huidige onderzoek was dan ook om de invloed van 
influenza vaccinatie op zowel de immunologische als klinische uitkomsten te onder-
zoeken in een poging om de validiteit van gebruikte serologische parameters voor 
klinische bescherming te onderbouwen. De uitkomst hiervan is beschreven in het 
overzichtsartikel in hoofdstuk 7.
Hoofdstuk 1 beschrijft de achtergrond van het onderzoek. Dit hoofdstuk geeft 
een kort historisch overzicht, een samenvatting van de epidemiologie van influenza 
infecties, de symptomatologie van influenza infecties, de doelen van influenzavac-
cinatie en legt uit hoe het vaccinatieprogramma in Nederland is ontworpen. Verder 
geeft dit hoofdstuk een korte samenvatting van de literatuur met betrekking tot 
de immuunrespons en de klinisch bescherming na influenza vaccinatie, vooral in 
oudere personen. Tenslotte worden de criteria voor het jaarlijks herregistreren van 
influenza vaccines kort bediscussieerd. 
Hoofdstuk 2 beschrijft de eerste cohortstudie die we uitvoerden in de IPCI (In-
tegrated Primary Care Information) database met als doel om de effectiviteit van 
influenza vaccinatie in ouderen te onderzoeken. Voor deze studie werd de influenza 
epidemie van 1996-1997 onderzocht in personen die op 1 januari 1996 vijfenzestig 
jaar of ouder waren, en die een permanente status in een deelnemende praktijk in 
de IPCI bronpopulatie hadden. Er werden 2 groepen gedefinieerd op basis van vac-
cinatie status. In deze groepen werd het verschil in risico op overlijden, het ontwik-
kelen van pneumonie of een klinische influenza infectie onderzocht. De influenza 
epidemie van 1996-1997 werd gekarakteriseerd door een milde tot matig ernstige 
influenza activiteit en een goede antigene “match” tussen circulerende influenza 
virusstammen en vaccinstammen. Vaccinatie was geassocieerd met een verminderde 
mortaliteit en minder influenza infecties bij zelfstandig wonende oudere personen. 
In hoofdstuk 3 beschrijft het onderzoek de jaarlijkse influenzavaccinatie. Hoewel 
veel studies het effect van influenzavaccinatie hebben bestudeerd, is het klinisch 
nut van het jaarlijks vaccineren niet eerder systematisch onderzocht.  Het doel van 
het onderzoek was daarom om het effect van jaarlijkse influenzavaccinatie op het 
risico op overlijden te onderzoeken bij oudere personen. Deze op de Nederlandse 
populatie gebaseerde cohortstudie liep van 1996-2002. Elk jaar werd de individuele 
cumulatieve vaccinatiestatus bepaald in de geselecteerde oudere personen. Perso-
nen werden geselecteerd indien ze 65 jaar of ouder waren op 1 januari van het jaar 
waarin zij in de studie startten (tussen 1996-2001). De associatie tussen het aantal 
opeenvolgende influenzavaccinaties en mortaliteit werd bestudeerd met personen 
die niet eerder waren gevaccineerd tegen influenza als vergelijkingsgroep. Hiervoor 
werd een in tijd variërend multivariate Cox-proportional hazard model ontwikkeld, 
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gecorrigeerd voor leeftijd, geslacht, chronische ziekten van luchtwegen, hart en 
bloedvaten, hypertensie, diabetes mellitus, chronische nierinsufficiëntie en kanker. 
Van de 26071 geselecteerde personen overleden er 3485 gedurende de studie. In 
het algemeen leek een eerste vaccinatie geassocieerd met een niet-significante daling 
van 10% in het risico op overlijden gedurende het jaar (95% betrouwbaarheidsinter-
val (BI
95%
): -3%- 22%), revaccinatie verminderde echter het risico op overlijden met 
24% (BI
95%
: 17-30%). Vergeleken met een 1ste vaccinatie was revaccinatie geassocieerd 
met een vermindering van het jaarlijkse overlijdensrisico van 15% (BI
95%
: 4-25%). 
Tijdens de influenza-epidemieën was deze vermindering zelfs 28% (BI
95%
: 4-47%). 
Vergelijkbare resultaten werden gevonden voor personen met of zonder onderlig-
gend lijden en personen van 70 jaar of ouder aan het begin van de studie. In deze 
studie werd bij 304 gevaccineerden één overlijden voorkómen bij een vaccinatie-
graad die varieerde tussen 64% en 74%. In deze eerste studie toonden we aan dat 
jaarlijkse influenza vaccinatie geassocieerd was met een vermindering in mortaliteit 
bij zelfstandig wonende oudere personen, ook op hogere leeftijd. 
In hoofdstuk 4 wordt het effect van jaarlijkse vaccinatie op het risico van plotse-
linge hartdood beschreven. Influenza infecties zijn geassocieerd met een verhoogd 
risico op acute cardiale gebeurtenissen. Hoewel eerder was gesuggereerd dat in-
fluenzavaccinatie het risico op acute hartdood kon verminderen, was dit nog niet 
eerder systematisch onderzocht. Deze cohortstudie werd uitgevoerd in dezelfde 
populatie als omschreven in hoofdstuk 3, met uitzondering van personen waarin 
een maligniteit was gediagnosticeerd. Ook in deze studie werd het risico op acute 
hartdood na een eerste vaccinatie of een revaccinatie vergeleken met het risico in 
personen zonder vaccinatie, gebruik makend van een in tijd variërend multivariaat 
Cox-proportional hazard model, en gecorrigeerd voor leeftijd, geslacht, en onderlig-
gende ziekten. In het algemeen leek influenzavaccinatie of revaccinatie te zijn geas-
socieerd met een niet-significante vermindering van het risico op acute hartdood. Er 
was een verhoogd risico na een eerste vaccinatie, dat statistisch significant bleek in 
de groep personen zonder onderliggend lijden en in diegenen die jonger waren dan 
70 jaar aan het begin van de studie. Deze resultaten vormen een ondersteuning voor 
het belang van jaarlijkse vaccinatie.
Hoofdstuk 5 beschrijft een cohortstudie waarin het effect werd onderzocht van 
jaarlijkse vaccinatie op het risico op lagere luchtweginfecties (acute bronchitis, acute 
exacerbatie van chronische bronchitis en pneumonie) bij zelfstandig wonende oude-
ren. Acute bronchitis is de meest voorkomende complicatie na een influenza infectie 
en het risico neemt toe bij hogere leeftijd en bij onderliggende chronische ziekten. 
Maar er is weinig bekend over de effectiviteit van influenza vaccinatie, vooral in 
relatie tot acute bronchitis, en er zijn geen studies die de relatie tussen het risico op 
lagere luchtweginfectie en revaccinatie hebben onderzocht. 
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In onze studie was een eerste vaccinatie niet geassocieerd met een verminderd 
risico op lagere luchtweginfecties. Tijdens de influenza epidemieën verminderde het 
risico na revaccinatie echter met 33% (BI
95%
: 8-52%) bij personen zonder onderlig-
gende chronische ziekten. 
Hoofdstuk 6 beschrijft de serologische resultaten van een groot aantal studies, 
die gedurende de periode 1992-2002 bij het College ter Beoordeling van Genees-
middelen werden ingediend als onderdeel van de jaarlijkse verplichting van de 
registratiehouders om de nieuwe samenstelling van hun influenza vaccin te laten 
herregistreren.
De studies werden geanalyseerd volgens de vereisten zoals deze zijn beschreven 
in de zogenaamde Committee of Human Medicinal Products Note for Guidance on 
harmonisation of requirements for influenza vaccines (CHMP NfG). Deze richtlijn is 
bedoeld om registratiehouders bij te staan in de planning, uitvoering en evaluatie 
van de preklinische en klinische studies voor de jaarlijkse herregistratie. Van de 
48 studies voldeden er 45 aan de CHMP criteria. Hogere prevaccinatie antistof-
concentraties droegen significant bij aan het postvaccinatie seroprotectie criterium. 
De postvaccinatie parameters waren sterk afhankelijk van leeftijd. Studies waarin 
de gevaccineerden een gemiddeld lagere leeftijd hebben, voldeden vaker aan alle 
criteria. Een voorgeschiedenis van influenzavaccinatie had een statistisch significante 
invloed op de antistofconcentraties voorafgaand aan vaccinatie maar niet op de 
antistofconcentraties na vaccinatie. De CHMP criteria bleken ernstige methodolo-
gische beperkingen te hebben, die van invloed waren op hun mogelijkheid om de 
immunogeniciteit van de individuele geïnactiveerde trivalente influenzavaccins vast 
te stellen. De waarde en noodzaak van deze studies voor de jaarlijkse herregistratie 
van de geïnactiveerde influenza vaccins zou ter discussie gesteld moeten worden. 
Hoofdstuk 7 is een overzichtsartikel over de invloed van het jaarlijks vaccineren 
tegen influenza op serologische en klinische uitkomsten en de validiteit van de ge-
bruikte serologische parameters voor klinische bescherming. De effectiviteit van de 
jaarlijkse variaties in influenzavaccins wordt gemeten aan de hand van serologische 
parameters en er is weinig bekend over hun correlatie met klinische bescherming, 
vooral bij het jaarlijks vaccineren en bij oudere personen. 
Via Medline werden publicaties geselecteerd van studies, die het gebruik van 
geïnactiveerde trivalente influenza vaccins bij oudere personen beschreven, alsmede 
relevante overzichtsartikelen. In 23 publicaties met serologische gegevens werden 
geen correlaties gevonden tussen de postvaccinatie seroprotectie graad en de sero-
respons. In 30 publicaties met klinische uitkomsten werd een significant bescher-
mend effect van influenzavaccinatie gevonden voor de uitkomsten dood, pneumonie 
of influenza. Dit hoofdstuk bevestigt het klinisch nut van jaarlijkse vaccinatie van 
oudere personen. Het vormt echter geen ondersteuning voor het gebruik van sero-
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logische parameters in plaats van klinische uitkomsten in studies. De waarde van 
serologische eindpunten als surrogaat parameter voor klinische bescherming blijft 
onduidelijk, mede door een opvallend tekort aan studies waarin beide uitkomsten 
zijn gemeten en gecorreleerd. De belangrijkste vraag blijft waarom klinische be-
scherming aanhoudt bij diegenen die zich jaarlijks laten vaccineren tegen influenza, 
terwijl de serorespons lijkt te verminderen bij het toenemen van de leeftijd en na 
herhaalde vaccinatie. 
Hoofdstuk 8 is de algemene discussie. In dit hoofdstuk worden de belangrijkste 
bevindingen uit de verschillende studies samengevat en besproken in de context 
van  de gepubliceerde literatuur. Ook bespreken we in dit hoofdstuk enkele metho-
dologische punten.
Tenslotte eindigt het hoofdstuk met enkele ideeën voor verder onderzoek en de 
jaarlijkse herregistratie van influenza vaccins .
Referenties
 1. Nicholson, K.G., Historical introduction, in Textbook of influenza, K.G. Nicholson, R.G. Web-
ster, and H. A.J., Editors. 1998, reprint 2000, Blackwell sciences ltd.: London. p. 3-26.
 2. NIVEL, Nederlands Instituut voor de eerste lijns gezondheidszorg. Continue morbiditeitsregi-
stratie peilstations Nederland 1988/89. 1991, Nivel: Utrecht.
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Dankwoord
Dan nu het leukste deel, het dankwoord. Voor iemand die gewend is altijd teveel 
woorden te gebruiken ook nog een hele kunst om dat enigszins binnen de perken 
te houden. 
Science is organized knowledge. Wisdom is organized life (Immanuel Kant)
Allereerst zijn er mijn promotoren Prof. dr. B.H.Ch. Stricker en Prof. Dr. J. van der 
Lei en mijn copromotor Dr. M.C.J.M. Sturkenboom.
Bruno, toen je na onze pilot studie zei, met of zonder mij, verder te willen met 
dit project, had ik niet gedacht dat ik me werkelijk nog eens voor een promotie 
onderzoek zou laten strikken. Maar het is je toch (mede door de overtuigingskracht 
van professor van der Noordaa) gelukt en ik heb er geen spijt van gehad. Het 
probleem van jaren vanuit één perspectief naar een onderwerp kijken is dat je denkt 
er veel van te weten. Je vragen, kritische opmerkingen en discussies hebben me 
laten zien dat er nog heel veel te leren was en is. Ik ben onder de indruk van de 
doortastendheid waarmee je dit project hebt getrokken, terwijl er toch aardig wat 
beren op de weg bleken. Vooral ook door je geloof in de goede afloop (“als je nu 
niet promoveert ligt het in ieder geval niet aan mij”) en je aanstekelijk enthousiasme 
heb ik erg genoten van deze 4 jaar. Ik hoop ook echt dat we de samenwerking in de 
toekomst kunnen voortzetten. 
Johan, vanaf het begin was je enthousiast over het project. Al die jaren heb ik me 
welkom gevoeld op je afdeling en alle steun gehad die nodig was, en dat is soms erg 
nodig voor een relatieve computerleek op een afdeling vol “computer- wizards”.
Miriam, je bent misschien wel eens moedeloos geworden van me. Maar geloof 
me, ik heb al je aanwijzingen, kritiek en ideeën steeds “aan boord genomen” en heb 
het erg gewaardeerd. Je methodologische kennis en vooral ook je schrijftalent heeft 
een grote indruk op me gemaakt. Verder weet ik nog steeds niet hoe je zoveel werk 
kan verzetten met 2 kleine kinderen (je commentaren waren bijna altijd als eerste 
binnen!!).
Heel erg bedankt leden van de leescommissie, voor de bereidheid het manuscript te 
beoordelen en zitting te nemen in de promotiecommissie. 
Professor van der Noordaa, bedankt voor al die jaren van vertrouwen. Als collegelid 
beschouwde ik u als mijn “sparring partner” en u was instrumenteel in mijn besliss-
ing om verder te gaan met het onderzoek. We waren kritisch over wat we konden 
verwachten, maar de resultaten hebben ons denk ik allebei verrast. Dit kwam ook 
weer terug in onze discussies over het review, het sluitstuk waar in eerste instantie 
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alles mee begonnen was. Jaren terug spraken we al over de klinische relevantie van 
de serologische data, nu staat het op papier. 
Professor Osterhaus, vier jaar geleden, tijdens ons eerste gesprek, kwam er direct 
een stortvloed van ideeën over me heen. Deze waren helaas op dat moment niet 
direct uitvoerbaar, maar ze hebben wel geleid tot een productieve samenwerking 
met de afdeling Virologie. Bedankt hiervoor.
Professor Coutinho sprak ik jaren terug, tijdens de module infectieziekten epi-
demiologie in het kader van mijn MPH opleiding, over mijn plannen om influenza 
onderzoek te doen. Het werd uiteindelijk Rotterdam, maar gelukkig bent u er toch 
nog bij betrokken.
We don’t accomplish anything in this world alone ... and whatever happens is the result 
of the whole tapestry of one’s life and all the weavings of individual threads from one 
to another that creates something (Sandra Day O’Connor).  
Geen enkel stuk schrijf je alleen. 
Paul van der Linden was mijn steun en toeverlaat bij de pilot studie. Als FoxPro-
leek zat ik daar met twee linker handen. Bedankt voor alle hulp.
Zonder Jeanne had ik de datasets in FoxPro voor de revaccinatie studie nooit voor 
elkaar gekregen. Bovendien ben je een kei in het kritisch analyseren van data en 
manuscripten.
Derek Smith, you are scientifically one of the most original people I have met. 
Thanks for all the time you were willing to spent to elaborate on revaccination and 
effectiveness and the possible impact of (temporarily) interruption, but also all your 
efforts to improve the manuscripts and correct my English.  
Professor Stijnen bedankt voor uw statistisch “vernuft”. Leeftijd in dagen als follow-
up en vaccinatie stoppers als aparte categorie, het waren gouden ideeën. Bovendien 
heel erg bedankt voor al het geduld om dat ook nog herhaaldelijk te bespreken en 
uit te leggen. 
Collega Beyer, beste Walter, van het voorstel van Jan om contact op te nemen heb 
ik geen seconde spijt gehad. Mijn goed bedoelde pogingen om de serologische data 
weer te geven werden in een paar weken omgetoverd tot wat ze nu zijn. Heel erg 
bedankt voor alle hulp. Ik hoop dat we het manuscript spoedig kunnen publiceren 
en we de mogelijkheid krijgen om verder aan dit soort data te werken.
Dan is er mijn vriend (nee niet mijn man!), collega en treinmaatje André. Bedankt 
voor al het rekenwerk en het steeds maar vragen blijven stellen. Er zijn vervelender 
manieren om aan artikelen te werken dan op zondagmiddag bij jou, met koffie, rosé 
en nootjes. 
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In Rotterdam heb ik ruim 4 jaar mogen vertoeven op de afdeling medische infor-
matica. In eerste instantie op de kamer met Albert, Georgio, Mark, Mees, Katia en 
Manon. Een volle bak, maar wel erg gezellig. Mees en Georgio, bedankt voor al het 
geduld als mijn computer weer niet deed wat ik wilde. Katia, jij was de eerste van 
de 3 musketiers. Het combineren van werk, gezin en promotie, vonden we eigenlijk 
wel een prestatie. Maar jij spande echt de kroon door ook nog elke week uit Gent 
te komen rijden en als eerste klaar te zijn. Nu de 3de musketier ook klaar is, moeten 
we dat ook maar eens met zijn drieën vieren.
Het laatste jaar op de kamer samen met Jeanne en Miriam. Dit bleek een zeer 
vruchtbare omgeving. Naast het feit dat de meeste stukken in dat jaar werden ge-
schreven werden we ook alle 3 zwanger. Dat kan geen toeval zijn. 
Désirée, Ineke Sylvia en Ria bedankt voor alle hulp en de gezelligheid.
Professor Hofman zou ik willen bedanken voor de gelegenheid om op zijn afdeling 
te werken en de waardevolle discussies tijdens de vele interessante lunchbesprekin-
gen.
De farmaco-epidemiologie collega’s Albert-Jan, Bert, Cornelis, Claire, Dika, Fernie, 
Geert, Georgio, Gysèle, Hedy, Ingo, Katia, Mariëtte, Loes, Martina, Mendel en Sabine 
vooral bedankt voor de discussies tijdens de dinsdagmiddag besprekingen. Hoewel 
ik slechts zo nu en dan op de farmaco-epi gang langs kwam had ik altijd het gevoel 
er welkom te zijn.
Ron Fouchier en Guus Rimmelzwaan van de afdeling Virologie, bedankt voor jullie 
adviezen, hulp bij mijn vragen en “het entertainen” van cameramensen voor USA 
Networks. 
Jan de Jong, bedankt dat je zo bereidwillig was om alle noodzakelijke epidemio-
logische gegevens ter beschikking te stellen. En wie had ooit gedacht dat ook ik 
nog aan de meta-analyses zou gaan? Bovendien was je een belangrijke schakel naar 
Derek en Walter. 
Dan zijn er de collega’s uit den Haag. Het is heel bijzonder om vier jaar lang 2 dagen 
per week “vrij” te krijgen om die dingen te doen die je leuk vindt. André Broekmans 
en Peter Koopmans, bedankt voor het vertrouwen en het creëren van de ruimte 
hiervoor. 
Frits Lekkerkerker, Barbara van Zwieten, bedankt voor jullie niet aflatende inte-
resse. Jullie geven altijd het gevoel te waarderen wat ik doe, of het nu om influenza 
gaat, een beoordeling of een andere vaccin activiteit. Het maakt het allemaal een 
stuk leuker.
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Simon, binnen onze beoordelingsgroep heb je het mogelijk voor me gemaakt 
dit project te doen. Dat dit een belasting voor jou en mijn andere CBG collega’s 
betekende heb ik me goed gerealiseerd. Heel erg bedankt!
Mijn (oud) collegae klinici Christine, Esther, Gerard, Ineke, Jitschak, Liesbeth, Mar-
jolein, Martin, Maxime en Tamar van FT1 wil ik bedanken voor alle belangstelling, 
betrokkenheid en collegialiteit. Jan bedankt voor al die koffie en koeken! Tekla, het 
moet niet altijd gemakkelijk zijn met zo’ n chaotische kamergenoot, maar ik vind het 
erg gezellig, zeker nu met onze gemeenschappelijke baby ervaringen. Bovendien 
zijn we een aardig vaccin beoordelingsduo aan het worden. Met Kora is het al 
jaren een één-tweetje als het om vaccins gaat. Die vanzelfsprekendheid maakte mijn 
gedeeltelijke afwezigheid een stuk makkelijker. Ad, Carla, Els, Eric, Hans, Maaike, 
Peter, Petra en Sabine Velders jullie weten me altijd en overal te vinden. Maar de 
gezamenlijke projecten zijn wel altijd deze moeite waard. De MA’s wil ik bedanken 
voor het geregel van al mijn uitstapjes met of zonder Kristien en alle andere beslom-
meringen. Liz, op sommige momenten was je mijn belangrijkste schakel naar het 
CBG, bedankt voor al je inspanningen en interesse. Rob, hoewel pas sinds kort mijn 
baas, bedankt voor het vertrouwen en de ruimte die je geeft. 
André van Niel, bedankt voor al die literatuur die inmiddels bijna het zicht aan 
mijn bureau belemmert. Ik durf niet te beloven dat de aanvragen af zullen nemen, ik 
heb nog heel wat te lezen. Henk Batens, bedankt voor alle kopieën, hand en span 
diensten en altijd die jovialiteit! De mannen van de Repro afdeling, bedankt dat jullie 
er altijd weer iets moois van weten te maken. 
Tenslotte, mijn oud CBG collega Henk Nab was degene die het idee opperde om 
het onderzoek bij Bruno Stricker te doen en dat was een goede keuze. 
We must learn our limits. We are all something, but none of us are everything (Blaise 
Pascal).
De collega leden en adviseurs van de Gezondheidsraad commissies herziening RVP 
en antivirale middelen bij een grieppandemie wil ik bedanken voor alle discussies. 
Ik leer elke keer weer. De waarheid is een stuk breder dan het registratie dossier.
My colleagues at the EMEA vaccines working party, I want to thank you for all 
discussions, sharing of common interest and friendship. Especially, I want thank my 
dear friends and colleagues Ingrid Uhnoo and Stephania Salmaso for all the time you 
were willing to listen, discuss and comment on the various drafts of the revaccination 
studies. Roland Dobbelaer, thanks for all these years of trust both at EMEA and WHO 
and your willingness to act as opponent.   
Dear Ivana Knezevic, I hope we will continue our WHO collaboration. It is always 
good to work with you and you had some great ideas.
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Good friends, good books and a sleepy conscience: this is the ideal life (Mark Twain).  
Antoinette, Mariët, Nicole en Josi bedankt voor al die vrijdagochtenden van ontspan-
nen tennisballen slaan, frustraties wegmeppen en vooral veel kletsen en harten 
luchten. 
Annemarie, Anke, Caroline, Hoky en Rebecca, de meiden van Belegen Blauw, 
ook na 22 jaar blijft het nog leuk. In 2008 zullen we zadelpijn in de schaduw laten 
staan. 
Sylvia, de vriendschap die 26 jaar geleden begon bij het hospiteren is altijd geble-
ven. Al die tijd bleef het als vanouds. Sommige dingen veranderen nooit.
Brigitte, 2 jaar waren kamergenoten. Samen schreven we het eerste projectvoorstel 
wat uiteindelijk tot dit proefschrift heeft geleid. Helaas ging je weg, maar gelukkig is 
de vriendschap gebleven. Bedankt dat je er was als het nodig was! 
André en Mariët, sinds mijn start bij het CBG zijn we vrienden. We hebben heel 
wat geborreld, gegeten en plezier gehad, maar ook veel gedeeld. André, 20 juli 2004 
zal ik nooit vergeten. Mariët die zondagmiddagen blijven van ons. Jullie zijn gewoon 
bijzonder.
The loneliest woman in the world is a woman without a close woman friend (George 
Santayana The Life of Reason, 1905-1906).
Verder heb ik de beste paranimfen die je kunt bedenken. Sabine en Inge, met jullie 
gaat deze dag gewoon lukken. 
Sabine, samen den Haag, samen Rotterdam, samen promoveren, samen paranim-
fen en samen publiceren. Het was en is een belevenis samen met jou. Ik zit volgens 
jou altijd “on-line” maar jij antwoordt ook altijd direct. Al onze mailtjes met vragen, 
opmerkingen, frustraties, opbeurende verhalen en (soms smeuïge) commentaren 
zijn al een boek op zich. Bordeaux zal ik altijd blijven herkennen aan zijn winkel-
straten.
Inge, al aan het begin van dit project heb ik je gevraagd paranimf te zijn om er 
zeker van te zijn dat je kwam. Deze dag is niet hetzelfde zonder jou erbij. Het blijkt 
dat voor echte vriendschap afstand niet relevant is. Bovendien, terwijl jij bestellingen 
aan het plaatsen was, liet ik SAS draaien en stuurde de eerste versie van het latere 
JAMA stuk uit. Niet iedere coauteur had door dat ook uit kaaswinkels manuscripten 
kunnen komen. 
Om een groot verschil te willen maken, moeten we niet de kleine dagelijkse verschil-
len vergeten. Deze kunnen over de tijd optellen tot een groot verschil dat we niet op 
voorhand kunnen voorspellen (naar Marian Wright Edelman)
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Ageeth, al jou zorg en inspanning voor de kinderen en ons, ik weet niet hoe ik je er 
in een paar woorden voor moet bedanken. Je bent uniek en we zijn je erg dankbaar. 
Ik heb nu meer tijd, beloof me, ga jij het nu ook rustiger aan doen? 
De ene generatie plant de boom, de volgende krijgt de schaduw (Chinees gezegde).
Papa en mama ik zo blij dat jullie hier nog bij kunnen zijn. Bedankt voor al de ba-
gage die jullie me hebben meegegeven. Van mama hoop ik geleerd te hebben nooit 
op te geven. Papa ik bewonder u om de manier waarop u van dingen kunt genieten. 
Heerlijk dat u nog steeds zo geïnteresseerd bent in alles wat ik doe. 
Like all the best families, we have our share of eccentricities, of impetuous and 
wayward youngsters and of family disagreements (Elisabeth II).
Gerrit, Cockie en Ans, jullie zien ook kleine zusjes worden groot. Gerrit, je bent m’n 
grote broer en grote voorbeeld. Cockie ik hoop dat je met Kees je geluk gevonden 
hebt. Ans ik bewonder je dynamiek en betrokkenheid. 
Ouders kunnen alleen goed advies geven of hun kinderen op het goede pad zetten, 
maar de vorming van hun karakter ligt in hun eigen handen (Anne Frank).
En dan nu de allerbelangrijkste en diegenen waar het uit eindelijk allemaal om gaat, 
Michaël, Laureanne en Kristien. 
Ik geloof in geluk en hoe harder ik werk hoe meer geluk ik heb (naar Thomas Jefferson).
Michaël wees trots op jezelf, in ieder geval ben ik heel trots op jou. Niemand doet 
je na.
Je hebt chaos in je ziel nodig om een dansende ster geboren te laten worden (naar 
Nietzsche).
Laureanne jij kunt alles. Als jij je dromen volgt dan wordt het vast heel leuk. 
Geluk zit in een klein hoekje (mama).
Kleine Kristien, als jij later net zo van het leven geniet als wij nu van jou, wordt het 
prachtig.
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Family life is full of major and minor crises -- the ups and downs of health, success 
and failure in career and marriage -- and all kinds of characters. It is tied to places and 
events and histories. With all of these felt details, life etches itself into memory and 
personality. It’s difficult to imagine anything more nourishing to the soul (naar Thomas 
Moore).
Tenslotte Michiel. Zonder jou steun en je onvoorwaardelijke geloof in mij was dit 
nooit gelukt. Het waren bewogen jaren, maar het blijkt, samen kunnen we echt alles 
aan. Ik ben gelukkig met jou, trots op jou en trots op ons. 
En nu is het de tijd voor leuke dingen. Michaël en Laureanne, in ieder geval hebben 
jullie de pc terug. Dit blaadje ligt in de prullenbak.
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